US20110281850A1 - Intracellular kinase inhibitors - Google Patents
Intracellular kinase inhibitors Download PDFInfo
- Publication number
- US20110281850A1 US20110281850A1 US13/177,657 US201113177657A US2011281850A1 US 20110281850 A1 US20110281850 A1 US 20110281850A1 US 201113177657 A US201113177657 A US 201113177657A US 2011281850 A1 US2011281850 A1 US 2011281850A1
- Authority
- US
- United States
- Prior art keywords
- lymphoma
- compounds
- leukemia
- alkyl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]N([2*])C([3*])([4*])C([5*])([6*])C(=O)[Ar] Chemical compound [1*]N([2*])C([3*])([4*])C([5*])([6*])C(=O)[Ar] 0.000 description 35
- MHCQWVUOAKFZBT-UHFFFAOYSA-N Cl.O=C(CCN1CCOCC1)C1=CC2=CC=CC=C2C=C1 Chemical compound Cl.O=C(CCN1CCOCC1)C1=CC2=CC=CC=C2C=C1 MHCQWVUOAKFZBT-UHFFFAOYSA-N 0.000 description 6
- OLWJLNYKBDXKTD-UHFFFAOYSA-N CC(C)N(CCC(=O)C1=CC2=CC=CC=C2C=C1)C(C)C Chemical compound CC(C)N(CCC(=O)C1=CC2=CC=CC=C2C=C1)C(C)C OLWJLNYKBDXKTD-UHFFFAOYSA-N 0.000 description 5
- XJFBPDQALDIFFU-UHFFFAOYSA-N CN(C)C1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)C1 Chemical compound CN(C)C1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)C1 XJFBPDQALDIFFU-UHFFFAOYSA-N 0.000 description 4
- NXEUVYOKCMQSEF-UHFFFAOYSA-N CN(C)C1CCN(CCC(=O)C2=CC3=C(C=C2)OCC(=O)C3)C1 Chemical compound CN(C)C1CCN(CCC(=O)C2=CC3=C(C=C2)OCC(=O)C3)C1 NXEUVYOKCMQSEF-UHFFFAOYSA-N 0.000 description 3
- MTXSLOTXKWCTNU-UHFFFAOYSA-N CN(C)CCN1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1 Chemical compound CN(C)CCN1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1 MTXSLOTXKWCTNU-UHFFFAOYSA-N 0.000 description 3
- WYGYLVASORRXNA-UHFFFAOYSA-N CN(CCC(=O)C1=CC2=CC=CC=C2C=C1)CC1=CC=C(F)C=C1 Chemical compound CN(CCC(=O)C1=CC2=CC=CC=C2C=C1)CC1=CC=C(F)C=C1 WYGYLVASORRXNA-UHFFFAOYSA-N 0.000 description 3
- IKUSCBOQDLHKRC-UHFFFAOYSA-N CN(CCC(=O)C1=CC2=CC=CC=C2C=C1)CC1=CC=CC=C1 Chemical compound CN(CCC(=O)C1=CC2=CC=CC=C2C=C1)CC1=CC=CC=C1 IKUSCBOQDLHKRC-UHFFFAOYSA-N 0.000 description 3
- MSKCNVJKSSBDOT-UHFFFAOYSA-N COC1=CC2=C(C=C1OC)CN(CCC(=O)C1=CC3=CC=CC=C3C=C1)CC2 Chemical compound COC1=CC2=C(C=C1OC)CN(CCC(=O)C1=CC3=CC=CC=C3C=C1)CC2 MSKCNVJKSSBDOT-UHFFFAOYSA-N 0.000 description 3
- IAAALGVTGBEFSY-UHFFFAOYSA-N NC(=O)C1=CC2=C(C=C1)C=C(C(=O)CCN1CCOCC1)C=C2 Chemical compound NC(=O)C1=CC2=C(C=C1)C=C(C(=O)CCN1CCOCC1)C=C2 IAAALGVTGBEFSY-UHFFFAOYSA-N 0.000 description 3
- LIKKSGHZJJOFDK-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC2=C(C=C1)OC=C2 Chemical compound O=C(CCN1CCOCC1)C1=CC2=C(C=C1)OC=C2 LIKKSGHZJJOFDK-UHFFFAOYSA-N 0.000 description 3
- ZLGPSAUGCOHPGC-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC=C(F)C=C1 Chemical compound O=C(CCN1CCOCC1)C1=CC=C(F)C=C1 ZLGPSAUGCOHPGC-UHFFFAOYSA-N 0.000 description 3
- VKWNGORZQNVGMV-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC=CC=C1Cl Chemical compound O=C(CCN1CCOCC1)C1=CC=CC=C1Cl VKWNGORZQNVGMV-UHFFFAOYSA-N 0.000 description 3
- ZGLPREULFAREMI-UHFFFAOYSA-N O=C1COC2=C(C=C(C(=O)CCN3CCOCC3)C=C2)C1 Chemical compound O=C1COC2=C(C=C(C(=O)CCN3CCOCC3)C=C2)C1 ZGLPREULFAREMI-UHFFFAOYSA-N 0.000 description 3
- MLLJVNNJWUEPQC-UHFFFAOYSA-N CC(C)N(C)CCC(=O)C1=CC2=CC=CC=C2C=C1 Chemical compound CC(C)N(C)CCC(=O)C1=CC2=CC=CC=C2C=C1 MLLJVNNJWUEPQC-UHFFFAOYSA-N 0.000 description 2
- JGGCAYFMVBIPQG-UHFFFAOYSA-N CC1=CC=C(C(=O)CCN2CCOCC2)C=C1 Chemical compound CC1=CC=C(C(=O)CCN2CCOCC2)C=C1 JGGCAYFMVBIPQG-UHFFFAOYSA-N 0.000 description 2
- PJNKREVXXMJIFC-UHFFFAOYSA-N CC1=CC=CC(C(=O)CCN2CCOCC2)=C1 Chemical compound CC1=CC=CC(C(=O)CCN2CCOCC2)=C1 PJNKREVXXMJIFC-UHFFFAOYSA-N 0.000 description 2
- LXAFIRYKGYBVNL-UHFFFAOYSA-N CC1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1 Chemical compound CC1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1 LXAFIRYKGYBVNL-UHFFFAOYSA-N 0.000 description 2
- MSXLZTFYOTWRBB-UHFFFAOYSA-N CN(C)C1CCN(CCC(=O)C2=CC3=C(C=CC=C3)C=C2)CC1 Chemical compound CN(C)C1CCN(CCC(=O)C2=CC3=C(C=CC=C3)C=C2)CC1 MSXLZTFYOTWRBB-UHFFFAOYSA-N 0.000 description 2
- WZIOJYCFLAYASE-UHFFFAOYSA-N CN(C)CCC(=O)C1=CC2=CC=CC=C2C=C1 Chemical compound CN(C)CCC(=O)C1=CC2=CC=CC=C2C=C1 WZIOJYCFLAYASE-UHFFFAOYSA-N 0.000 description 2
- PBEFRUYCPAVLKC-UHFFFAOYSA-N CN(CCC(=O)C1=CC2=CC=CC=C2C=C1)CC1=CC=CO1 Chemical compound CN(CCC(=O)C1=CC2=CC=CC=C2C=C1)CC1=CC=CO1 PBEFRUYCPAVLKC-UHFFFAOYSA-N 0.000 description 2
- RRXXNJUOZDYSKF-UHFFFAOYSA-N CN1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1 Chemical compound CN1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1 RRXXNJUOZDYSKF-UHFFFAOYSA-N 0.000 description 2
- YFTSLJXUKVTHQL-UHFFFAOYSA-N COC1=C(OC)C=C(C(=O)CCN2CCOCC2)C=C1 Chemical compound COC1=C(OC)C=C(C(=O)CCN2CCOCC2)C=C1 YFTSLJXUKVTHQL-UHFFFAOYSA-N 0.000 description 2
- UGGCHEIUFZXMBE-UHFFFAOYSA-N COC1=CC2=C(C=C1OC)CN(CCC(=O)C1=CC3=C(C=C1)OCC(=O)C3)CC2 Chemical compound COC1=CC2=C(C=C1OC)CN(CCC(=O)C1=CC3=C(C=C1)OCC(=O)C3)CC2 UGGCHEIUFZXMBE-UHFFFAOYSA-N 0.000 description 2
- NCFRAGGYIQFQPU-UHFFFAOYSA-N COC1=CC=CC(C(=O)CCN2CCOCC2)=C1 Chemical compound COC1=CC=CC(C(=O)CCN2CCOCC2)=C1 NCFRAGGYIQFQPU-UHFFFAOYSA-N 0.000 description 2
- NVOKBQBPIVIAGG-UHFFFAOYSA-N Cl.O=C(CCN1CCCC1)C1=CC2=CC=CC=C2C=C1 Chemical compound Cl.O=C(CCN1CCCC1)C1=CC2=CC=CC=C2C=C1 NVOKBQBPIVIAGG-UHFFFAOYSA-N 0.000 description 2
- IICLHZNVXBODBH-UHFFFAOYSA-N O=C(CCN1CC2=C(C=CC=C2)C1)C1=CC2=CC=CC=C2C=C1 Chemical compound O=C(CCN1CC2=C(C=CC=C2)C1)C1=CC2=CC=CC=C2C=C1 IICLHZNVXBODBH-UHFFFAOYSA-N 0.000 description 2
- UWBBWRLNHPZRMJ-UHFFFAOYSA-N O=C(CCN1CCC(CC2=CC=CC=C2)CC1)C1=CC2=CC=CC=C2C=C1 Chemical compound O=C(CCN1CCC(CC2=CC=CC=C2)CC1)C1=CC2=CC=CC=C2C=C1 UWBBWRLNHPZRMJ-UHFFFAOYSA-N 0.000 description 2
- JJXJPQJAYSUUBN-UHFFFAOYSA-N O=C(CCN1CCC2=C(C=CC=C2)C1)C1=CC2=CC=CC=C2C=C1 Chemical compound O=C(CCN1CCC2=C(C=CC=C2)C1)C1=CC2=CC=CC=C2C=C1 JJXJPQJAYSUUBN-UHFFFAOYSA-N 0.000 description 2
- QSBSNIZXCGEQES-QGZVFWFLSA-N O=C(CCN1CCC[C@@H]1CO)C1=CC2=CC=CC=C2C=C1 Chemical compound O=C(CCN1CCC[C@@H]1CO)C1=CC2=CC=CC=C2C=C1 QSBSNIZXCGEQES-QGZVFWFLSA-N 0.000 description 2
- UTWZEAFHTFHBKG-UHFFFAOYSA-N O=C(CCN1CCN(C2=CC=CC=C2)CC1)C1=CC2=CC=CC=C2C=C1 Chemical compound O=C(CCN1CCN(C2=CC=CC=C2)CC1)C1=CC2=CC=CC=C2C=C1 UTWZEAFHTFHBKG-UHFFFAOYSA-N 0.000 description 2
- GXVMCCNFRDEZID-UHFFFAOYSA-N O=C(CCN1CCN(C2=NC=CC=C2)CC1)C1=CC2=CC=CC=C2C=C1 Chemical compound O=C(CCN1CCN(C2=NC=CC=C2)CC1)C1=CC2=CC=CC=C2C=C1 GXVMCCNFRDEZID-UHFFFAOYSA-N 0.000 description 2
- VDTWJHBDTNZYDW-UHFFFAOYSA-N O=C(CCN1CCN(CC2=CC=CC=C2)CC1)C1=CC2=CC=CC=C2C=C1 Chemical compound O=C(CCN1CCN(CC2=CC=CC=C2)CC1)C1=CC2=CC=CC=C2C=C1 VDTWJHBDTNZYDW-UHFFFAOYSA-N 0.000 description 2
- FEWGPLDUEKHOTJ-UHFFFAOYSA-N O=C(CCN1CCN(CC2CCCCC2)CC1)C1=CC2=CC=CC=C2C=C1 Chemical compound O=C(CCN1CCN(CC2CCCCC2)CC1)C1=CC2=CC=CC=C2C=C1 FEWGPLDUEKHOTJ-UHFFFAOYSA-N 0.000 description 2
- RAKOOZFXFOXAOL-UHFFFAOYSA-N O=C(CCN1CCOCC1)/C1=C/C2=C(C=CC=C2)S1 Chemical compound O=C(CCN1CCOCC1)/C1=C/C2=C(C=CC=C2)S1 RAKOOZFXFOXAOL-UHFFFAOYSA-N 0.000 description 2
- FCGMRESDDAEWAS-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC(F)=CC=C1 Chemical compound O=C(CCN1CCOCC1)C1=CC(F)=CC=C1 FCGMRESDDAEWAS-UHFFFAOYSA-N 0.000 description 2
- ZANXDXOHDQRFDA-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC2=CC=CC=C2C=N1 Chemical compound O=C(CCN1CCOCC1)C1=CC2=CC=CC=C2C=N1 ZANXDXOHDQRFDA-UHFFFAOYSA-N 0.000 description 2
- SKWREJXZIHDJSL-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC=C(Cl)C=C1 Chemical compound O=C(CCN1CCOCC1)C1=CC=C(Cl)C=C1 SKWREJXZIHDJSL-UHFFFAOYSA-N 0.000 description 2
- BNQONYIUNLROJE-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CSC2=C1C=CC=C2 Chemical compound O=C(CCN1CCOCC1)C1=CSC2=C1C=CC=C2 BNQONYIUNLROJE-UHFFFAOYSA-N 0.000 description 2
- GBSYJYHELVHMLH-UHFFFAOYSA-N O=C(CCN1CCS(=O)(=O)CC1)C1=CC2=CC=CC=C2C=C1 Chemical compound O=C(CCN1CCS(=O)(=O)CC1)C1=CC2=CC=CC=C2C=C1 GBSYJYHELVHMLH-UHFFFAOYSA-N 0.000 description 2
- NSKWTVJVOJDSIP-UHFFFAOYSA-N OC(CCN1CCOCC1)C1=CC2=CC=CC=C2C=C1 Chemical compound OC(CCN1CCOCC1)C1=CC2=CC=CC=C2C=C1 NSKWTVJVOJDSIP-UHFFFAOYSA-N 0.000 description 2
- YSUAJNKTJCXAPZ-UHFFFAOYSA-N BC1=CC(C(C)=O)=CC=C1.CC(=O)C1=CC(C2=CC(Cl)=NC=C2)=CC=C1.OB(O)C1=CC(Cl)=NC=C1 Chemical compound BC1=CC(C(C)=O)=CC=C1.CC(=O)C1=CC(C2=CC(Cl)=NC=C2)=CC=C1.OB(O)C1=CC(Cl)=NC=C1 YSUAJNKTJCXAPZ-UHFFFAOYSA-N 0.000 description 1
- BNMNVFMWVRRFMR-UHFFFAOYSA-N C.C.C.C.C.C.C.C.C.C.CC(C)(C)C1=CC2=C(C=C1)NC=N2.CC(C)(C)C1=CC2=C(C=CC=C2)C1.CC(C)(C)C1=CC2=CC3=C(C=C2C=C1)C(C(N)=O)=NC3.CC(C)(C)C1=CC2=CC3=C(C=C2C=C1)C(N)=NC3.CC(C)(C)C1=CC2=CC=CN=C2C=C1.CC(C)(C)C1=COC2=C1C=CC=C2.CC(C)(C)C1=NC2=C(C=CC=C2)C1.CC(C)(C)C1=NC2=C(C=CC=C2)O1.CC(C)(C)C1=NC2=C(C=CC=C2)S1.CC(C)N1C=NC2=C1C1=C(C=C2)C=C(C(C)(C)C)C=C1.CN1C=NC2=C1C1=C(C=C2)C=C(C(C)(C)C)C=C1.COC1=CC(C(C)(C)C)=CC(CO)=C1CO Chemical compound C.C.C.C.C.C.C.C.C.C.CC(C)(C)C1=CC2=C(C=C1)NC=N2.CC(C)(C)C1=CC2=C(C=CC=C2)C1.CC(C)(C)C1=CC2=CC3=C(C=C2C=C1)C(C(N)=O)=NC3.CC(C)(C)C1=CC2=CC3=C(C=C2C=C1)C(N)=NC3.CC(C)(C)C1=CC2=CC=CN=C2C=C1.CC(C)(C)C1=COC2=C1C=CC=C2.CC(C)(C)C1=NC2=C(C=CC=C2)C1.CC(C)(C)C1=NC2=C(C=CC=C2)O1.CC(C)(C)C1=NC2=C(C=CC=C2)S1.CC(C)N1C=NC2=C1C1=C(C=C2)C=C(C(C)(C)C)C=C1.CN1C=NC2=C1C1=C(C=C2)C=C(C(C)(C)C)C=C1.COC1=CC(C(C)(C)C)=CC(CO)=C1CO BNMNVFMWVRRFMR-UHFFFAOYSA-N 0.000 description 1
- NAGVEQQQLSXKSP-UHFFFAOYSA-N C.C.C.C.C.C.C.C.C.CC(C)(C)C1=CC2=C(C=C1)N=CC2.CC(C)(C)C1=CC2=C(C=C1)NC=N2.CC(C)(C)C1=CC2=C(C=C1)NN=C2.CC(C)(C)C1=CC2=C(C=C1)OC=N2.CC(C)(C)C1=CC2=C(C=C1)SC=N2.CC(C)(C)C1=CC2=C(C=CC2)C=C1.CC(C)(C)C1=CC2=C(C=CO2)C=C1.CC(C)(C)C1=CC2=C(C=CS2)C=C1.CC(C)(C)C1=CC2=CC(CC3=NNC(=S)S3)=CC=C2C=C1.CC(C)(C)C1=CC2=CC=C(C(N)=O)C=C2C=C1.CC(C)(C)N1C=CC2=C1C=CC=C2.COC1=CC(C(C)(C)C)=CC2=C1CNC(=O)N2C1=CC=CC=C1.COC1=CC(C(C)(C)C)=CC2=C1OCC(=O)C2 Chemical compound C.C.C.C.C.C.C.C.C.CC(C)(C)C1=CC2=C(C=C1)N=CC2.CC(C)(C)C1=CC2=C(C=C1)NC=N2.CC(C)(C)C1=CC2=C(C=C1)NN=C2.CC(C)(C)C1=CC2=C(C=C1)OC=N2.CC(C)(C)C1=CC2=C(C=C1)SC=N2.CC(C)(C)C1=CC2=C(C=CC2)C=C1.CC(C)(C)C1=CC2=C(C=CO2)C=C1.CC(C)(C)C1=CC2=C(C=CS2)C=C1.CC(C)(C)C1=CC2=CC(CC3=NNC(=S)S3)=CC=C2C=C1.CC(C)(C)C1=CC2=CC=C(C(N)=O)C=C2C=C1.CC(C)(C)N1C=CC2=C1C=CC=C2.COC1=CC(C(C)(C)C)=CC2=C1CNC(=O)N2C1=CC=CC=C1.COC1=CC(C(C)(C)C)=CC2=C1OCC(=O)C2 NAGVEQQQLSXKSP-UHFFFAOYSA-N 0.000 description 1
- YGLVKHULBXAUSG-TWEDJNSPSA-N C.C.C.C.C.C.C=C(N1CCC(CNCCC(=O)C2=CC3=CC=CC=C3C=C2)CC1)C(F)(F)F.CC(C)(C)NC(=O)N1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1.CN(C)C[C@@H]1CCCN1CCC(=O)C1=CC2=CC=CC=C2C=C1.CN(C)C[C@H]1CCCN1CCC(=O)C1=CC2=CC=CC=C2C=C1.CNC(=O)[C@H]1CCCN1CCC(=O)C1=CC2=CC=CC=C2C=C1.O=C(CCN1CCC[C@@H]1C(=O)O)C1=CC2=CC=CC=C2C=C1.O=C(CCN1CCC[C@H]1CO)C1=CC2=CC=CC=C2C=C1 Chemical compound C.C.C.C.C.C.C=C(N1CCC(CNCCC(=O)C2=CC3=CC=CC=C3C=C2)CC1)C(F)(F)F.CC(C)(C)NC(=O)N1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1.CN(C)C[C@@H]1CCCN1CCC(=O)C1=CC2=CC=CC=C2C=C1.CN(C)C[C@H]1CCCN1CCC(=O)C1=CC2=CC=CC=C2C=C1.CNC(=O)[C@H]1CCCN1CCC(=O)C1=CC2=CC=CC=C2C=C1.O=C(CCN1CCC[C@@H]1C(=O)O)C1=CC2=CC=CC=C2C=C1.O=C(CCN1CCC[C@H]1CO)C1=CC2=CC=CC=C2C=C1 YGLVKHULBXAUSG-TWEDJNSPSA-N 0.000 description 1
- BXJXHUFBORBGRX-UHFFFAOYSA-N C.C.C.C.C.C.CC(C)(C)C1=CC2=CC=C(NC(N)=O)C=C2C=C1.CC(C)(C)C1=CC2=CC=C(NC3=NC=CC=C3)C=C2C=C1.CC(C)(C)C1=CC2=CC=C(NC3=NNC(=O)N3)C=C2C=C1.CC(C)(C)C1=CC2=CC=C(NC3=NNC(=S)S3)C=C2C=C1.CN1C=NC(C(N)=O)=C1C1=CC=C(C(C)(C)C)C=C1.CSC1=NC(NC2=CC=C3C=C(C(C)(C)C)C=CC3=C2)=NN1 Chemical compound C.C.C.C.C.C.CC(C)(C)C1=CC2=CC=C(NC(N)=O)C=C2C=C1.CC(C)(C)C1=CC2=CC=C(NC3=NC=CC=C3)C=C2C=C1.CC(C)(C)C1=CC2=CC=C(NC3=NNC(=O)N3)C=C2C=C1.CC(C)(C)C1=CC2=CC=C(NC3=NNC(=S)S3)C=C2C=C1.CN1C=NC(C(N)=O)=C1C1=CC=C(C(C)(C)C)C=C1.CSC1=NC(NC2=CC=C3C=C(C(C)(C)C)C=CC3=C2)=NN1 BXJXHUFBORBGRX-UHFFFAOYSA-N 0.000 description 1
- BIDWXCBXNLOCQP-PPCZFRGFSA-N C.C.C.C.C.C=C(N1CCCCC1)N1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1.C=S1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1.CC1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1.CCOC(=O)N1CCC(CNCCC(=O)C2=CC3=CC=CC=C3C=C2)CC1.CCOC(=O)NCC1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1.CNC(=O)[C@@H]1CCCN1CCC(=O)C1=CC2=CC=CC=C2C=C1.O=C(CCN1CCC[C@H]1C(=O)O)C1=CC2=CC=CC=C2C=C1 Chemical compound C.C.C.C.C.C=C(N1CCCCC1)N1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1.C=S1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1.CC1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1.CCOC(=O)N1CCC(CNCCC(=O)C2=CC3=CC=CC=C3C=C2)CC1.CCOC(=O)NCC1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1.CNC(=O)[C@@H]1CCCN1CCC(=O)C1=CC2=CC=CC=C2C=C1.O=C(CCN1CCC[C@H]1C(=O)O)C1=CC2=CC=CC=C2C=C1 BIDWXCBXNLOCQP-PPCZFRGFSA-N 0.000 description 1
- FYGSGVXMYVSFDT-UHFFFAOYSA-N C.C.C.CN(C)C1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1.O=C(CCN1CCC(C2=CC=CC=N2)C1)C1=CC2=CC=CC=C2C=C1.O=C(CCN1CCN(CC2=NC=CC=C2)CC1)C1=CC2=CC=CC=C2C=C1 Chemical compound C.C.C.CN(C)C1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1.O=C(CCN1CCC(C2=CC=CC=N2)C1)C1=CC2=CC=CC=C2C=C1.O=C(CCN1CCN(CC2=NC=CC=C2)CC1)C1=CC2=CC=CC=C2C=C1 FYGSGVXMYVSFDT-UHFFFAOYSA-N 0.000 description 1
- NVPMHSOUWHRAHR-UHFFFAOYSA-N C.C.C=C(C1=CC=NC=C1)C(C)(C)C.C=C(CCC(C)(C)C)C(F)(F)F.C=C(CCC(C)(C)C)C1=CC=NC=C1.C=C(N1CCOCC1)C(C)(C)C.CC(C)(C)CC1=CC=CO1 Chemical compound C.C.C=C(C1=CC=NC=C1)C(C)(C)C.C=C(CCC(C)(C)C)C(F)(F)F.C=C(CCC(C)(C)C)C1=CC=NC=C1.C=C(N1CCOCC1)C(C)(C)C.CC(C)(C)CC1=CC=CO1 NVPMHSOUWHRAHR-UHFFFAOYSA-N 0.000 description 1
- CLLBZOHOHUSUNV-UHFFFAOYSA-N C.C.CC(C)(C)N1CCCC1.CC(C)(C)N1CCCCC1 Chemical compound C.C.CC(C)(C)N1CCCC1.CC(C)(C)N1CCCCC1 CLLBZOHOHUSUNV-UHFFFAOYSA-N 0.000 description 1
- SJLSXFVPXUZJHS-UHFFFAOYSA-N C.C=C(N)C1=C(C(C)(C)C)N(C(C)C)C=N1.C=C(N)C1=C(C(C)(C)C)N(C)C=N1.C=C(N)C1=NNC(C(C)C)=C1C(C)(C)C.C=C(N)C1=NNC(C)=C1C(C)(C)C.CC(C)(C)C1=CNC2=C1C=CN=C2 Chemical compound C.C=C(N)C1=C(C(C)(C)C)N(C(C)C)C=N1.C=C(N)C1=C(C(C)(C)C)N(C)C=N1.C=C(N)C1=NNC(C(C)C)=C1C(C)(C)C.C=C(N)C1=NNC(C)=C1C(C)(C)C.CC(C)(C)C1=CNC2=C1C=CN=C2 SJLSXFVPXUZJHS-UHFFFAOYSA-N 0.000 description 1
- PNBLCQSCFFXJNG-UHFFFAOYSA-N C.C=C(N1CCC(CNCCC(=O)C2=CC3=CC=CC=C3C=C2)CC1)C(F)(F)F.CC(C)C1=C(C2=CC=C(C(=O)CCN3CCCCC3)C=C2)C(C(N)=O)=NN1.CCOC(=O)N1CCC(CNCCC(=O)C2=CC3=CC=CC=C3C=C2)CC1.O=C(CCN1CCCCC1)C1=CC2=CC=C(NC3=NC=CC=C3)C=C2C=C1 Chemical compound C.C=C(N1CCC(CNCCC(=O)C2=CC3=CC=CC=C3C=C2)CC1)C(F)(F)F.CC(C)C1=C(C2=CC=C(C(=O)CCN3CCCCC3)C=C2)C(C(N)=O)=NN1.CCOC(=O)N1CCC(CNCCC(=O)C2=CC3=CC=CC=C3C=C2)CC1.O=C(CCN1CCCCC1)C1=CC2=CC=C(NC3=NC=CC=C3)C=C2C=C1 PNBLCQSCFFXJNG-UHFFFAOYSA-N 0.000 description 1
- KHPXKGCKSDNVHL-UHFFFAOYSA-N C.CC(=O)NC1=NC(C2=CC=C(C(C)(C)C)N2)=CC=N1 Chemical compound C.CC(=O)NC1=NC(C2=CC=C(C(C)(C)C)N2)=CC=N1 KHPXKGCKSDNVHL-UHFFFAOYSA-N 0.000 description 1
- ZOYUBLMZVXTIHJ-UHFFFAOYSA-N C.CC1=CC=C(C(=O)C(C)CN2CCCCC2)C=C1 Chemical compound C.CC1=CC=C(C(=O)C(C)CN2CCCCC2)C=C1 ZOYUBLMZVXTIHJ-UHFFFAOYSA-N 0.000 description 1
- KYGJPGADMYQDAB-UHFFFAOYSA-N C.O=C1C2=CC3=CC=CC=C3C=C2NC1CN1CCCCC1.O=C1C2=CC3=CC=CC=C3C=C2OC1CN1CCCCC1.O=C1C2=CC3=CC=CC=C3C=C2SC1CN1CCCCC1 Chemical compound C.O=C1C2=CC3=CC=CC=C3C=C2NC1CN1CCCCC1.O=C1C2=CC3=CC=CC=C3C=C2OC1CN1CCCCC1.O=C1C2=CC3=CC=CC=C3C=C2SC1CN1CCCCC1 KYGJPGADMYQDAB-UHFFFAOYSA-N 0.000 description 1
- DRJAMAPQRUFQRI-UHFFFAOYSA-N C.O=C1C2=CC3=CC=CC=C3C=C2NCC1CN1CCCCC1.O=C1C2=CC3=CC=CC=C3C=C2OCC1CN1CCCCC1.O=C1C2=CC3=CC=CC=C3C=C2SCC1CN1CCCCC1 Chemical compound C.O=C1C2=CC3=CC=CC=C3C=C2NCC1CN1CCCCC1.O=C1C2=CC3=CC=CC=C3C=C2OCC1CN1CCCCC1.O=C1C2=CC3=CC=CC=C3C=C2SCC1CN1CCCCC1 DRJAMAPQRUFQRI-UHFFFAOYSA-N 0.000 description 1
- STEWBVBHJYSWEX-UHFFFAOYSA-N C1=CC2=C(C=C1)NC=C2.C1=CC2=C(C=C1)NN=C2.C1=CC2=CC=NC=C2C=C1.C1=CC=C2N=CCC2=C1.C1=CC=C2OC=CC2=C1.C1=CC=C2SC=CC2=C1.C1=CN=C2C=CC=CC2=C1.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C Chemical compound C1=CC2=C(C=C1)NC=C2.C1=CC2=C(C=C1)NN=C2.C1=CC2=CC=NC=C2C=C1.C1=CC=C2N=CCC2=C1.C1=CC=C2OC=CC2=C1.C1=CC=C2SC=CC2=C1.C1=CN=C2C=CC=CC2=C1.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C STEWBVBHJYSWEX-UHFFFAOYSA-N 0.000 description 1
- YBAMWTHRKZYAPN-UHFFFAOYSA-N C1=CN=C2NC=CC2=C1.[O-][N+]1=C2NC=CC2=CC=C1 Chemical compound C1=CN=C2NC=CC2=C1.[O-][N+]1=C2NC=CC2=CC=C1 YBAMWTHRKZYAPN-UHFFFAOYSA-N 0.000 description 1
- LJWWFVNWDABBBC-UHFFFAOYSA-N C=CC(=O)C1=CC2=CC=CC=C2C=C1.C=CC(O)C1=CC2=CC=CC=C2C=C1 Chemical compound C=CC(=O)C1=CC2=CC=CC=C2C=C1.C=CC(O)C1=CC2=CC=CC=C2C=C1 LJWWFVNWDABBBC-UHFFFAOYSA-N 0.000 description 1
- PVFJXXPBSBLSIG-UHFFFAOYSA-N C=CC(O)C1=CC2=CC=CC=C2C=C1.[H]C(=O)C1=CC2=CC=CC=C2C=C1 Chemical compound C=CC(O)C1=CC2=CC=CC=C2C=C1.[H]C(=O)C1=CC2=CC=CC=C2C=C1 PVFJXXPBSBLSIG-UHFFFAOYSA-N 0.000 description 1
- ZOPSTPDTJFOJPT-UHFFFAOYSA-N CC(=O)C(C)CN1CCCC1 Chemical compound CC(=O)C(C)CN1CCCC1 ZOPSTPDTJFOJPT-UHFFFAOYSA-N 0.000 description 1
- MYCYNNJHNKKXSP-UHFFFAOYSA-N CC(=O)C1=CC=C(B(O)O)C=C1.CC(=O)C1=CC=C(C2=C3C=CNC3=NC=C2)C=C1.ClC1=C2C=[C+]NC2=NC=C1 Chemical compound CC(=O)C1=CC=C(B(O)O)C=C1.CC(=O)C1=CC=C(C2=C3C=CNC3=NC=C2)C=C1.ClC1=C2C=[C+]NC2=NC=C1 MYCYNNJHNKKXSP-UHFFFAOYSA-N 0.000 description 1
- ZOZAGQDATKACCL-UHFFFAOYSA-N CC(=O)C1=CC=CC(C2=CC(Cl)=NC=C2)=C1.CC(=O)C1=CC=CC(C2=CC(NC(=O)C3=CC=CC=C3)=NC=C2)=C1 Chemical compound CC(=O)C1=CC=CC(C2=CC(Cl)=NC=C2)=C1.CC(=O)C1=CC=CC(C2=CC(NC(=O)C3=CC=CC=C3)=NC=C2)=C1 ZOZAGQDATKACCL-UHFFFAOYSA-N 0.000 description 1
- KRBPMFUGXQQZFZ-UHFFFAOYSA-N CC(=O)C1=CC=CC(C2=CC=NC(Cl)=C2)=C1.CC(=O)C1=CC=CC(C2=CC=NC(NC(=O)C3=CC=C(C(C)(C)C)C=C3)=C2)=C1 Chemical compound CC(=O)C1=CC=CC(C2=CC=NC(Cl)=C2)=C1.CC(=O)C1=CC=CC(C2=CC=NC(NC(=O)C3=CC=C(C(C)(C)C)C=C3)=C2)=C1 KRBPMFUGXQQZFZ-UHFFFAOYSA-N 0.000 description 1
- VSOWVTNWFKKKQL-UHFFFAOYSA-N CC(=O)C1=CC=CC(C2=CC=NC(Cl)=C2)=C1.CC(=O)NC1=CC(C2=CC(C(C)=O)=CC=C2)=CC=N1 Chemical compound CC(=O)C1=CC=CC(C2=CC=NC(Cl)=C2)=C1.CC(=O)NC1=CC(C2=CC(C(C)=O)=CC=C2)=CC=N1 VSOWVTNWFKKKQL-UHFFFAOYSA-N 0.000 description 1
- UZVUHNJAANDTGV-UHFFFAOYSA-N CC(=O)C1=CC=CC(C2=CC=NC(NC(=O)C3=CC=C(C(C)(C)C)C=C3)=C2)=C1.CC(C)(C)C1=CC=C(C(=O)NC2=CC(C3=CC(C(=O)CCN4CCOCC4)=CC=C3)=CC=N2)C=C1 Chemical compound CC(=O)C1=CC=CC(C2=CC=NC(NC(=O)C3=CC=C(C(C)(C)C)C=C3)=C2)=C1.CC(C)(C)C1=CC=C(C(=O)NC2=CC(C3=CC(C(=O)CCN4CCOCC4)=CC=C3)=CC=N2)C=C1 UZVUHNJAANDTGV-UHFFFAOYSA-N 0.000 description 1
- JVXLKJBJRZVRAD-UHFFFAOYSA-N CC(=O)C1=CC=CC(C2=CC=NC(NC(=O)C3=CC=CC=C3)=C2)=C1.O=C(CCN1CCOCC1)C1=CC=CC(C2=CC=NC(NC(=O)C3=CC=CC=C3)=C2)=C1 Chemical compound CC(=O)C1=CC=CC(C2=CC=NC(NC(=O)C3=CC=CC=C3)=C2)=C1.O=C(CCN1CCOCC1)C1=CC=CC(C2=CC=NC(NC(=O)C3=CC=CC=C3)=C2)=C1 JVXLKJBJRZVRAD-UHFFFAOYSA-N 0.000 description 1
- CHNACVYWMMAFQX-UHFFFAOYSA-N CC(=O)CC1=CC=CC(C(=O)CCN2CCCCC2)=C1.CC(CN1CCCCC1)C(=O)C1=CC=C(F)C=C1.CC1=CC=C(C(=O)CCN2CCCCC2)C=C1.CCCC(CN1CCCCC1)C(=O)C1=CC=C(F)C=C1.CN(C)C1=CC=CC(C(=O)CCN2CCCCC2)=C1.COC1=C(OC)C=C(C(=O)CCN2CCCCC2)C=C1.COC1=CC=C(C(=O)CCN2CCCCC2)C=C1.O=C(CCN1CCCCC1)C1=C(Cl)C=CC=C1Cl.O=C(CCN1CCCCC1)C1=CC(F)=C(F)C=C1 Chemical compound CC(=O)CC1=CC=CC(C(=O)CCN2CCCCC2)=C1.CC(CN1CCCCC1)C(=O)C1=CC=C(F)C=C1.CC1=CC=C(C(=O)CCN2CCCCC2)C=C1.CCCC(CN1CCCCC1)C(=O)C1=CC=C(F)C=C1.CN(C)C1=CC=CC(C(=O)CCN2CCCCC2)=C1.COC1=C(OC)C=C(C(=O)CCN2CCCCC2)C=C1.COC1=CC=C(C(=O)CCN2CCCCC2)C=C1.O=C(CCN1CCCCC1)C1=C(Cl)C=CC=C1Cl.O=C(CCN1CCCCC1)C1=CC(F)=C(F)C=C1 CHNACVYWMMAFQX-UHFFFAOYSA-N 0.000 description 1
- HMKKDPDYSJDQNF-UHFFFAOYSA-N CC(=O)CC1=CC=CC(C(=O)CCN2CCOCC2)=C1 Chemical compound CC(=O)CC1=CC=CC(C(=O)CCN2CCOCC2)=C1 HMKKDPDYSJDQNF-UHFFFAOYSA-N 0.000 description 1
- BTSLFXJMPNGLJS-UHFFFAOYSA-N CC(=O)CCN1CCC(C(C2=CC=CC=C2)C2=CC=CC=C2)CC1 Chemical compound CC(=O)CCN1CCC(C(C2=CC=CC=C2)C2=CC=CC=C2)CC1 BTSLFXJMPNGLJS-UHFFFAOYSA-N 0.000 description 1
- YTGBEYRPLWLWQE-UHFFFAOYSA-N CC(=O)N1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1 Chemical compound CC(=O)N1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1 YTGBEYRPLWLWQE-UHFFFAOYSA-N 0.000 description 1
- PMRSREXIPORWJF-UHFFFAOYSA-N CC(=O)NC1=CC(C2=CC(C(=O)CCN3CCOCC3)=CC=C2)=CC=N1.CC(=O)NC1=CC(C2=CC(C(C)=O)=CC=C2)=CC=N1 Chemical compound CC(=O)NC1=CC(C2=CC(C(=O)CCN3CCOCC3)=CC=C2)=CC=N1.CC(=O)NC1=CC(C2=CC(C(C)=O)=CC=C2)=CC=N1 PMRSREXIPORWJF-UHFFFAOYSA-N 0.000 description 1
- CBUMNOQNJKRPPG-UHFFFAOYSA-N CC(=O)NC1=NC(C2=CC=C(C(=O)CCN3CCCCC3)N2)=CC=N1.CC(C)(CC(=O)C1=CC2=C(C=CC=C2)C=C1)N1CCCCC1.CC(CC(=O)C1=CC2=C(C=CC=C2)C=C1)N1CCCCC1.CC(CN1CCCCC1)C(=O)C1=CC2=C(C=CC=C2)C=C1.O=C(CCN1CCCCC1)C1=CC2=C(C=CC=N2)C=C1.O=C(CCN1CCCCC1)C1=CC2=C(C=CN=C2)C=C1.O=C(CCN1CCCCC1)C1=CC2=CC=C3NN=CC3=C2C=C1.O=C1CC2=C(C=C3C=C(C(=O)CCN4CCCCC4)C=CC3=C2)C1 Chemical compound CC(=O)NC1=NC(C2=CC=C(C(=O)CCN3CCCCC3)N2)=CC=N1.CC(C)(CC(=O)C1=CC2=C(C=CC=C2)C=C1)N1CCCCC1.CC(CC(=O)C1=CC2=C(C=CC=C2)C=C1)N1CCCCC1.CC(CN1CCCCC1)C(=O)C1=CC2=C(C=CC=C2)C=C1.O=C(CCN1CCCCC1)C1=CC2=C(C=CC=N2)C=C1.O=C(CCN1CCCCC1)C1=CC2=C(C=CN=C2)C=C1.O=C(CCN1CCCCC1)C1=CC2=CC=C3NN=CC3=C2C=C1.O=C1CC2=C(C=C3C=C(C(=O)CCN4CCCCC4)C=CC3=C2)C1 CBUMNOQNJKRPPG-UHFFFAOYSA-N 0.000 description 1
- OECPUBRNDKXFDX-UHFFFAOYSA-N CC(C)(C)C(=O)C1=CC=CC=C1 Chemical compound CC(C)(C)C(=O)C1=CC=CC=C1 OECPUBRNDKXFDX-UHFFFAOYSA-N 0.000 description 1
- GFUOTJRIWCNCCB-UHFFFAOYSA-N CC(C)(C)C(=O)N1CCCCC1 Chemical compound CC(C)(C)C(=O)N1CCCCC1 GFUOTJRIWCNCCB-UHFFFAOYSA-N 0.000 description 1
- OHVPXJUKPUEMAF-UHFFFAOYSA-N CC(C)(C)C(=O)N1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1 Chemical compound CC(C)(C)C(=O)N1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1 OHVPXJUKPUEMAF-UHFFFAOYSA-N 0.000 description 1
- VNMQJWPTYZPZDM-UHFFFAOYSA-N CC(C)(C)C1=CC2=C(C=CN2)C=C1 Chemical compound CC(C)(C)C1=CC2=C(C=CN2)C=C1 VNMQJWPTYZPZDM-UHFFFAOYSA-N 0.000 description 1
- OXBYCLNRPDBKFL-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C(=O)CC2=CC(C3=CC=CC(C(=O)N4CCOCC4)=C3)=CC=N2)C=C1.O=C(CC1=CC(C2=CC=CC(C(=O)N3CCOCC3)=C2)=CC=N1)C1=CC=CC=C1 Chemical compound CC(C)(C)C1=CC=C(C(=O)CC2=CC(C3=CC=CC(C(=O)N4CCOCC4)=C3)=CC=N2)C=C1.O=C(CC1=CC(C2=CC=CC(C(=O)N3CCOCC3)=C2)=CC=N1)C1=CC=CC=C1 OXBYCLNRPDBKFL-UHFFFAOYSA-N 0.000 description 1
- YUDOGIIXJVQHJA-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C(=O)CCN2CCCCC2)C=C1.CC(C)(CN1CCCCC1)C(=O)C1=CC=CC=C1.CCOC1=CC=CC=C1C(=O)CCN1CCCCC1.O=C(CCN1CCCCC1)C1=C(F)C=CC=C1F.O=C(CCN1CCCCC1)C1=CC=CC=C1 Chemical compound CC(C)(C)C1=CC=C(C(=O)CCN2CCCCC2)C=C1.CC(C)(CN1CCCCC1)C(=O)C1=CC=CC=C1.CCOC1=CC=CC=C1C(=O)CCN1CCCCC1.O=C(CCN1CCCCC1)C1=C(F)C=CC=C1F.O=C(CCN1CCCCC1)C1=CC=CC=C1 YUDOGIIXJVQHJA-UHFFFAOYSA-N 0.000 description 1
- PRUSFXWFJCMTTB-UHFFFAOYSA-N CC(C)(C)N1CCC(C[Ar])CC1.CCN1CCN(C(C)(C)C)CC1 Chemical compound CC(C)(C)N1CCC(C[Ar])CC1.CCN1CCN(C(C)(C)C)CC1 PRUSFXWFJCMTTB-UHFFFAOYSA-N 0.000 description 1
- AWUWFILTMXVLSK-UHFFFAOYSA-N CC(C)(C)N1CCCC1.CC(C)(C)N1CCCCC1.CC(C)(C)N1CCCCCC1 Chemical compound CC(C)(C)N1CCCC1.CC(C)(C)N1CCCCC1.CC(C)(C)N1CCCCCC1 AWUWFILTMXVLSK-UHFFFAOYSA-N 0.000 description 1
- QGSYZVXUQSFRLA-UHFFFAOYSA-N CC(C)(C)N1CCCCCC1 Chemical compound CC(C)(C)N1CCCCCC1 QGSYZVXUQSFRLA-UHFFFAOYSA-N 0.000 description 1
- HTOXBXOZWFLHMX-UHFFFAOYSA-N CC(C)(CN1CCCCC1)C(=O)C1=CC2=CC=CC=C2C=C1 Chemical compound CC(C)(CN1CCCCC1)C(=O)C1=CC2=CC=CC=C2C=C1 HTOXBXOZWFLHMX-UHFFFAOYSA-N 0.000 description 1
- FWAHHZDINBQVGO-UHFFFAOYSA-N CC(C)C1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)C1 Chemical compound CC(C)C1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)C1 FWAHHZDINBQVGO-UHFFFAOYSA-N 0.000 description 1
- JRILINWMCCWRDR-UHFFFAOYSA-N CC(C)C1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1 Chemical compound CC(C)C1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1 JRILINWMCCWRDR-UHFFFAOYSA-N 0.000 description 1
- FFLZJYYKJWMKDW-UHFFFAOYSA-N CC(C)CN(C)CCC(=O)C1=CC2=CC=CC=C2C=C1 Chemical compound CC(C)CN(C)CCC(=O)C1=CC2=CC=CC=C2C=C1 FFLZJYYKJWMKDW-UHFFFAOYSA-N 0.000 description 1
- FDCJGFQVAXHMID-UHFFFAOYSA-N CC(C)N(CCC(=O)C1=CC2=C(C=C1)OCC(=O)C2)C(C)C Chemical compound CC(C)N(CCC(=O)C1=CC2=C(C=C1)OCC(=O)C2)C(C)C FDCJGFQVAXHMID-UHFFFAOYSA-N 0.000 description 1
- SGVDWRQIQXJUDU-UHFFFAOYSA-N CC(C)N1C=NC(C(N)=O)=C1C1=CC=C(C(=O)CCN2CCCCC2)C=C1.CC1=C(C2=CC=C(C(=O)CCN3CCCCC3)C=C2)C(C(N)=O)=NN1.CSC1=NC(NC2=CC=C3C=C(C(=O)CCN4CCCCC4)C=CC3=C2)=NN1.NC(=O)NC1=CC=C2C=C(C(=O)CCN3CCCCC3)C=CC2=C1.O=C(CCN1CCCCC1)C1=CC2=CC(CC3=NNC(=S)S3)=CC=C2C=C1.O=C1NN=C(NC2=CC=C3C=C(C(=O)CCN4CCCCC4)C=CC3=C2)N1 Chemical compound CC(C)N1C=NC(C(N)=O)=C1C1=CC=C(C(=O)CCN2CCCCC2)C=C1.CC1=C(C2=CC=C(C(=O)CCN3CCCCC3)C=C2)C(C(N)=O)=NN1.CSC1=NC(NC2=CC=C3C=C(C(=O)CCN4CCCCC4)C=CC3=C2)=NN1.NC(=O)NC1=CC=C2C=C(C(=O)CCN3CCCCC3)C=CC2=C1.O=C(CCN1CCCCC1)C1=CC2=CC(CC3=NNC(=S)S3)=CC=C2C=C1.O=C1NN=C(NC2=CC=C3C=C(C(=O)CCN4CCCCC4)C=CC3=C2)N1 SGVDWRQIQXJUDU-UHFFFAOYSA-N 0.000 description 1
- CXCDMVALSNBCSJ-UHFFFAOYSA-N CC(C)N1C=NC2=C1C1=C(C=C2)C=C(C(=O)CCN2CCCCC2)C=C1.COC1=CC(C(=O)CCN2CCCCC2)=CC2=C1OCC(=O)C2.O=C(CCN1CCCCC1)/C1=N/C2=C(C=CC=C2)O1.O=C(CCN1CCCCC1)/C1=N/C2=C(C=CC=C2)S1.O=C(CCN1CCCCC1)C1=CC2=C(C=C1)NC=N2.O=C(CCN1CCCCC1)C1=CC2=CC=C(NC3=NNC(=S)S3)C=C2C=C1.O=C(CCN1CCCCC1)C1=COC2=C1C=CC=C2 Chemical compound CC(C)N1C=NC2=C1C1=C(C=C2)C=C(C(=O)CCN2CCCCC2)C=C1.COC1=CC(C(=O)CCN2CCCCC2)=CC2=C1OCC(=O)C2.O=C(CCN1CCCCC1)/C1=N/C2=C(C=CC=C2)O1.O=C(CCN1CCCCC1)/C1=N/C2=C(C=CC=C2)S1.O=C(CCN1CCCCC1)C1=CC2=C(C=C1)NC=N2.O=C(CCN1CCCCC1)C1=CC2=CC=C(NC3=NNC(=S)S3)C=C2C=C1.O=C(CCN1CCCCC1)C1=COC2=C1C=CC=C2 CXCDMVALSNBCSJ-UHFFFAOYSA-N 0.000 description 1
- UCWSUWIBONHDBW-UHFFFAOYSA-N CC(C)N1CC[O](CC(C)(C)N2CCCCCC2)CC1 Chemical compound CC(C)N1CC[O](CC(C)(C)N2CCCCCC2)CC1 UCWSUWIBONHDBW-UHFFFAOYSA-N 0.000 description 1
- POICBNKBRDNEQW-UHFFFAOYSA-N CC(Nc1cc(-c2cccc(C(CCN3CCOCC3)=O)c2)ccn1)=O Chemical compound CC(Nc1cc(-c2cccc(C(CCN3CCOCC3)=O)c2)ccn1)=O POICBNKBRDNEQW-UHFFFAOYSA-N 0.000 description 1
- PRJLZLUSJSRFRF-UHFFFAOYSA-N CC(c1cc(-c2ccnc(NC(C)=O)c2)ccc1)=O Chemical compound CC(c1cc(-c2ccnc(NC(C)=O)c2)ccc1)=O PRJLZLUSJSRFRF-UHFFFAOYSA-N 0.000 description 1
- CSFSUMNDUGLDIR-UHFFFAOYSA-N CC.CC.CC(C(=O)C1=CC=CC=C1)C(C)N(C)C Chemical compound CC.CC.CC(C(=O)C1=CC=CC=C1)C(C)N(C)C CSFSUMNDUGLDIR-UHFFFAOYSA-N 0.000 description 1
- WZKMCOJTGXYXGQ-UHFFFAOYSA-N CC.CC.CC.CCC(C)C(=O)C1=CC=CC=C1 Chemical compound CC.CC.CC.CCC(C)C(=O)C1=CC=CC=C1 WZKMCOJTGXYXGQ-UHFFFAOYSA-N 0.000 description 1
- PZFWUQFOQWYXBR-UHFFFAOYSA-N CC.CC1=C(CO)C=CC(C(=O)C(C)CN2CCCC2)=C1C.CC1=C(CO)C=CC(C(=O)C(C)CN2CCCC2)=C1C.O=C(CCN1CCCCC1)C1=CC=C(F)C=C1.O=C(CCN1CCCCC1)C1=CC=C(F)C=C1.O=C1COC2=CC=C(C(=O)CCN3CCCCC3)C=C2C1 Chemical compound CC.CC1=C(CO)C=CC(C(=O)C(C)CN2CCCC2)=C1C.CC1=C(CO)C=CC(C(=O)C(C)CN2CCCC2)=C1C.O=C(CCN1CCCCC1)C1=CC=C(F)C=C1.O=C(CCN1CCCCC1)C1=CC=C(F)C=C1.O=C1COC2=CC=C(C(=O)CCN3CCCCC3)C=C2C1 PZFWUQFOQWYXBR-UHFFFAOYSA-N 0.000 description 1
- HILXPFXAFOMQNA-UHFFFAOYSA-N CC.CN1CCN(CCC(=O)C2=CC=CC=C2)CC1 Chemical compound CC.CN1CCN(CCC(=O)C2=CC=CC=C2)CC1 HILXPFXAFOMQNA-UHFFFAOYSA-N 0.000 description 1
- MTRCOLGJMQUSSF-UHFFFAOYSA-N CC1=C(C)C=C(C(=O)CCN(C)C)C=C1 Chemical compound CC1=C(C)C=C(C(=O)CCN(C)C)C=C1 MTRCOLGJMQUSSF-UHFFFAOYSA-N 0.000 description 1
- FVYLROKCQIVOIO-UHFFFAOYSA-N CC1=C(C)C=C(C(=O)CCN2CCCCC2)C=C1.COC1=CC=C(C(=O)CCN2CCCCC2)C(OC)=C1 Chemical compound CC1=C(C)C=C(C(=O)CCN2CCCCC2)C=C1.COC1=CC=C(C(=O)CCN2CCCCC2)C(OC)=C1 FVYLROKCQIVOIO-UHFFFAOYSA-N 0.000 description 1
- VYRIIMZKRPQICH-UHFFFAOYSA-N CC1=C(C)C=C(C(=O)CCN2CCOCC2)C=C1 Chemical compound CC1=C(C)C=C(C(=O)CCN2CCOCC2)C=C1 VYRIIMZKRPQICH-UHFFFAOYSA-N 0.000 description 1
- UANJFIDLFCSMLJ-UHFFFAOYSA-N CC1=CC(C)=C(C(=O)CCN2CCCCC2)C(C)=C1.CC1=CC=C(C(=O)CCN2CCCCC2)C(C)=C1.CC1=CC=CC(C(=O)CCN2CCCCC2)=C1.CC1=CC=CC=C1C(=O)CCN1CCCCC1.O=C(CCN1CCCCC1)C1=CC(F)=CC=C1.O=C(CCN1CCCCC1)C1=CC(F)=CC=C1F.O=C(CCN1CCCCC1)C1=CC=C(F)C=C1C(F)(F)F.O=C(CCN1CCCCC1)C1=CC=CC=C1C(F)(F)F.O=C(CCN1CCCCC1)C1=CC=CC=C1Cl Chemical compound CC1=CC(C)=C(C(=O)CCN2CCCCC2)C(C)=C1.CC1=CC=C(C(=O)CCN2CCCCC2)C(C)=C1.CC1=CC=CC(C(=O)CCN2CCCCC2)=C1.CC1=CC=CC=C1C(=O)CCN1CCCCC1.O=C(CCN1CCCCC1)C1=CC(F)=CC=C1.O=C(CCN1CCCCC1)C1=CC(F)=CC=C1F.O=C(CCN1CCCCC1)C1=CC=C(F)C=C1C(F)(F)F.O=C(CCN1CCCCC1)C1=CC=CC=C1C(F)(F)F.O=C(CCN1CCCCC1)C1=CC=CC=C1Cl UANJFIDLFCSMLJ-UHFFFAOYSA-N 0.000 description 1
- IHFORVTVAMUVSX-UHFFFAOYSA-N CC1=CC=C(C(=O)CCN2CCC(C)C2)C=C1 Chemical compound CC1=CC=C(C(=O)CCN2CCC(C)C2)C=C1 IHFORVTVAMUVSX-UHFFFAOYSA-N 0.000 description 1
- LGKGZQBYEDXJBZ-UHFFFAOYSA-N CC1=CC=C(C(=O)CCN2CCOCC2)C(C)=C1 Chemical compound CC1=CC=C(C(=O)CCN2CCOCC2)C(C)=C1 LGKGZQBYEDXJBZ-UHFFFAOYSA-N 0.000 description 1
- TWNAFRSZEWFOIS-UHFFFAOYSA-N CC1=CC=CC=C1C(=O)CCN1CCOCC1 Chemical compound CC1=CC=CC=C1C(=O)CCN1CCOCC1 TWNAFRSZEWFOIS-UHFFFAOYSA-N 0.000 description 1
- ZWNFXLPRWRFPFD-UHFFFAOYSA-N CC1CC(C)C(C)N(CC(C)(C)C(=O)[Ar])C1 Chemical compound CC1CC(C)C(C)N(CC(C)(C)C(=O)[Ar])C1 ZWNFXLPRWRFPFD-UHFFFAOYSA-N 0.000 description 1
- YNDHWOGCAGWGKT-UHFFFAOYSA-N CC1CCCN1CCC(=O)C1=CC2=CC=CC=C2C=C1 Chemical compound CC1CCCN1CCC(=O)C1=CC2=CC=CC=C2C=C1 YNDHWOGCAGWGKT-UHFFFAOYSA-N 0.000 description 1
- MMCRZPPNZZQRDX-UHFFFAOYSA-N CCC(=O)C1=CC2=CC=CC=C2C=C1.O=C(CCN1CCCCC1)C1=CC2=CC=CC=C2C=C1 Chemical compound CCC(=O)C1=CC2=CC=CC=C2C=C1.O=C(CCN1CCCCC1)C1=CC2=CC=CC=C2C=C1 MMCRZPPNZZQRDX-UHFFFAOYSA-N 0.000 description 1
- DGZJLMWKIQOQFA-UHFFFAOYSA-N CCC(C)C(=O)C1=CC=CC=C1 Chemical compound CCC(C)C(=O)C1=CC=CC=C1 DGZJLMWKIQOQFA-UHFFFAOYSA-N 0.000 description 1
- ZLYNWOYPRYHKNO-UHFFFAOYSA-N CCCC(=O)C1=CC2=CC=CC=C2S1 Chemical compound CCCC(=O)C1=CC2=CC=CC=C2S1 ZLYNWOYPRYHKNO-UHFFFAOYSA-N 0.000 description 1
- XNLICIUVMPYHGG-UHFFFAOYSA-N CCCC(C)=O Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 1
- XOGNZKXYXCPWES-UHFFFAOYSA-N CCOC1=CC=CC=C1C(=O)CCN1CCOCC1 Chemical compound CCOC1=CC=CC=C1C(=O)CCN1CCOCC1 XOGNZKXYXCPWES-UHFFFAOYSA-N 0.000 description 1
- ONCUCFJJDYWBJN-UHFFFAOYSA-N CCS(=O)(=O)O.CN(C)CCC(=O)[Ar] Chemical compound CCS(=O)(=O)O.CN(C)CCC(=O)[Ar] ONCUCFJJDYWBJN-UHFFFAOYSA-N 0.000 description 1
- MUSPEXFZFFOFJF-UHFFFAOYSA-N CN(C)C(=O)N1CCC(CNCCC(=O)C2=CC3=CC=CC=C3C=C2)CC1 Chemical compound CN(C)C(=O)N1CCC(CNCCC(=O)C2=CC3=CC=CC=C3C=C2)CC1 MUSPEXFZFFOFJF-UHFFFAOYSA-N 0.000 description 1
- MTWFUNSTAUVMAY-UHFFFAOYSA-N CN(C)C(=O)N1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1 Chemical compound CN(C)C(=O)N1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1 MTWFUNSTAUVMAY-UHFFFAOYSA-N 0.000 description 1
- XOABCGGHKYIGKY-UHFFFAOYSA-N CN(C)C1=CC=CC(C(=O)CCN2CCOCC2)=C1 Chemical compound CN(C)C1=CC=CC(C(=O)CCN2CCOCC2)=C1 XOABCGGHKYIGKY-UHFFFAOYSA-N 0.000 description 1
- FMBSWLRLRMOMJX-UHFFFAOYSA-N CN(C)C1CCN(CCC(=O)C2=CC3=C(C=C2)OCC(=O)C3)C1.O=C(CCN1CCOCC1)C1=CC2=C(C=C1)OCCO2 Chemical compound CN(C)C1CCN(CCC(=O)C2=CC3=C(C=C2)OCC(=O)C3)C1.O=C(CCN1CCOCC1)C1=CC2=C(C=C1)OCCO2 FMBSWLRLRMOMJX-UHFFFAOYSA-N 0.000 description 1
- JTWLRWOERDHYSF-UHFFFAOYSA-N CN(C)C1CCN(CCC(=O)C2=CC3=C(C=C2)OCC(=O)C3)CC1 Chemical compound CN(C)C1CCN(CCC(=O)C2=CC3=C(C=C2)OCC(=O)C3)CC1 JTWLRWOERDHYSF-UHFFFAOYSA-N 0.000 description 1
- BLJBXKKWHNCNMZ-UHFFFAOYSA-N CN(C)C1CCN(CCC(=O)C2=CC3CCC(=O)OC3C=C2)CC1 Chemical compound CN(C)C1CCN(CCC(=O)C2=CC3CCC(=O)OC3C=C2)CC1 BLJBXKKWHNCNMZ-UHFFFAOYSA-N 0.000 description 1
- XUSJCEPFESYHJH-UHFFFAOYSA-N CN(C)CCC(=O)C1=CC2=CC=CC=C2S1 Chemical compound CN(C)CCC(=O)C1=CC2=CC=CC=C2S1 XUSJCEPFESYHJH-UHFFFAOYSA-N 0.000 description 1
- QMNXJNURJISYMS-UHFFFAOYSA-N CN(C)CCC(=O)C1=CC=CC=C1 Chemical compound CN(C)CCC(=O)C1=CC=CC=C1 QMNXJNURJISYMS-UHFFFAOYSA-N 0.000 description 1
- NNSCNTCQEYVCJP-UHFFFAOYSA-N CN(C)CCN1CCN(CCC(=O)C2=CC3=C(C=C2)OCC(=O)C3)CC1 Chemical compound CN(C)CCN1CCN(CCC(=O)C2=CC3=C(C=C2)OCC(=O)C3)CC1 NNSCNTCQEYVCJP-UHFFFAOYSA-N 0.000 description 1
- CXBAQVVLFYLGBY-UHFFFAOYSA-N CN(CCC(=O)C1=CC2=C(C=C1)OCC(=O)C2)CC1=CC=C(F)C=C1 Chemical compound CN(CCC(=O)C1=CC2=C(C=C1)OCC(=O)C2)CC1=CC=C(F)C=C1 CXBAQVVLFYLGBY-UHFFFAOYSA-N 0.000 description 1
- OBSJYDIITVBMOP-UHFFFAOYSA-N CN(CCC(=O)C1=CC2=CC=CC=C2C=C1)CC1=CC=C(C(F)(F)F)C=C1 Chemical compound CN(CCC(=O)C1=CC2=CC=CC=C2C=C1)CC1=CC=C(C(F)(F)F)C=C1 OBSJYDIITVBMOP-UHFFFAOYSA-N 0.000 description 1
- RZJPJBIWQTTZQO-UHFFFAOYSA-N CN(CCC(=O)C1=CC2CCC(=O)OC2C=C1)CC1=CC=C(F)C=C1 Chemical compound CN(CCC(=O)C1=CC2CCC(=O)OC2C=C1)CC1=CC=C(F)C=C1 RZJPJBIWQTTZQO-UHFFFAOYSA-N 0.000 description 1
- MFPJMYZOLSBPPG-UHFFFAOYSA-N CN1C=NC2=C1C1=C(C=C2)C=C(C(=O)CCN2CCCCC2)C=C1.NC(=O)C1=NCC2=C1C=C1C=CC(C(=O)CCN3CCCCC3)=CC1=C2.NC(=O)C1=NNC2=CC=C3C=C(C(=O)CCN4CCCCC4)C=CC3=C21.NC1=NCC2=C1C=C1C=CC(C(=O)CCN3CCCCC3)=CC1=C2.O=C(CCN1CCCCC1)/C1=C/C2=C(C=CC=C2)C1.O=C(CCN1CCCCC1)/C1=N/C2=C(C=CC=C2)C1.O=C(CCN1CCCCC1)C1=CC2=C(C=C1)N=CC=C2 Chemical compound CN1C=NC2=C1C1=C(C=C2)C=C(C(=O)CCN2CCCCC2)C=C1.NC(=O)C1=NCC2=C1C=C1C=CC(C(=O)CCN3CCCCC3)=CC1=C2.NC(=O)C1=NNC2=CC=C3C=C(C(=O)CCN4CCCCC4)C=CC3=C21.NC1=NCC2=C1C=C1C=CC(C(=O)CCN3CCCCC3)=CC1=C2.O=C(CCN1CCCCC1)/C1=C/C2=C(C=CC=C2)C1.O=C(CCN1CCCCC1)/C1=N/C2=C(C=CC=C2)C1.O=C(CCN1CCCCC1)C1=CC2=C(C=C1)N=CC=C2 MFPJMYZOLSBPPG-UHFFFAOYSA-N 0.000 description 1
- NICBCNKEJQMVMS-UHFFFAOYSA-N COC1=C(N(=O)=O)C=C(C(=O)CCN2CCOCC2)C=C1 Chemical compound COC1=C(N(=O)=O)C=C(C(=O)CCN2CCOCC2)C=C1 NICBCNKEJQMVMS-UHFFFAOYSA-N 0.000 description 1
- HRYLGHBCGHJIQB-UHFFFAOYSA-N COC1=C(OC)C=C(C(=O)CCN2CCC(N(C)C)CC2)C=C1 Chemical compound COC1=C(OC)C=C(C(=O)CCN2CCC(N(C)C)CC2)C=C1 HRYLGHBCGHJIQB-UHFFFAOYSA-N 0.000 description 1
- PXEARDCYPWLJQU-UHFFFAOYSA-N COC1=CC(C(=O)CCN2CCCCC2)=CC2=C1CNC(=O)N2C1=CC=CC=C1.O=C(CCN1CCCCC1)C1=CC2=C(C=C1)NN=C2 Chemical compound COC1=CC(C(=O)CCN2CCCCC2)=CC2=C1CNC(=O)N2C1=CC=CC=C1.O=C(CCN1CCCCC1)C1=CC2=C(C=C1)NN=C2 PXEARDCYPWLJQU-UHFFFAOYSA-N 0.000 description 1
- REVPMRZZDDRTFT-UHFFFAOYSA-N COC1=CC(C)=CC(OC)=C1C(=O)CCN(C)C Chemical compound COC1=CC(C)=CC(OC)=C1C(=O)CCN(C)C REVPMRZZDDRTFT-UHFFFAOYSA-N 0.000 description 1
- VPBUWBUGIZNXQA-UHFFFAOYSA-N COC1=CC(CO)=CC=C1C(=O)CCN1CCOCC1 Chemical compound COC1=CC(CO)=CC=C1C(=O)CCN1CCOCC1 VPBUWBUGIZNXQA-UHFFFAOYSA-N 0.000 description 1
- MQOKXKLUYMNQBK-UHFFFAOYSA-N COC1=CC(OC)=CC(C(=O)CCN2CCOCC2)=C1 Chemical compound COC1=CC(OC)=CC(C(=O)CCN2CCOCC2)=C1 MQOKXKLUYMNQBK-UHFFFAOYSA-N 0.000 description 1
- MARDRZQLSPCWMG-UHFFFAOYSA-N COC1=CC=C(C(=O)CCN2CCOCC2)C=C1 Chemical compound COC1=CC=C(C(=O)CCN2CCOCC2)C=C1 MARDRZQLSPCWMG-UHFFFAOYSA-N 0.000 description 1
- FTFZJEVFCGHCMH-UHFFFAOYSA-N CS(=O)(=O)C1=CC=C(C(=O)CCN2CCOCC2)C=C1 Chemical compound CS(=O)(=O)C1=CC=C(C(=O)CCN2CCOCC2)C=C1 FTFZJEVFCGHCMH-UHFFFAOYSA-N 0.000 description 1
- DZOQGKVVZJSLMX-UHFFFAOYSA-N ClC1=C2C=CNC2=NC=C1.[O-][N+]1=C2NC=CC2=CC=C1 Chemical compound ClC1=C2C=CNC2=NC=C1.[O-][N+]1=C2NC=CC2=CC=C1 DZOQGKVVZJSLMX-UHFFFAOYSA-N 0.000 description 1
- DMYSGGNPMSDIOW-UHFFFAOYSA-N N#CC1=CC=C(C(=O)CCN2CCOCC2)C=C1 Chemical compound N#CC1=CC=C(C(=O)CCN2CCOCC2)C=C1 DMYSGGNPMSDIOW-UHFFFAOYSA-N 0.000 description 1
- ZWBAFAYYPNTZCV-UHFFFAOYSA-N N#CC1=CC=CC(C(=O)CCN2CCOCC2)=C1 Chemical compound N#CC1=CC=CC(C(=O)CCN2CCOCC2)=C1 ZWBAFAYYPNTZCV-UHFFFAOYSA-N 0.000 description 1
- WWODONSXWRNQNX-JOANWZHQSA-N NC(=O)C1=CC=C2C=C(C(=O)C[C@@H](C3=CC=CC=C3)N3CCCCC3)C=CC2=C1.O=C(CCN1CCCCC1)C1=CC2=C(C=C1)N=CC2.O=C(CCN1CCCCC1)C1=CC2=C(C=C1)NC=N2.O=C(CCN1CCCCC1)C1=CC2=C(C=C1)OC=N2.O=C(CCN1CCCCC1)C1=CC2=C(C=C1)SC=N2.O=C(CCN1CCCCC1)C1=CC2=C(C=CC2)C=C1.O=C(CCN1CCCCC1)C1=CC2=C(C=CO2)C=C1.O=C(CCN1CCCCC1)C1=CC2=C(C=CS2)C=C1.O=C(CCN1CCCCC1)N1C=CC2=C1C=CC=C2 Chemical compound NC(=O)C1=CC=C2C=C(C(=O)C[C@@H](C3=CC=CC=C3)N3CCCCC3)C=CC2=C1.O=C(CCN1CCCCC1)C1=CC2=C(C=C1)N=CC2.O=C(CCN1CCCCC1)C1=CC2=C(C=C1)NC=N2.O=C(CCN1CCCCC1)C1=CC2=C(C=C1)OC=N2.O=C(CCN1CCCCC1)C1=CC2=C(C=C1)SC=N2.O=C(CCN1CCCCC1)C1=CC2=C(C=CC2)C=C1.O=C(CCN1CCCCC1)C1=CC2=C(C=CO2)C=C1.O=C(CCN1CCCCC1)C1=CC2=C(C=CS2)C=C1.O=C(CCN1CCCCC1)N1C=CC2=C1C=CC=C2 WWODONSXWRNQNX-JOANWZHQSA-N 0.000 description 1
- BWJUZSODMBSJHL-UHFFFAOYSA-N NC(=O)N1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1 Chemical compound NC(=O)N1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1 BWJUZSODMBSJHL-UHFFFAOYSA-N 0.000 description 1
- IONCPZZJDUSDRY-UHFFFAOYSA-N NC1=CC(C2=CC(C(=O)CCN3CCOCC3)=CC=C2)=CC=N1.O=C(CCN1CCOCC1)C1=CC=CC(C2=CC=NC(NC(=O)C3=CC=CC=C3)=C2)=C1 Chemical compound NC1=CC(C2=CC(C(=O)CCN3CCOCC3)=CC=C2)=CC=N1.O=C(CCN1CCOCC1)C1=CC=CC(C2=CC=NC(NC(=O)C3=CC=CC=C3)=C2)=C1 IONCPZZJDUSDRY-UHFFFAOYSA-N 0.000 description 1
- HHPBEGQENAWSGK-UHFFFAOYSA-N NCC1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1 Chemical compound NCC1CCN(CCC(=O)C2=CC3=CC=CC=C3C=C2)CC1 HHPBEGQENAWSGK-UHFFFAOYSA-N 0.000 description 1
- NMECVHFFFLYEHY-UHFFFAOYSA-N O=C(CCN1CCC(C(=O)C2=CC=NC=C2)CC1)C1=CC2=CC=CC=C2C=C1 Chemical compound O=C(CCN1CCC(C(=O)C2=CC=NC=C2)CC1)C1=CC2=CC=CC=C2C=C1 NMECVHFFFLYEHY-UHFFFAOYSA-N 0.000 description 1
- ATIWHAUCBKCFSB-UHFFFAOYSA-N O=C(CCN1CCC(C2=CC=CC=C2)C1)C1=CC2=CC=CC=C2C=C1 Chemical compound O=C(CCN1CCC(C2=CC=CC=C2)C1)C1=CC2=CC=CC=C2C=C1 ATIWHAUCBKCFSB-UHFFFAOYSA-N 0.000 description 1
- XURLKQLSXYVBCT-UHFFFAOYSA-N O=C(CCN1CCC(C2=CC=CC=N2)C1)C1=CC2=CC=CC=C2C=C1 Chemical compound O=C(CCN1CCC(C2=CC=CC=N2)C1)C1=CC2=CC=CC=C2C=C1 XURLKQLSXYVBCT-UHFFFAOYSA-N 0.000 description 1
- UYKCVUXMDXPZLS-UHFFFAOYSA-N O=C(CCN1CCC(CNC(=O)C(F)(F)F)CC1)C1=CC2=CC=CC=C2C=C1 Chemical compound O=C(CCN1CCC(CNC(=O)C(F)(F)F)CC1)C1=CC2=CC=CC=C2C=C1 UYKCVUXMDXPZLS-UHFFFAOYSA-N 0.000 description 1
- WOAKYVMSSDJZAW-UHFFFAOYSA-N O=C(CCN1CCCCC1)C1=CC(F)=CC(F)=C1 Chemical compound O=C(CCN1CCCCC1)C1=CC(F)=CC(F)=C1 WOAKYVMSSDJZAW-UHFFFAOYSA-N 0.000 description 1
- SWVZNNNOKMRCOT-UHFFFAOYSA-N O=C(CCN1CCCCC1)C1=CC2=CC=CC=C2C=C1 Chemical compound O=C(CCN1CCCCC1)C1=CC2=CC=CC=C2C=C1 SWVZNNNOKMRCOT-UHFFFAOYSA-N 0.000 description 1
- ULTRNSYDZGYDIO-UHFFFAOYSA-N O=C(CCN1CCCCC1)C1=CC2=CC=CC=C2S1 Chemical compound O=C(CCN1CCCCC1)C1=CC2=CC=CC=C2S1 ULTRNSYDZGYDIO-UHFFFAOYSA-N 0.000 description 1
- GEIVNZMOJNUPGU-UHFFFAOYSA-N O=C(CCN1CCCCNC1)C1=CC2=CC=CC=C2C=C1 Chemical compound O=C(CCN1CCCCNC1)C1=CC2=CC=CC=C2C=C1 GEIVNZMOJNUPGU-UHFFFAOYSA-N 0.000 description 1
- OIEVGDKOEWQVPI-UHFFFAOYSA-N O=C(CCN1CCN(C(=O)C2=CC=NC=C2)CC1)C1=CC2=CC=CC=C2C=C1 Chemical compound O=C(CCN1CCN(C(=O)C2=CC=NC=C2)CC1)C1=CC2=CC=CC=C2C=C1 OIEVGDKOEWQVPI-UHFFFAOYSA-N 0.000 description 1
- JQMGIRDWYBZVDJ-UHFFFAOYSA-N O=C(CCN1CCN(C(=O)N2CCOCC2)CC1)C1=CC2=CC=CC=C2C=C1 Chemical compound O=C(CCN1CCN(C(=O)N2CCOCC2)CC1)C1=CC2=CC=CC=C2C=C1 JQMGIRDWYBZVDJ-UHFFFAOYSA-N 0.000 description 1
- LECOLDAKKOMGIA-UHFFFAOYSA-N O=C(CCN1CCNCC1)C1=CC2=CC=CC=C2C=C1 Chemical compound O=C(CCN1CCNCC1)C1=CC2=CC=CC=C2C=C1 LECOLDAKKOMGIA-UHFFFAOYSA-N 0.000 description 1
- RJCNFBYURMGJJI-UHFFFAOYSA-N O=C(CCN1CCOCC1)/C1=C/C2=C(C=CC=C2)O1 Chemical compound O=C(CCN1CCOCC1)/C1=C/C2=C(C=CC=C2)O1 RJCNFBYURMGJJI-UHFFFAOYSA-N 0.000 description 1
- NCFWAUVCPMRPPT-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=C(Cl)C=CC=C1Cl Chemical compound O=C(CCN1CCOCC1)C1=C(Cl)C=CC=C1Cl NCFWAUVCPMRPPT-UHFFFAOYSA-N 0.000 description 1
- KVAZIHRLKMIGFK-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=C2/C=C\C=C/C2=CC=C1 Chemical compound O=C(CCN1CCOCC1)C1=C2/C=C\C=C/C2=CC=C1 KVAZIHRLKMIGFK-UHFFFAOYSA-N 0.000 description 1
- MEUKWJCCATXJSE-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC(Br)=CC=C1 Chemical compound O=C(CCN1CCOCC1)C1=CC(Br)=CC=C1 MEUKWJCCATXJSE-UHFFFAOYSA-N 0.000 description 1
- RHFCWIPRVBBNHK-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC(Cl)=C(Cl)C=C1 Chemical compound O=C(CCN1CCOCC1)C1=CC(Cl)=C(Cl)C=C1 RHFCWIPRVBBNHK-UHFFFAOYSA-N 0.000 description 1
- WKAYIQAAQWZTIN-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC(Cl)=CC=C1 Chemical compound O=C(CCN1CCOCC1)C1=CC(Cl)=CC=C1 WKAYIQAAQWZTIN-UHFFFAOYSA-N 0.000 description 1
- ZIOQORGANLVOCL-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC(F)=C(F)C=C1 Chemical compound O=C(CCN1CCOCC1)C1=CC(F)=C(F)C=C1 ZIOQORGANLVOCL-UHFFFAOYSA-N 0.000 description 1
- YFCJAGHXKRRLGS-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC(F)=CC=C1Cl Chemical compound O=C(CCN1CCOCC1)C1=CC(F)=CC=C1Cl YFCJAGHXKRRLGS-UHFFFAOYSA-N 0.000 description 1
- XSNBMVWYNCAUJK-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC(F)=CC=C1F Chemical compound O=C(CCN1CCOCC1)C1=CC(F)=CC=C1F XSNBMVWYNCAUJK-UHFFFAOYSA-N 0.000 description 1
- UJCHQWMNWOIWKD-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC(OC2=CC=CC=C2)=CC=C1 Chemical compound O=C(CCN1CCOCC1)C1=CC(OC2=CC=CC=C2)=CC=C1 UJCHQWMNWOIWKD-UHFFFAOYSA-N 0.000 description 1
- WYBQVELTNLULLT-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC2=C(C=C1)OCCO2 Chemical compound O=C(CCN1CCOCC1)C1=CC2=C(C=C1)OCCO2 WYBQVELTNLULLT-UHFFFAOYSA-N 0.000 description 1
- REMDMIQSDWDVGM-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC2=C(C=C1)OCO2 Chemical compound O=C(CCN1CCOCC1)C1=CC2=C(C=C1)OCO2 REMDMIQSDWDVGM-UHFFFAOYSA-N 0.000 description 1
- SDJNGFMKGJCMDL-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC2=C(C=C1)SC=C2 Chemical compound O=C(CCN1CCOCC1)C1=CC2=C(C=C1)SC=C2 SDJNGFMKGJCMDL-UHFFFAOYSA-N 0.000 description 1
- VZWZWLQXLGPSQH-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC2=CC=C(O)C=C2C=C1 Chemical compound O=C(CCN1CCOCC1)C1=CC2=CC=C(O)C=C2C=C1 VZWZWLQXLGPSQH-UHFFFAOYSA-N 0.000 description 1
- WDGBBIVYVRJZEW-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC2=CC=CC=C2N=C1 Chemical compound O=C(CCN1CCOCC1)C1=CC2=CC=CC=C2N=C1 WDGBBIVYVRJZEW-UHFFFAOYSA-N 0.000 description 1
- LEVUOWPKAZBDFW-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC=C(Br)C=C1 Chemical compound O=C(CCN1CCOCC1)C1=CC=C(Br)C=C1 LEVUOWPKAZBDFW-UHFFFAOYSA-N 0.000 description 1
- DLAJKMFWSGZPKV-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC=C(C2=CC=CC=C2)C=C1 Chemical compound O=C(CCN1CCOCC1)C1=CC=C(C2=CC=CC=C2)C=C1 DLAJKMFWSGZPKV-UHFFFAOYSA-N 0.000 description 1
- ONXGOSCHTVEEOI-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC=C(C2=CC=CN=C2)C=C1 Chemical compound O=C(CCN1CCOCC1)C1=CC=C(C2=CC=CN=C2)C=C1 ONXGOSCHTVEEOI-UHFFFAOYSA-N 0.000 description 1
- MJUPPKJLRBZHSB-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC=C(F)C=C1C(F)(F)F Chemical compound O=C(CCN1CCOCC1)C1=CC=C(F)C=C1C(F)(F)F MJUPPKJLRBZHSB-UHFFFAOYSA-N 0.000 description 1
- OQAMFFTUBLQCAJ-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC=C(F)C=C1F Chemical compound O=C(CCN1CCOCC1)C1=CC=C(F)C=C1F OQAMFFTUBLQCAJ-UHFFFAOYSA-N 0.000 description 1
- LVTHVEDYTZKAKV-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC=C(N2CCOCC2)C=C1 Chemical compound O=C(CCN1CCOCC1)C1=CC=C(N2CCOCC2)C=C1 LVTHVEDYTZKAKV-UHFFFAOYSA-N 0.000 description 1
- RRKBXWMEHNUGNQ-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC=C(OC2=CC=CC=C2)C=C1 Chemical compound O=C(CCN1CCOCC1)C1=CC=C(OC2=CC=CC=C2)C=C1 RRKBXWMEHNUGNQ-UHFFFAOYSA-N 0.000 description 1
- GYEHRDKLYZQUCX-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC=CC=C1Br Chemical compound O=C(CCN1CCOCC1)C1=CC=CC=C1Br GYEHRDKLYZQUCX-UHFFFAOYSA-N 0.000 description 1
- GZRWCNRLGJHYIU-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CC=CC=C1C(F)(F)F Chemical compound O=C(CCN1CCOCC1)C1=CC=CC=C1C(F)(F)F GZRWCNRLGJHYIU-UHFFFAOYSA-N 0.000 description 1
- BFOCNRFPIXQHIJ-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=CNC2=C1C=CC=C2 Chemical compound O=C(CCN1CCOCC1)C1=CNC2=C1C=CC=C2 BFOCNRFPIXQHIJ-UHFFFAOYSA-N 0.000 description 1
- NUGSPQSSXGCKKN-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=NC2=CC=CC=C2C=C1 Chemical compound O=C(CCN1CCOCC1)C1=NC2=CC=CC=C2C=C1 NUGSPQSSXGCKKN-UHFFFAOYSA-N 0.000 description 1
- ITWWPHJXIKRIRT-UHFFFAOYSA-N O=C(CCN1CCOCC1)C1=NNC2=C1C=CC=C2 Chemical compound O=C(CCN1CCOCC1)C1=NNC2=C1C=CC=C2 ITWWPHJXIKRIRT-UHFFFAOYSA-N 0.000 description 1
- VTFWYJJVTNRIQQ-UHFFFAOYSA-N O=C(CCN1CCSCC1)C1=CC2=CC=CC=C2C=C1 Chemical compound O=C(CCN1CCSCC1)C1=CC2=CC=CC=C2C=C1 VTFWYJJVTNRIQQ-UHFFFAOYSA-N 0.000 description 1
- OJAOBMWCHHDOCG-UHFFFAOYSA-N O=C(CCNCC1CCN(C(=O)C2=CC=NC=C2)CC1)C1=CC2=CC=CC=C2C=C1 Chemical compound O=C(CCNCC1CCN(C(=O)C2=CC=NC=C2)CC1)C1=CC2=CC=CC=C2C=C1 OJAOBMWCHHDOCG-UHFFFAOYSA-N 0.000 description 1
- RZKLZLPHYPKJBT-UHFFFAOYSA-N O=C(CCNCC1CCNCC1)C1=CC2=CC=CC=C2C=C1 Chemical compound O=C(CCNCC1CCNCC1)C1=CC2=CC=CC=C2C=C1 RZKLZLPHYPKJBT-UHFFFAOYSA-N 0.000 description 1
- CLOCZUZMHSBRJA-UHFFFAOYSA-N O=C(O)C1=CC2=C(C=C1)C=C(C(=O)CCN1CCOCC1)C=C2 Chemical compound O=C(O)C1=CC2=C(C=C1)C=C(C(=O)CCN1CCOCC1)C=C2 CLOCZUZMHSBRJA-UHFFFAOYSA-N 0.000 description 1
- KMZZQQCLQSVTGX-ODHDQMIASA-N O=C1C2=CC3=CC=CC=C3C=C2[2H]C1CN1CCOCC1 Chemical compound O=C1C2=CC3=CC=CC=C3C=C2[2H]C1CN1CCOCC1 KMZZQQCLQSVTGX-ODHDQMIASA-N 0.000 description 1
- VEVVRZZRGWWUAL-ZVDSADNZSA-N O=C1C2=CC3=CC=CC=C3C=C2[2H]CC1CN1CCCCC1 Chemical compound O=C1C2=CC3=CC=CC=C3C=C2[2H]CC1CN1CCCCC1 VEVVRZZRGWWUAL-ZVDSADNZSA-N 0.000 description 1
- FMMKASLLTTYNOS-UHFFFAOYSA-N O=C1CC(N2CCOCC2)C2=CC3=CC=CC=C3C=C12 Chemical compound O=C1CC(N2CCOCC2)C2=CC3=CC=CC=C3C=C12 FMMKASLLTTYNOS-UHFFFAOYSA-N 0.000 description 1
- DEYGKQWKDZWLPG-UHFFFAOYSA-N O=C1CC(N2CCOCC2)C2=CC3=CC=CC=C3C=C12.O=C1NC(N2CCOCC2)C2=CC3=CC=CC=C3C=C12 Chemical compound O=C1CC(N2CCOCC2)C2=CC3=CC=CC=C3C=C12.O=C1NC(N2CCOCC2)C2=CC3=CC=CC=C3C=C12 DEYGKQWKDZWLPG-UHFFFAOYSA-N 0.000 description 1
- OATHPPPMXRHJSY-UHFFFAOYSA-N O=CNC1=CC=C2C=C(C(=O)CCN3CCOCC3)C=CC2=C1 Chemical compound O=CNC1=CC=C2C=C(C(=O)CCN3CCOCC3)C=CC2=C1 OATHPPPMXRHJSY-UHFFFAOYSA-N 0.000 description 1
- WXIYYSTXCVFFNO-MJINNBMQSA-N [3H]C1=C(C(=O)N2CCOCC2)C([U])=C([V])C(C2=C3C=CCC3=NC=C2)=C1[W] Chemical compound [3H]C1=C(C(=O)N2CCOCC2)C([U])=C([V])C(C2=C3C=CCC3=NC=C2)=C1[W] WXIYYSTXCVFFNO-MJINNBMQSA-N 0.000 description 1
- CJXGMKSSGJFNJV-DZRAADDDSA-N [3H]C1=C(C(=O)N2CCOCC2)C([W])=C(C2=CC=NC3=C2C=CC3)C([V])=C1[U] Chemical compound [3H]C1=C(C(=O)N2CCOCC2)C([W])=C(C2=CC=NC3=C2C=CC3)C([V])=C1[U] CJXGMKSSGJFNJV-DZRAADDDSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/54—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/56—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the invention relates to intracellular kinase inhibitors and their therapeutic uses.
- Intracellular kinases play important functions in cells of the immune system.
- interleukin-2 inducible tyrosine kinase ITK plays a key role in T cell development and differentiation; it regulates IL-2 production via phospholipase C ⁇ 1 (PLC ⁇ 1) and nuclear factor of activated T cells (NFAT); it mediates Th2 cell differentiation; and it regulates T cell migration and recruitment to lymphatic organs.
- PLC ⁇ 1 phospholipase C ⁇ 1
- NFAT nuclear factor of activated T cells
- BTK Bruton's tyrosine kinase is involved in signal transduction pathways which regulate growth and differentiation of 13 lymphoid cells.
- BTK also is involved in platelet physiology by regulating the glycoprotein VI/Fc receptor ⁇ chain (GPVI-FcR ⁇ )-coupled collagen receptor signaling pathway.
- inhibitors of intracellular kinases are useful for treating blood cell malignancies, solid tumors and for suppressing the immune system, for example in patients with autoimmune disorders or organ transplants.
- Intracellular kinase inhibitors also are useful for preventing or reducing the risk of thromboembolism.
- FIG. 1 Results of a BIACORE® experiment in which the ITK kinase domain was immobilized on a biosensor and evaluated for its ability to bind and dissociate from a small molecule.
- FIG. 2 Alignment of human ITK (SEQ ID NO:1) and BTK (SEQ ID NO:2).
- FIG. 3 Alignment of kinase domains. Bolded amino acids, hinge; bolded and underlined amino acids, gatekeeper; italicized and bolded amino acids, Cys442 equivalents.
- the invention provides compounds which inhibit intracellular kinases, particularly ITK and BTK, with an IC 50 of 1 ⁇ M or below in an in vitro kinase assay as disclosed herein.
- the invention also provides pharmaceutical compositions and methods of using the compounds therapeutically. Patients who can be treated include those with blood cell malignancies, solid tumors, autoimmune disorders, and transplanted organs.
- the compounds are pyrrolopyridines (e.g., US 2005/0215582).
- the compounds are methyl dimethylbenzoates that belong thiazolyl family of compounds (e.g., US 2004/0077695).
- these published compounds differ from the compounds disclosed herein based on the following parameters: the compounds do not correspond to the general structure shown in this application, do not require the amino acid triad DKC found in the kinase binding site and necessary for optimal compound inhibitory capability described herein, do not undergo elimination, and do not bind covalently to the kinase binding pocket.
- Compounds of the invention which inhibit ITK can be used, e.g., to treat T cell malignancies.
- Preferred compounds of the invention inhibit both ITK and BTK with an IC 50 of 1 ⁇ M or below for each enzyme.
- Such compounds can be used, e.g., to treat both T and B cell malignancies, as well as EGFR or HER positive tumors.
- the Tec family of kinases share a common subunit structure composed of a Src homology domain 2 (SH 2 ), an SH 3 and a catalytic kinase domain. Further, they are uniquely identified by the presence of a Tec homology region (TH) and a pleckstrin homology (PH) domain. There are four known crystallographic structures described for the Tec family of kinases.
- the ITK kinase domain (residues 357-620) can be broken down into two components: the N-terminal lobe (residues 357-437) and the C-terminal lobe (residues 438-620).
- the connecting region between the two lobes is a flexible hinge region described below, that forms part of the catalytic active site.
- the ordered nature of the C-helix places the catalytically important residues of Glu406, Lys391 and Asp500 in an orientation typical of the active form of a protein kinase.
- the Gly-rich loop (residues 362-378), commonly observed in kinases, assumes an extended and open conformation typical of an active kinase.
- the boundaries of the ATP binding site are demarcated by the following residues: (a) the glycine-rich loop (Gly370, Ser371, Gly372, Gln373, Phe374 and Gly375); (b) the hinge region (Phe435, Glu436, Phe437, Met438, Glu439, His440, Gly441 and Cys442); and (c) the catalytic residues Lys391 and Asp500. Additionally, the active site also comprises several other hydrophobic residues including Ala389, Ile369, Val377, Val419, and Leu 489 as well as the hydrophilic residue Ser499.
- the hinge region of ITK contains two backbone carbonyls and one backbone amino group as potential hydrogen bond acceptor and donor sites respectively. Similar backbone interactions have been observed in the interaction of kinases with the adenine base of ATP and several competitive inhibitors have been designed pursuing this concept.
- the “gatekeeper” residue Phe435. This residue blocks access to an internal hydrophobic pocket, and, at the same time, provides a potential site of interaction for aromatic or hydrophobic groups. This “gatekeeper” residue is a significant difference between ITK and BTK.
- Alkyl is a monovalent linear or branched saturated hydrocarbon radical and can be substituted or unsubstituted. Linear or branched alkyls typically have between 1 and 12 carbon atoms (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12). Lower alkyls, or “C 1 -C 6 alkyls,” have between 1 and 6 carbon atoms (e.g., 1, 2, 3, 4, 5, or 6).
- Optional substitutents include halogen, hydroxyl, alkoxy, aryloxy, amino, N-alkylamino, N,N-dialkylamino, alkylcarbamoyl, arylcarbamoyl, aminocarbamoyl, N-alkylaminocarbamoyl, N,N-dialkylaminocarbamoyl, alkylsulfonylamino, arylsulfonylamino, carboxy, carboxyalkyl, N-alkylcarboxamido, N,N-dialkylcarboxamido, alkylthio, alkylsulfinyl, alkylsulfonyl, trihaloalkylsulfonylamino (e.g., trifluoromethylsulfonylamino), arylthio, arylsulfinyl, arylsulfonyl, and heterocyclyl.
- linear or branched C 1 -C 6 alkyl examples include methyl, ethyl, propyl, isopropyl, sec-butyl, tert-butyl, n-butyl, n-pentyl, sec-pentyl, tert-pentyl, n-hexyl, isopentyl, fluoromethyl, trifluoromethyl, hydroxybutyl, dimethylcarboxyalkyl, aminoalkyl, and benzylpropyl.
- acyl (or “alkylcarbonyl”) is the radical —C(O)R 8 , wherein R 8 is an optionally substituted lower alkyl.
- examples of acyl include, but are not limited to, acetyl, propionyl, n-butyryl, sec-butyryl, t-butyryl, iodoacetyl, and benzylacetyl.
- acyloxy is the radical —OC(O)R 8 , wherein R 8 is an optionally substituted lower alkyl.
- examples of acyloxy include, but are not limited to, acetoxy, propionyloxy, butyryloxy, trifluoroacetoxy, and diiodobutyryloxy.
- Alkoxy is the radical —OR 8 , wherein R 8 is an optionally substituted lower alkyl. Examples of alkoxy include methoxy, ethoxy, propoxy, 2-propoxy, butoxy, sec-butoxy, tert-butoxy, pentyloxy, hexyloxy, fluoromethoxy, and iodoethoxy.
- Alkylamino is the radical —NR 7 R 8 , wherein R 7 is hydrogen or an optionally substituted lower alkyl and R 8 is an optionally substituted lower alkyl.
- alkylamino groups are methylamino, ethylamino, isopropylamino, dimethylamino, diethylamino, and trifluoromethylamino.
- Alkylaminocarbonyl (or “alkylcarbamoyl”) is the radical —C(O)NR 7 R 8 , wherein R 7 is hydrogen or an optionally substituted lower alkyl and R 8 is an optionally substituted lower alkyl.
- alkylaminocarbonyl include, but are not limited to, methylaminocarbonyl, dimethylaminocarbonyl, t-butylaminocarbonyl, n-butylaminocarbonyl, iso-propylaminocarbonyl, and trifluoromethylaminocarbonyl.
- Alkylaminosulfonyl is the radical —S(O) 2 NR 7 R 8 , wherein R 7 is hydrogen or an optionally substituted lower alkyl and R 8 is an optionally substituted lower alkyl.
- alkylaminosulfonyl include, but are not limited to, methylaminosulfonyl, dimethylaminosulfonyl, and triiodomethylaminosulfonyl.
- Alkoxycarbonyl or “alkyl ester” is the radical —C(O)OR 8 , wherein R 8 is an optionally substituted lower alkyl.
- alkoxycarbonyl radicals include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, sec-butoxycarbonyl, isopropyloxycarbonyl, and difluoromethoxycarbonyl.
- Alkylcarbonylamino is the radical —NR 7 C(O)R 8 , wherein R 7 is hydrogen or an optionally substituted lower alkyl and R 8 is an optionally substituted lower alkyl.
- alkylcarbonylamino include, but are not limited to, methylcarbonylamino, iso-propylcarbonylamino, and t-butylcarbonylamino.
- Alkylcarboxamido is the radical —C(O)NR 7 R 8 , wherein R 7 is hydrogen or an optionally substituted lower alkyl and R 8 is an optionally substituted lower alkyl.
- alkylcarboxamidos are methylcarboxamido, ethylcarboxamido, isopropylcarboxamido, and n-propylcarboxamido.
- Alkylsulfonyl is the radical —S(O) 2 R 8 , wherein R 8 is an optionally substituted lower alkyl.
- alkylsulfonyl include, but are not limited to, methylsulfonyl, trifluoromethylsulfonyl, and propylsulfonyl.
- Alkylsulfonylamino is the radical —NR 7 S(O) 2 R 8 , wherein R 7 is hydrogen or an optionally substituted lower alkyl and R 8 is an optionally substituted lower alkyl.
- alkylsulfonylamino include, but are not limited to, methylsulfonylamino, propylsulfonylamino, and trifluoromethylsulfonylamino.
- Aryl is the monovalent aromatic carbocyclic radical of one individual aromatic ring or two or three fused rings in which at least one of the fused rings is aromatic.
- Aryls can be optionally substituted on one or more rings with one or more of halogen, hydroxyl, alkoxy, aryloxy, amino, N-alkylamino, N,N-dialkylamino, alkylcarbamoyl, arylcarbamoyl, aminocarbamoyl, N-alkylaminocarbamoyl, N,N-dialkylaminocarbamoyl, alkylsulfonylamino, arylsulfonylamino, carboxy, carboxyalkyl, N-alkylcarboxamido, N,N-dialkylcarboxamido, alkylthio, alkylsulfinyl, alkylsulfonyl, trifluoromethylsulfonylamino, arylthio
- aryls are phenyl, naphthyl, tetrahydronaphthyl, indanyl, indanonyl, tetralinyl, tetralonyl, fluorenonyl, phenanthryl, anthryl, and acenaphthyl.
- Arylalkoxycarbonyl or “arylalkyl ester” is the radical —C(O)OR 8 X, wherein R 8 is an optionally substituted lower alkyl and X is an optionally substituted aryl.
- aryloxycarbonyl radicals include, but are not limited to, benzyl ester, phenyl ethyl ester, and dimethylphenyl ester.
- Arylalkylcarbamoyl is the radical —C(O)NHR 8 X, wherein R 8 is an optionally substituted lower alkyl and X is an optionally substituted aryl.
- arylalkylcarbamoyl include, but are not limited to, benzylcarbamoyl, phenylethylcarbamoyl, and cyanophenylcarbamoyl.
- Arylalkylcarbonyl (or “aralkylcarbonyl”) is the radical —C(O)R 8 X, wherein R 8 is an optionally substituted lower alkyl and X is an optionally substituted aryl.
- arylalkylcarbonyl radicals include, but are not limited to, phenylacetyl and fluorophenylacetyl.
- Arylaminocarbonyl (or “arylcarbamoyl”) is the radical —C(O)NXX′, wherein X is an optionally substituted aryl and X′ is hydrogen or an optionally substituted aryl.
- arylaminocarbonyl include, but are not limited to, phenylaminocarbonyl, methoxyphenylaminocarbonyl, diphenylaminocarbonyl, and dimethoxyphenyl-aminocarbonyl.
- Arylaminosulfonyl is the radical —S(O) 2 NXX′, wherein X is an optionally substituted aryl and X′ is hydrogen or an optionally substituted aryl.
- arylaminosulfonyl include, but are not limited to, phenylaminosulfonyl, methoxyphenylaminosulfonyl, and triiodomethylaminosulfonyl.
- Arylcarbonyl is the radical —C(O)X, wherein X is an optionally substituted aryl.
- arylcarbonyl radicals include, but are not limited to, benzoyl, naphthoyl, and difluorophenylcarbonyl.
- Arylcarbonylamino is the radical —NHC(O)X, wherein X is an optionally substituted aryl.
- arylcarbonylamino include, but are not limited to, phenylcarbonylamino, tosylcarbonylamino, and cyanophenylcarbonylamino.
- Aryloxy is —OX, wherein X is an optionally substituted aryl.
- aryloxys include phenyloxy, naphthyloxy, tetrahydronaphthyloxy, indanyloxy, indanonyloxy, biphenyloxy, tetralinyloxy, tetralonyloxy, fluorenonyloxy, phenanthryloxy, anthryloxy, and acenaphthyloxy.
- Aryloxycarbonyl or “aryl ester” is the radical —C(O)OX, wherein X is an optionally substituted aryl.
- aryloxycarbonyl radicals include, but are not limited to, phenyl ester, naphthyl ester, dimethylphenyl ester, and trifluorophenyl ester.
- Arylsulfonyl is the radical —S(O) 2 X, wherein X is an optionally substituted aryl.
- arylsulfonyl include, but are not limited to, phenylsulfonyl, nitrophenylsulfonyl, methoxyphenylsulfonyl, and 3,4,5-trimethoxyphenylsulfonyl.
- Arylsulfonylamino is the radical —NS(O) 2 X, wherein X is an optionally substituted aryl.
- arylsulfonylamino include, but are not limited to, phenylsulfonylamino, naphthylsulfonylamino, 2-butoxyphenylsulfonylamino, 4-chlorophenylsulfonylamino, 2,5-diethoxysulfonylamino, 4-hexyloxyphenylsulfonylamino, 4-methylphenylsulfonyl-amino, naphtylsulfonylamino, 4-methoxyphenylsulfonylamino, N-methylphenylsulfonyl-amino, and 4-cyanophenylsulfonylamino, phenylsulfonylamino, 4-methylphenylsulfonyl-
- Arylsulfonyloxy is the radical —OS(O) 2 X, wherein X is an optionally substituted aryl.
- arylsulfonyloxy include, but are not limited to, benzenesulfonyloxy and 4-chloro-benzenesulfonyloxy.
- Cycloalkyl is a monovalent saturated carbocyclic radical consisting of one or more rings, preferably one, of three to seven carbons per ring and can be optionally substituted with one or more of hydroxyl, alkoxy, aryloxy, amino, N-alkylamino, N,N-dialkylamino, alkylcarbamoyl, arylcarbamoyl, aminocarbamoyl, N-alkylaminocarbamoyl, N,N-dialkylaminocarbamoyl, alkylsulfonylamino, arylsulfonylamino, carboxy, carboxyalkyl, N-alkylcarboxamido, N,N-dialkylcarboxamido, alkylthio, alkylsulfinyl, alkylsulfonyl, trifluoromethylsulfonylamino, arylthio, arylsulfinyl,
- cycloalkyls are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, cyclooctyl, cycloheptyl, tetrahydro-naphthalene, methylenecylohexyl, indanyl, indenyl, and fluorenyl.
- Cycloalkylcarbonyl is the radical —C(O)R, wherein R is an optionally substituted cycloalkyl radical.
- Examples of cycloalkylcarbonyl radicals include, but are not limited to, cyclobutanoyl, cyclopentanoyl, cyclohexanoyl, and trifluorocyclopentanoyl.
- Halogen includes fluorine, chlorine, bromine, and iodine.
- Heteroaryl is a monovalent aromatic cyclic radical having one or more rings, preferably one to three rings, of four to eight atoms per ring, incorporating one or more heteroatoms selected independently from nitrogen, oxygen, silicon, and sulfur. Heteroaryls can be optionally substituted on one or more rings with one or more of halogen, hydroxyl, alkoxy, aryloxy, amino, N-alkylamino, N,N-dialkylamino, alkylcarbamoyl, arylcarbamoyl, aminocarbamoyl, N-alkylaminocarbamoyl, N,N-dialkylaminocarbamoyl, alkylsulfonylamino, arylsulfonylamino, carboxy, carboxyalkyl, N-alkylcarboxamido, N,N-dialkylcarboxamido, alkylthio, alkylsulfinyl, alkylsulf
- monocyclic ring system heteroaryls include, but are not limited to, azetidinyl, azepinyl, aziridinyl, diazepinyl, 1,3-dioxolanyl, dioxanyl, dithianyl, furyl, imidazolyl, imidazolinyl, imidazolidinyl, isothiazolyl, isothiazolinyl, isothiazolidinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolyl, oxadiazolinyl, oxadiazolidinyl, oxazolyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyri
- Bicyclic ring systems include any of the above monocyclic ring systems fused to an aryl group, a cycloalkyl group, or another heteroaryl monocyclic ring system.
- Representative examples of bicyclic ring systems include but are not limited to, benzimidazolyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, benzofuranyl, benzopyranyl, benzothiopyranyl, benzodioxinyl, 1,3-benzodioxolyl, cinnolinyl, indazolyl, indolyl, indolinyl, indolizinyl, naphthyridinyl, isobenzofuranyl, isobenzothiophenyl, isoindolyl, isoindolinyl, isoquinolyl, phthalazinyl, pyranopyridyl, quinolyl, quinolizinyl, quinoxaliny
- Tricyclic rings systems include any of the above bicyclic ring systems fused to an aryl group, a cycloalkyl group, or a heteroaryl monocyclic ring system.
- Representative examples of tricyclic ring systems include, but are not limited to, acridinyl, carbazolyl, carbolinyl, dibenzofuranyl, dibenzothiophenyl, naphthofuranyl, naphthothiophenyl, oxanthrenyl, phenazinyl, phenoxathiinyl, phenoxazinyl, phenothiazinyl, thianthrenyl, thioxanthenyl, and xanthenyl.
- Heteroarylaminocarbonyl is the radical —C(O)NZZ′, wherein Z is an optionally substituted heteroaryl and Z′ is hydrogen or an optionally substituted heteroaryl.
- heteroarylaminocarbonyl include, but are not limited to, pyridinylaminocarbonyl, and thienylaminocarbonyl, furanylaminocarbonyl.
- Heteroarylaminosulfonyl is the radical —S(O) 2 NZZ′, wherein Z is an optionally substituted heteroaryl and Z′ is hydrogen or an optionally substituted heteroaryl.
- heteroarylaminosulfonyl include, but are not limited to, thienylaminosulfonyl, piperidinylamino sulfonyl, furanylaminosulfonyl, and imidazolylaminosulfonyl.
- Heteroarylcarbonyl is the radical —C(O)Z, wherein Z is an optionally substituted heteroaryl.
- heteroarylcarbonyl radicals include, but are not limited to, pyridinoyl, 3-methylisoxazoloyl, isoxazoloyl, thienyl, and furoyl.
- Heteroarylsulfonyl is the radical —S(O) 2 Z, wherein Z is an optionally substituted heteroaryl.
- heteroarylsulfonyl include, but are not limited to, thienylsulfonyl, furanylsulfonyl, imidazolylsulfonyl, and N-methylimidazolylsulfonyl.
- Heteroarylsulfonyloxy is the radical —OS(O) 2 Z, wherein Z is an optionally substituted heteroaryl.
- An examples of hetroarylsulfonyloxy is thienylsulfonyloxy.
- Heterocycle is a saturated or partially unsaturated carbocyclic radical having one, two, or three rings each containing one or more heteroatoms selected independently from nitrogen, oxygen, silicon, and sulfur.
- a heterocycle can be unsubstituted or substituted on any or all of the rings with one or more of halogen, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, amino, N-alkylamino, N,N-dialkylamino, alkylsulfonylamino, arylsulfonylamino, alkylcarbamoyl, arylcarbamoyl, aminocarbamoyl, N-alkylaminocarbamoyl, N,N-dialkylaminocarbamoyl, carboxy, alkylcarboxy, N-alkylcarboxamido, N,N-dialkylcarboxamido, alkylthio, alkylsulfinyl, alkylsul
- Heterocyclylcarbonyl (or “heterocyclocarbonyl”) is the radical —C(O)M′, wherein M′ is an optionally substituted heterocycle.
- heterocyclylcarbonyl include, but are not limited to, piperazinoyl, morpholinoyl, and pyrrolindinoyl.
- Heterocyclylsulfonyl is the radical —S(O) 2 Z′, wherein M′ is an optionally substituted heterocycle.
- heterocyclylsulfonyl include, but are not limited to, piperidinylsulfonyl and piperazinylsulfonyl.
- Heterocyclylsulfonyloxy is the radical —OS(O) 2 M′, wherein M′ is an optionally substituted heterocycle.
- heterocyclylsulfohyloxy include, but are not limited to, 3,5,dimethyl-isoxazolesulfonyloxy and pyrrolidinylsulfonyloxy.
- This invention provides compounds which inhibit tyrosine kinases, particularly Tec (e.g., ITK, BTK), Src (Src, Lck, etc.) and EGFR kinases (e.g., EGFR1, Her 2, Her 4), and Jak kinase (e.g., Jak3), having structures that exploit a discrete mechanistic rationale described herein.
- This mechanism provides for the utilization of the kinase catalytic machinery, described in the ITK crystallographic structures as the acid-base pair residues Lys391 and Asp500 (herein referred to as the “catalytic dyad”), to trigger a transformation that activates the proposed inhibitory compounds within the enzyme active site.
- This transformation involves the elimination of a leaving group, resulting in the in situ formation of an electrophilic intermediate capable of forming a covalent adduct with an active site cysteine residue thereby irreversibly inhibiting the function of the target enzyme.
- This cysteine residue is identifiable as Cys442 in the ITK crystallographic structure.
- the group of kinases with the above described triad including ITK, BTK, BMX, Tec, TXK, BLK, EGFr, Her 2, Her 4 and JAK3, will be referred to as the DKC triad kinases.
- Various embodiments of the invention relate to this group, its possible sub-groupings, and to its individual members.
- the compounds described in this invention are unique in that the transformation that forms the electrophilic intermediate takes place preferentially in situ, i.e. within the enzyme active site. Outside of an appropriate active site, these compounds are much less likely to undergo beta-elimination and form adducts with other proteins.
- the compounds described within must first bind in the active site of the target kinase and achieve a specific conformational geometry with respect to the relevant catalytic residues in order to effectively trigger elimination of the leaving group, thereby unmasking the adduct-forming intermediate.
- This intermediate forms a covalent, irreversible adduct with the proximal active site cysteine residue.
- the reaction proceeds stepwise; in other embodiments it is concerted.
- additional portions of the inhibitor molecule interact with other portions of the kinase, particularly in the active site, to promote favorable binding affinity and positioning.
- Such interactions contribute to the specificity of various inhibitors so that some inhibitors are inhibit a single kinase whereas others inhibit multiple kinases with similar or different IC 50 s.
- this is the first example of an in situ formation of an active inhibitor in a kinase active site.
- the inhibition of the target kinase goes through the following sequence of steps to form the adduct with the inhibitory compounds:
- inhibitory activity of this class of compounds toward select kinases is dependent on their ability to bind effectively in proximity to the appropriate calalytic environment, the existence of a polarizable C ⁇ Y group (C ⁇ O in formula (I), below) with appropriate reactivity and an adjacent alpha proton to allow elimination of the beta leaving group.
- the elimination process that generates a reactive electrophilic species requires removal of the abstractable alpha proton that is facilitated by adequate positioning of the C ⁇ Y group in the catalytic environment.
- the generated electrophilic Michael acceptor in turn is required to be positioned within reactive distance of the key cysteine residue.
- pharmacophoric elements that include:
- the effective “reactive distance” to the cysteine sulfhydryl group as stated above is observed in the range of about 3-10 ⁇ using computational design methods that test the binding of inhibitors to the ITK ATP binding site, wherein the enzyme is maintained in a fixed conformation. While a distance of 10 ⁇ in a rigid system would be too far to effect a chemical reaction, the enzymatic nucleophilic moiety and the inhibitor's electrophilic moiety can readily be brought together through a series of low energy barrier rotations around the flexible inhibitor bonds as well as the cysteinyl side chain. Overall global conformational changes, common to kinase systems, cannot be ruled out either but are not readily measurable. Such conformational changes, which can be envisioned by computational predictions, are adequate in bringing the two reactive pieces in close enough proximity to effect covalent bond formation.
- Ar is optionally substituted aryl or optionally substituted heteroaryl
- R 3 , R 4 , R 5 , and R 6 are independently hydrogen or optionally substituted C 1 -C 6 alkyl
- R 1 and R 2 (a) are independently hydrogen, optionally substituted C 1 -C 6 alkyl, piperidine, or furanyl; or (b) are taken together with the nitrogen atom to which they are attached to form (i) a 5- to 7-membered optionally substituted aryl, (ii) a 5- to 7-membered optionally substituted heteroaryl, or (iii) a 5- to 7-membered optionally substituted heterocycle which may be unfused or fused to an optionally substituted aryl.
- A, B, E, and Q are independently CH, O, or N; and D and D′ are independently CH 2 , NH, O, or S.
- Examples of 5- to 7-membered heterocycles include:
- G is N, CH, or S
- G′ is NH, CH, or S
- n 0-2; R 1 and R 2 are as defined above; and R 7 is hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl.
- Preferred 5- to 7-membered heterocycles are piperazinyl, piperidinyl, pyrrolidinyl, and morpholinyl.
- Preferred substituents for piperazinyl are C 1 -C 6 alkyl, dialkyl C 1 -C 6 aminoalkyl, aryl, aralkyl, cycloalkyl, and cycloalkyl-alkyl.
- Preferred substituents for piperidinyl are C 1 -C 6 alkyl and aralkyl.
- piperidinyl is benzofused to form isoquinolinyl.
- Preferred substituents for pyrrolidinyl are C 1 -C 6 alkyl, aryl, and aralkyl.
- pyrrolidinyl is benzofused to form isoindolyl.
- Preferred substituents for morpholinyl are C 1 -C 6 alkyl and arylalkyl.
- R 1 and R 2 are as defined above, with the exception of
- R 3 , R 4 , R 5 , R 6 , and R 10 are as defined above.
- R 15 is halogen or C 1 -C 4 alkyl and R 16 is C 1 -C 4 alkyl
- R 1 and R 2 together with the nitrogen to which they are attached form an aryl group selected from
- R 1 and R 2 are independently hydrogen or C 1 -C 4 alkyl
- R 3 , R 4 , R 5 , and R 6 are as defined above.
- R 3 , R 4 , R 5 , and R 6 are as defined above and wherein R 1 is hydrogen and R 2 is
- R 19 is selected from hydrogen and
- A is N or O
- R 20 is phenyl-C 1 -C 4 alkyl optionally substituted with one or more halogens, hydrogen, C 1 -C 4 alkyl, amino-C 1 -C 4 alkyl,
- R 17 and R 18 are independently hydrogen or —OCH 3 ;
- R 21 is —CONR′R′′, —COR′,
- R′ and R′′ are independently selected from hydrogen and C 1 -C 4 alkyl.
- R 3 , R 4 , R 5 , and R 6 are as defined above and wherein R 22 is selected from hydrogen, C 1 -C 4 alkyl, —NR′R′′, —COH, —COOH, —CNR′R′′, and —CONHR′, wherein R′ and R′′ are as defined above.
- R 3 , R 4 , R 5 , R 6 , G, and G′ are as defined above; and R 23 is hydrogen, —NR′R′′ C 1 -C 4 linear alkyl, C 1 -C 4 alkyl, phenyl-C 1 -C 4 alkyl, —CONH 2 , and —COR′R′′, wherein R′ and R′′ are as defined above.
- R 3 , R 4 , R 5 , and R 6 are as defined above and wherein R 24 is
- R 3 , R 4 , R 5 , and R 6 are as defined above.
- T, U, V, and W independently are selected from hydrogen; halogen; —O; C 1 -C 3 alkyl; and C 1 -C 3 alkyloxy; and wherein R 25 is hydrogen or C 1 -C 3 alkyl.
- Representative compounds include:
- T, U, V, and W independently are selected from hydrogen; halogen; —O; C 1 -C 3 alkyl; and C 1 -C 3 alkyloxy; and wherein R 8 is hydrogen or C 1 -C 3 alkyl.
- T, U, V, and W independently are selected from hydrogen; halogen; —O; C 1 -C 3 alkyl; and C 1 -C 3 alkyloxy; and wherein R 8 is hydrogen or C 1 -C 3 alkyl.
- D is S, O, or NH
- G′ is NH or CH; i.e.,
- the invention also includes the compounds identified in Examples 15 and 16.
- the compounds of the present invention may have asymmetric centers and may occur as racemates, stereoisomers, and tautomers.
- the invention includes all possible racemates, tautomers, stereoisomers, and mixtures thereof
- Compounds of the invention preferably do not have one or more of the following activities: vasodilator, hypotensive, bradycardiac, anti-depressant, anti-arrhythmic, anti-arteriosclerotic, serum cholesterol lowering, triglyceride level lowering, neuroleptic, anti-inflammatory, tranquilizing, anti-convulsant, anesthetic, muscle relaxing, anti-fungal, anti-bacterial, insecticidal, fumigant, anti-parasitic, central nervous system depressant, antagonization of sedation, antipollakiurea, antihistamine, anti-allergy, bronchodilating, analgesic, spasmolytic, muscarinic antagonist, preventing or decreasing production of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease, hypolipidemic, male anti-fertility, anti-sporicidal, inhibition of nitric oxide production, or central nervous system stimulant activities.
- Y is alkyl, halogen, halogenoalkyl, alkyoxy, alkylthio, halogenoalkyloxy, halogenoalkylthio, cycloalkyl, or a cyane radical;
- R 3 is hydrogen or C 1 -C 4 alkyl; and X 22 , X 23 , and X 24 are independently alkyl; halogen, or a halogeno-C 1 -C 4 alkyl, C 1 -C 4 alkoxy, alkylthio, halogeno-C 1 -C 4 alkoxy, halogeno-C 1 -C 4 alkylthio, cycloalkyl 3 to 7 carbon atoms, or cyano;
- L 8 is a carbonyl, sulfonyl, methylene, or methylene substituted with optionally substituted phenyl; and Ar is an aryl group;
- compositions of the invention can be formulated as pharmaceuticals using methods well known in the art.
- Pharmaceutical formulations of the invention typically comprise at least one compound of the invention mixed with a carrier, diluted with a diluent, and/or enclosed or encapsulated by an ingestible carrier in the form of a capsule, sachet, cachet, paper or other container or by a disposable container such as an ampoule.
- a carrier or diluent can be a solid, semi-solid or liquid material.
- Some examples of diluents or carriers which may be employed in the pharmaceutical compositions of the present invention are lactose, dextrose, sucrose, sorbitol, mannitol, propylene glycol, liquid paraffin, white soft paraffin, kaolin, microcrystalline cellulose, calcium silicate, silica polyvinylpyrrolidone, cetostearyl alcohol, starch, gum acacia, calcium phosphate, cocoa butter, oil of theobroma, arachis oil, alginates, tragacanth, gelatin, methyl cellulose, polyoxyethylene sorbitan monolaurate, ethyl lactate, propylhydroxybenzoate, sorbitan trioleate, sorbitan sesquioleate and oleyl alcohol.
- compositions of the invention can be manufactured by methods well known in the art, including conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.
- the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as acetate, Hanks's solution, Ringer's solution, or physiological saline buffer.
- physiologically compatible buffers such as acetate, Hanks's solution, Ringer's solution, or physiological saline buffer.
- the solutions are sterile and non-pyrogenic.
- penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
- the active compound(s) can be combined with pharmaceutically acceptable carriers which enable the compound(s) to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like.
- Fillers can be used, such as gelatin, sugars (e.g., lactose, sucrose, mannitol, or sorbitol); cellulose preparations (e.g., maize starch, wheat starch, rice starch, potato starch, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose); and/or polyvinylpyrrolidone (PVP).
- disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- Dragee cores are provided with suitable coatings.
- suitable coatings For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- compositions which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compound(s) may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers may be added. All formulations for oral administration preferably are in dosages suitable for such administration.
- compositions may take the form of tablets or lozenges formulated in conventional manner.
- compositions of the invention can be delivered in the form of an aerosol sprays from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
- a valve can be used to deliver a metered amount.
- Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of a compound and a suitable powder base such as lactose or starch.
- Compounds of the invention can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
- Formulations for injection can be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
- the compositions can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- compositions for parenteral administration include aqueous solutions of the active compounds. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
- the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- a suitable vehicle e.g., sterile pyrogen-free water
- the compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
- Compounds of the invention typically are soluble and stable in 50 mM acetate at a concentration of 10 mg/ml or above, and can be delivered intraperitoneally and orally in this buffer. Some compounds are soluble in hydroxypropyl-b-cyclodextrin (HBPCD, 3-5%), and can be delivered intraperitoneally and orally in this solvent. For intravenous delivery, compounds can be suspended or dissolved in 5% mannitol.
- HPCD hydroxypropyl-b-cyclodextrin
- compositions also may comprise suitable solid or gel phase carriers or excipients.
- suitable solid or gel phase carriers or excipients include but are not limited to, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
- the compounds of the present invention may also be administered by controlled release means and/or delivery devices including ALZET® osmotic pumps which are available from Alza Corporation. Suitable delivery devices are described in U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 3,944,064 and 4,008,719.
- the identified compounds can be administered to a human patient, either alone or in pharmaceutical compositions where they are mixed with suitable carriers or excipient(s) at doses to treat or ameliorate blood-related cancers (e.g., lymphomas and leukemias) and autoimmune disorders. Reduction of intracellular kinase activity also is useful to suppress the immune system of transplant patients prior to, during, and/or after transplant.
- blood-related cancers e.g., lymphomas and leukemias
- autoimmune disorders e.g., autoimmune disorders.
- Reduction of intracellular kinase activity also is useful to suppress the immune system of transplant patients prior to, during, and/or after transplant.
- Lymphomas are malignant growths of B or T cells in the lymphatic system, including Hodgkin's lymphoma and non-Hodgkin's lymphoma.
- Non-Hodgkin's lymphomas include cutaneous T cell lymphomas (e.g., Sezary syndrome and Mycosis fungoides), diffuse large cell lymphoma, HTLV-1 associated T cell lymphoma, nodal peripheral T cell lymphoma, extranodal peripheral T cell lymphoma, central nervous system lymphoma, and AIDS-related lymphoma.
- Leukemias include acute and chronic types of both lymphocytic and myelogenous leukemia (e.g, acute lymphocytic or lymphoblastic leukemia, acute myelogenous leukemia, acute myeloid leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, T cell prolymphocytic leukemia, adult T cell leukemia, and hairy cell leukemia).
- lymphocytic and myelogenous leukemia e.g, acute lymphocytic or lymphoblastic leukemia, acute myelogenous leukemia, acute myeloid leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, T cell prolymphocytic leukemia, adult T cell leukemia, and hairy cell leukemia.
- Autoimmune disorders include systemic lupus erythematosus, anti-phospholipid antibody syndrome, multiple sclerosis, ulcerative colitis, Crohn's disease, rheumatoid arthritis, asthma, Hashimoto's thyroiditis, Reiter's syndrome, Sjögren's syndrome, Guillain-Barrésyndrome, myasthenia gravis, large vessel vasculitis, medium vessel vasculitis, polyarteritis nodosa, pemphigus vulgaris, scleroderma, Goodpasture's syndrome, glomerulonephritis, primary biliary cirrhosis, Grave's disease, membranous nephropathy, autoimmune hepatitis, celiac sprue, Addison's disease, polymyositis, dermatomyositis, monoclonal gammopathy, Factor VIII deficiency, cryoglobulinemia, peripheral neuropathy, IgM polyn
- compositions of the invention can be administered locally or systemically.
- routes of administration include oral, pulmonary, rectal, transmucosal, intestinal, parenteral (including intramuscular, subcutaneous, intramedullary routes), intranodal, intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, intraocular, transdermal, topical, and vaginal routes.
- dosage forms include, but are not limited to, tablets, troches, dispersions, suspensions, suppositories, solutions, capsules, creams, patches, minipumps and the like.
- Targeted delivery systems also can be used (for example, a liposome coated with target-specific antibody).
- a pharmaceutical composition of the invention comprises at least one active ingredient in a therapeutically effective amount.
- a “therapeutically effective dose” is the amount of an active agent which, when administered to a patient, results in a measurable improvement in a characteristic of the disease being treated (e.g., improved laboratory values, retarded development of a symptom, reduced severity of a symptom, improved levels of a biological marker such as CD25a or IL2). The improvement can be evident after a single administration of the therapeutically effective dose. More usually multiple administrations are utilized in order to achieve or maintain optimal effect. In preferred embodiments frequency of administration can range from twice a month to once a week to several times a day, for example 1-4 times a day.
- administration can be by time-release formulations, or extended or continuous infusions.
- the frequency of administration can be selected to achieve a systemic or local concentration at or above some predetermined level for a period of time.
- the period of time can be all or a substantial portion of the interval between administrations or comprise the period of time-release or infusion.
- the treatment schedule can require that a concentration of the compound be maintained for a period of time (e.g., several days or a week) and then allowed to decay by ceasing administration for a period of time (e.g., 1, 2, 3, or 4 weeks).
- a therapeutically effective dose initially can be estimated from in vitro enzyme assays, cell culture assays and/or animal models.
- a dose can be formulated in an animal model to achieve a circulating concentration range that includes the IC 50 as determined in an in vitro enzyme assay or in a cell culture (i.e., the concentration of the test compound which achieves a half-maximal inhibition of ITK or BTK activity).
- concentration range that includes the IC 50 as determined in an in vitro enzyme assay or in a cell culture (i.e., the concentration of the test compound which achieves a half-maximal inhibition of ITK or BTK activity).
- LD 50 the dose lethal to 50% of the population
- ED 50 the dose therapeutically effective in 50% of the population
- the dosage may vary depending upon the dosage form and route of administration used.
- human equivalent dose As is well known, the FDA guidance document “Guidance for Industry and Reviewers Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers” (HFA-305) provides an equation for use in calculating a human equivalent dose (HED) based on in vivo animal studies. Based on the studies described in Example 16, below, the human equivalent dose ranges between 1.5 mg/kg and 8 mg/kg, with some compounds showing considerable efficacy at lower or higher doses than those estimated by the HED. Thus, human dosages for systemic administration can range from, e.g., 1.5 mg/kg to 3 mg/kg; 2 mg/kg to 4 mg/kg; 5 mg/kg to 7 mg/kg; and 4 mg/kg to 8 mg/kg. The amount of composition administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the disorder, the manner of administration and the judgment of the prescribing physician.
- N- ⁇ 4-[3-(3-Morpholin-4-yl-propionyl)-phenyl]-pyridin-2-yl ⁇ -benzamide (100 mg, 0.32 mmol) was dissolved in HCl (2 mL, 6 N). The mixture was irradiated with microwaves at 140° C. for 30 minutes. The mixture was diluted with DCM (20 mL) and neutralized with NaOH to pH ⁇ 9. The layers were separated and the aqueous layer was washed further with DCM (2 ⁇ 15 mL). The combined organic layer was dried (Na 2 SO 4 ) and filtered.
- N-[4-(3-Acetyl-phenyl)-pyridin-2-yl]-benzamide N-[4-(3-Acetyl-phenyl)-pyridin-2-yl]-4-tert-butyl-benzamide (130 mg, 81%, slight impurity) was obtained from 1-[3-(2-Chloro-pyridin-4-yl)-phenyl]-ethanone (100 mg, 0.43 mmol) and 4-tert-butylbenzamide (153 mg, 0.86 mmol).
- Human T cell lines were plated in 96 well plates pre-coated with anti-CD3 monoclonal antibodies. Wells were either left untreated or treated with anti-CD28 for 2 days. The supernatant was collected and tested for IL-2 production in the presence or absence of a test compound using a human IL-2 ELISA assay.
- HITHUNTERTM enzyme fragment complementation method (Discoverx). Briefly, a recombinantly produced, N-terminally His-tagged ITK kinase domain (amino acids 352-617) was incubated with various concentrations of individual compounds. ATP and substrate were added, and the kinase reaction was allowed to proceed for 2-16 hours. Commercially available detection reagents were added and allowed to react for 2-4 hours. The reaction was evaluated by luminescence. Initial results were confirmed using full-length recombinant ITK protein.
- HITHUNTERTM commercially available reagents such as HITHUNTERTM were used to evaluate the effect of compounds on the activity of additional kinases.
- the kinase domains of BTK, LCK and ERK were expressed as recombinant purified proteins were used for these studies.
- the compounds in Table 1 were tested and shown to inhibit IL-2 production, to inhibit T cell proliferation, and to inhibit ITK with an IC 50 of less than 1 ⁇ M.
- NOD/SCID mice were implanted intraperitoneally with T cell leukemia/lymphoma cells.
- One group was treated with vehicle alone (mock treatment) while the other groups were treated with several small molecule inhibitors via intraperitoneal route.
- Tumor growth was evaluated by peritoneal lavage and FACS analysis. Table 6 summarizes percent inhibition of tumor growth relative to a mock group treated with vehicle alone. Doses of compounds evaluated in this study were below the maximal tolerated dose, and showed minimal toxicity.
- the compounds in Table 6 were tested and inhibited tumor growth by at least 50% at the concentrations shown.
- the compound class interacts selectively with kinase domains of such kinase families as Tec and EGFR, as well as a few additional kinases. There is evidence indicating that this class of compounds reacts irreversibly at the ATP binding site of the kinase binding domain, through a mechanism that involves the exposure of a reactive aminoethyl C ⁇ Y warhead through the in situ elimination of a leaving group.
- the compounds contain an abstractable proton adjacent to the C ⁇ Y group, which upon exposure to an appropriate catalytic environment in the active site of a kinase of interest will promote elimination of the beta-amino functionality.
- This elimination thus generates a reactive electrophilic species (commonly termed a Michael acceptor moiety) which, due to the existence of a proximal cysteine residue in the kinase active site, rapidly forms a covalent adduct between this cysteine residue and the in situ generated electrophylic species.
- a reactive electrophilic species commonly termed a Michael acceptor moiety
- the combination of a kinase with the catalytic environment in close proximity to a nucleophilic cysteine is a vital and unique requirement that describes this mechanism of action.
- the data below support that in situ elimination promotes the inhibitory activity of compounds in depicted in this invention. When a compound is modified in a manner that prevents elimination, the compound fails to exhibit inhibitory activity.
- BIACORE® is a SPR-based protein interaction approach, whereby the kinase is immobilized on the sensor chip, and a small molecule solution allowed to interact with the kinase. Detection of small molecule/kinase interaction occurs in real time, and is detected as a difference in SPR response.
- FIG. 1 shows a BIACORE® experiment in which the ITK kinase domain was immobilized on a biosensor, and evaluated for its ability to bind and dissociate form a small molecule. The data indicates that compounds depicted in this application bind to the ITK kinase domain irreversibly.
- 1-10 mM labeled compound is incubated with cell lysates from either kinase expressing or kinase lacking cells. The label is then used to precipitate the compound and any bound proteins. The mixture is separated by SDS-PAGE and proteins are identified by western blotting and/or Mass spectrophotometry.
Abstract
Description
- This application is a continuation of Ser. No. 11/750,866 filed on May 18, 2007, which claims the benefit of provisional application Ser. No. 60/801,074 filed May 18, 2006 and Ser. No. 60/869,664 filed Dec. 12, 2006.
- This application incorporates by reference the contents of a 25.1 kb text file created on Jun. 30, 2011 and named “sequencelisting.txt,” which is the sequence listing for this application.
- The invention relates to intracellular kinase inhibitors and their therapeutic uses.
- Intracellular kinases play important functions in cells of the immune system. For example, interleukin-2 inducible tyrosine kinase (ITK) plays a key role in T cell development and differentiation; it regulates IL-2 production via phospholipase C γ1 (PLCγ1) and nuclear factor of activated T cells (NFAT); it mediates Th2 cell differentiation; and it regulates T cell migration and recruitment to lymphatic organs. Bruton's tyrosine kinase (BTK) is involved in signal transduction pathways which regulate growth and differentiation of 13 lymphoid cells. BTK also is involved in platelet physiology by regulating the glycoprotein VI/Fc receptor γ chain (GPVI-FcRγ)-coupled collagen receptor signaling pathway. For these reasons, inhibitors of intracellular kinases are useful for treating blood cell malignancies, solid tumors and for suppressing the immune system, for example in patients with autoimmune disorders or organ transplants. Intracellular kinase inhibitors also are useful for preventing or reducing the risk of thromboembolism.
-
FIG. 1 . Results of a BIACORE® experiment in which the ITK kinase domain was immobilized on a biosensor and evaluated for its ability to bind and dissociate from a small molecule. -
FIG. 2 . Alignment of human ITK (SEQ ID NO:1) and BTK (SEQ ID NO:2). -
FIG. 3 . Alignment of kinase domains. Bolded amino acids, hinge; bolded and underlined amino acids, gatekeeper; italicized and bolded amino acids, Cys442 equivalents. - The invention provides compounds which inhibit intracellular kinases, particularly ITK and BTK, with an IC50 of 1 μM or below in an in vitro kinase assay as disclosed herein. The invention also provides pharmaceutical compositions and methods of using the compounds therapeutically. Patients who can be treated include those with blood cell malignancies, solid tumors, autoimmune disorders, and transplanted organs.
- A review of the literature and patent database revealed the existence of compounds that inhibit ITK or BTK kinases. However, these compounds differ significantly from the compounds disclosed herein. In several instances, the compounds are pyrrolopyridines (e.g., US 2005/0215582). In other instances, the compounds are methyl dimethylbenzoates that belong thiazolyl family of compounds (e.g., US 2004/0077695). In all cases, these published compounds differ from the compounds disclosed herein based on the following parameters: the compounds do not correspond to the general structure shown in this application, do not require the amino acid triad DKC found in the kinase binding site and necessary for optimal compound inhibitory capability described herein, do not undergo elimination, and do not bind covalently to the kinase binding pocket.
- Compounds of the invention which inhibit ITK can be used, e.g., to treat T cell malignancies. Preferred compounds of the invention inhibit both ITK and BTK with an IC50 of 1 μM or below for each enzyme. Such compounds can be used, e.g., to treat both T and B cell malignancies, as well as EGFR or HER positive tumors.
- The Tec family of kinases share a common subunit structure composed of a Src homology domain 2 (SH2), an SH3 and a catalytic kinase domain. Further, they are uniquely identified by the presence of a Tec homology region (TH) and a pleckstrin homology (PH) domain. There are four known crystallographic structures described for the Tec family of kinases. These include (a) two structures representing the phosphorylated and unphosphorylated staurosporine-bound ITK (PDB codes 1 SM2, 1SNU); (b) one structure of the unphosphorylated apo-form of ITK (PDB code 1SNX), and (c) one structure for the unphosphorylated apo-form of BTK (Mao et al. J. Biol. Chem. 2001, 276, 41435-41443). For the purpose of clarity of explanation, this disclosure will represent these kinase structures with those of the nearly identical ITK structures in (a) and (b) incorporated herein by reference (Brown et al. J. Biol. Chem. 2004, 279, 18727-18732) focusing attention on the ATP binding site. For the sake of uniformity, the residue numbering in these kinase structures as represented in the Protein Data Bank have been incorporated throughout this document to describe the kinase domain. The amino acid sequence of human ITK is shown in SEQ ID NO:1. The amino acid sequence of human BTK is shown in SEQ ID NO:2. Homologous residues in the other kinases and sequences from other sources may be numbered differently.
- Referring to
FIG. 2 , The ITK kinase domain (residues 357-620) can be broken down into two components: the N-terminal lobe (residues 357-437) and the C-terminal lobe (residues 438-620). Like most kinases, the connecting region between the two lobes is a flexible hinge region described below, that forms part of the catalytic active site. The ordered nature of the C-helix places the catalytically important residues of Glu406, Lys391 and Asp500 in an orientation typical of the active form of a protein kinase. The Gly-rich loop (residues 362-378), commonly observed in kinases, assumes an extended and open conformation typical of an active kinase. - The boundaries of the ATP binding site are demarcated by the following residues: (a) the glycine-rich loop (Gly370, Ser371, Gly372, Gln373, Phe374 and Gly375); (b) the hinge region (Phe435, Glu436, Phe437, Met438, Glu439, His440, Gly441 and Cys442); and (c) the catalytic residues Lys391 and Asp500. Additionally, the active site also comprises several other hydrophobic residues including Ala389, Ile369, Val377, Val419, and Leu 489 as well as the hydrophilic residue Ser499.
- Similar to other kinases, the hinge region of ITK contains two backbone carbonyls and one backbone amino group as potential hydrogen bond acceptor and donor sites respectively. Similar backbone interactions have been observed in the interaction of kinases with the adenine base of ATP and several competitive inhibitors have been designed pursuing this concept. At the N-terminal end of the hinge region lies the “gatekeeper” residue, Phe435. This residue blocks access to an internal hydrophobic pocket, and, at the same time, provides a potential site of interaction for aromatic or hydrophobic groups. This “gatekeeper” residue is a significant difference between ITK and BTK. Despite the strong overall sequence identity between BTK and ITK, the presence of the smaller threonine residue as a gatekeeper in the active site of BTK justifies a key similarity of the latter to the active site of several kinases such as Src/Abl/EGFR. The absence of the bulkier Phe gatekeeper allows access to an internal hydrophobic pocket for these kinases, a fact that has been exploited for the design of allosteric inhibitors, and to improve the affinity of ATP-competitive inhibitors through the addition of a hydrophobic pharmacophore.
- “Alkyl” is a monovalent linear or branched saturated hydrocarbon radical and can be substituted or unsubstituted. Linear or branched alkyls typically have between 1 and 12 carbon atoms (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12). Lower alkyls, or “C1-C6 alkyls,” have between 1 and 6 carbon atoms (e.g., 1, 2, 3, 4, 5, or 6). Optional substitutents include halogen, hydroxyl, alkoxy, aryloxy, amino, N-alkylamino, N,N-dialkylamino, alkylcarbamoyl, arylcarbamoyl, aminocarbamoyl, N-alkylaminocarbamoyl, N,N-dialkylaminocarbamoyl, alkylsulfonylamino, arylsulfonylamino, carboxy, carboxyalkyl, N-alkylcarboxamido, N,N-dialkylcarboxamido, alkylthio, alkylsulfinyl, alkylsulfonyl, trihaloalkylsulfonylamino (e.g., trifluoromethylsulfonylamino), arylthio, arylsulfinyl, arylsulfonyl, and heterocyclyl. Examples of linear or branched C1-C6 alkyl are methyl, ethyl, propyl, isopropyl, sec-butyl, tert-butyl, n-butyl, n-pentyl, sec-pentyl, tert-pentyl, n-hexyl, isopentyl, fluoromethyl, trifluoromethyl, hydroxybutyl, dimethylcarboxyalkyl, aminoalkyl, and benzylpropyl.
- “Acyl” (or “alkylcarbonyl”) is the radical —C(O)R8, wherein R8 is an optionally substituted lower alkyl. Examples of acyl include, but are not limited to, acetyl, propionyl, n-butyryl, sec-butyryl, t-butyryl, iodoacetyl, and benzylacetyl.
- “Acyloxy” is the radical —OC(O)R8, wherein R8 is an optionally substituted lower alkyl. Examples of acyloxy include, but are not limited to, acetoxy, propionyloxy, butyryloxy, trifluoroacetoxy, and diiodobutyryloxy.
- “Alkoxy” is the radical —OR8, wherein R8 is an optionally substituted lower alkyl. Examples of alkoxy include methoxy, ethoxy, propoxy, 2-propoxy, butoxy, sec-butoxy, tert-butoxy, pentyloxy, hexyloxy, fluoromethoxy, and iodoethoxy.
- “Alkylamino” is the radical —NR7R8, wherein R7 is hydrogen or an optionally substituted lower alkyl and R8 is an optionally substituted lower alkyl. Examples of alkylamino groups are methylamino, ethylamino, isopropylamino, dimethylamino, diethylamino, and trifluoromethylamino.
- “Alkylaminocarbonyl” (or “alkylcarbamoyl”) is the radical —C(O)NR7R8, wherein R7 is hydrogen or an optionally substituted lower alkyl and R8 is an optionally substituted lower alkyl. Examples of alkylaminocarbonyl include, but are not limited to, methylaminocarbonyl, dimethylaminocarbonyl, t-butylaminocarbonyl, n-butylaminocarbonyl, iso-propylaminocarbonyl, and trifluoromethylaminocarbonyl.
- “Alkylaminosulfonyl” is the radical —S(O)2NR7R8, wherein R7 is hydrogen or an optionally substituted lower alkyl and R8 is an optionally substituted lower alkyl. Examples of alkylaminosulfonyl include, but are not limited to, methylaminosulfonyl, dimethylaminosulfonyl, and triiodomethylaminosulfonyl.
- “Alkoxycarbonyl” or “alkyl ester” is the radical —C(O)OR8, wherein R8 is an optionally substituted lower alkyl. Examples of alkoxycarbonyl radicals include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, sec-butoxycarbonyl, isopropyloxycarbonyl, and difluoromethoxycarbonyl.
- “Alkylcarbonylamino” is the radical —NR7C(O)R8, wherein R7 is hydrogen or an optionally substituted lower alkyl and R8 is an optionally substituted lower alkyl. Examples of alkylcarbonylamino include, but are not limited to, methylcarbonylamino, iso-propylcarbonylamino, and t-butylcarbonylamino.
- “Alkylcarboxamido” is the radical —C(O)NR7R8, wherein R7 is hydrogen or an optionally substituted lower alkyl and R8 is an optionally substituted lower alkyl. Examples of alkylcarboxamidos are methylcarboxamido, ethylcarboxamido, isopropylcarboxamido, and n-propylcarboxamido.
- “Alkylsulfonyl” is the radical —S(O)2R8, wherein R8 is an optionally substituted lower alkyl. Examples of alkylsulfonyl include, but are not limited to, methylsulfonyl, trifluoromethylsulfonyl, and propylsulfonyl.
- “Alkylsulfonylamino” is the radical —NR7S(O)2R8, wherein R7 is hydrogen or an optionally substituted lower alkyl and R8 is an optionally substituted lower alkyl. Examples of alkylsulfonylamino include, but are not limited to, methylsulfonylamino, propylsulfonylamino, and trifluoromethylsulfonylamino.
- “Aryl” is the monovalent aromatic carbocyclic radical of one individual aromatic ring or two or three fused rings in which at least one of the fused rings is aromatic. Aryls can be optionally substituted on one or more rings with one or more of halogen, hydroxyl, alkoxy, aryloxy, amino, N-alkylamino, N,N-dialkylamino, alkylcarbamoyl, arylcarbamoyl, aminocarbamoyl, N-alkylaminocarbamoyl, N,N-dialkylaminocarbamoyl, alkylsulfonylamino, arylsulfonylamino, carboxy, carboxyalkyl, N-alkylcarboxamido, N,N-dialkylcarboxamido, alkylthio, alkylsulfinyl, alkylsulfonyl, trifluoromethylsulfonylamino, arylthio, arylsulfinyl, arylsulfonyl, hydroxyalkyl, alkoxyalkyl, aryloxalkyl, aminoalkyl, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, alkylcarbamoylalkyl, arylcarbamoylalkyl, aminocarbamoylalkyl, N-alkylaminocarbamoylalkyl N,N-dialkylaminocarbamoylalkyl, alkylsulfonylaminoalkyl, arylsulfonylaminoalkyl, alkylcarboxy, alkylcarboxyalkyl, N-alkylcarboxamindoalkyl, N,N-dialkylcarboxamindoalkyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, trifluoromethylsulfonylaminoalkyl, arylthioalkyl, arylsulfinylalkyl, and arylsulfonylalkyl. Examples of aryls are phenyl, naphthyl, tetrahydronaphthyl, indanyl, indanonyl, tetralinyl, tetralonyl, fluorenonyl, phenanthryl, anthryl, and acenaphthyl.
- “Arylalkoxycarbonyl” or “arylalkyl ester” is the radical —C(O)OR8X, wherein R8 is an optionally substituted lower alkyl and X is an optionally substituted aryl. Examples of aryloxycarbonyl radicals include, but are not limited to, benzyl ester, phenyl ethyl ester, and dimethylphenyl ester.
- “Arylalkylcarbamoyl” is the radical —C(O)NHR8X, wherein R8 is an optionally substituted lower alkyl and X is an optionally substituted aryl. Examples of arylalkylcarbamoyl include, but are not limited to, benzylcarbamoyl, phenylethylcarbamoyl, and cyanophenylcarbamoyl.
- “Arylalkylcarbonyl” (or “aralkylcarbonyl”) is the radical —C(O)R8X, wherein R8 is an optionally substituted lower alkyl and X is an optionally substituted aryl. Examples of arylalkylcarbonyl radicals include, but are not limited to, phenylacetyl and fluorophenylacetyl.
- “Arylaminocarbonyl” (or “arylcarbamoyl”) is the radical —C(O)NXX′, wherein X is an optionally substituted aryl and X′ is hydrogen or an optionally substituted aryl. Examples of arylaminocarbonyl include, but are not limited to, phenylaminocarbonyl, methoxyphenylaminocarbonyl, diphenylaminocarbonyl, and dimethoxyphenyl-aminocarbonyl.
- “Arylaminosulfonyl” is the radical —S(O)2NXX′, wherein X is an optionally substituted aryl and X′ is hydrogen or an optionally substituted aryl. Examples of arylaminosulfonyl include, but are not limited to, phenylaminosulfonyl, methoxyphenylaminosulfonyl, and triiodomethylaminosulfonyl.
- “Arylcarbonyl” is the radical —C(O)X, wherein X is an optionally substituted aryl. Examples of arylcarbonyl radicals include, but are not limited to, benzoyl, naphthoyl, and difluorophenylcarbonyl.
- “Arylcarbonylamino” is the radical —NHC(O)X, wherein X is an optionally substituted aryl. Examples of arylcarbonylamino include, but are not limited to, phenylcarbonylamino, tosylcarbonylamino, and cyanophenylcarbonylamino.
- “Aryloxy” is —OX, wherein X is an optionally substituted aryl. Examples of aryloxys include phenyloxy, naphthyloxy, tetrahydronaphthyloxy, indanyloxy, indanonyloxy, biphenyloxy, tetralinyloxy, tetralonyloxy, fluorenonyloxy, phenanthryloxy, anthryloxy, and acenaphthyloxy.
- “Aryloxycarbonyl” or “aryl ester” is the radical —C(O)OX, wherein X is an optionally substituted aryl. Examples of aryloxycarbonyl radicals include, but are not limited to, phenyl ester, naphthyl ester, dimethylphenyl ester, and trifluorophenyl ester.
- “Arylsulfonyl” is the radical —S(O)2X, wherein X is an optionally substituted aryl. Examples of arylsulfonyl include, but are not limited to, phenylsulfonyl, nitrophenylsulfonyl, methoxyphenylsulfonyl, and 3,4,5-trimethoxyphenylsulfonyl.
- “Arylsulfonylamino” is the radical —NS(O)2X, wherein X is an optionally substituted aryl. Examples of arylsulfonylamino include, but are not limited to, phenylsulfonylamino, naphthylsulfonylamino, 2-butoxyphenylsulfonylamino, 4-chlorophenylsulfonylamino, 2,5-diethoxysulfonylamino, 4-hexyloxyphenylsulfonylamino, 4-methylphenylsulfonyl-amino, naphtylsulfonylamino, 4-methoxyphenylsulfonylamino, N-methylphenylsulfonyl-amino, and 4-cyanophenylsulfonylamino, phenylsulfonylamino, 4-methylphenylsulfonyl-amino, naphtylsulfonylamino. phenylsulfonylamino, and 4-methylphenylsulfonylamino.
- “Arylsulfonyloxy” is the radical —OS(O)2X, wherein X is an optionally substituted aryl. Examples of arylsulfonyloxy include, but are not limited to, benzenesulfonyloxy and 4-chloro-benzenesulfonyloxy.
- “Cycloalkyl” is a monovalent saturated carbocyclic radical consisting of one or more rings, preferably one, of three to seven carbons per ring and can be optionally substituted with one or more of hydroxyl, alkoxy, aryloxy, amino, N-alkylamino, N,N-dialkylamino, alkylcarbamoyl, arylcarbamoyl, aminocarbamoyl, N-alkylaminocarbamoyl, N,N-dialkylaminocarbamoyl, alkylsulfonylamino, arylsulfonylamino, carboxy, carboxyalkyl, N-alkylcarboxamido, N,N-dialkylcarboxamido, alkylthio, alkylsulfinyl, alkylsulfonyl, trifluoromethylsulfonylamino, arylthio, arylsulfinyl, arylsulfonyl, hydroxyalkyl, alkoxyalkyl, aryloxalkyl, aminoalkyl, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, alkylcarbamoylalkyl, arylcarbamoylalkyl, aminocarbamoylalkyl, N-alkylaminocarbamoylalkyl N,N-dialkylaminocarbamoylalkyl, alkylsulfonylaminoalkyl, arylsulfonylaminoalkyl, alkylcarboxy, alkylcarboxyalkyl, N-alkylcarboxamindoalkyl, N,N-dialkylcarboxamindoalkyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, trifluoromethylsulfonylaminoalkyl, arylthioalkyl, arylsulfinylalkyl, and arylsulfonylalkyl. Examples of cycloalkyls are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, cyclooctyl, cycloheptyl, tetrahydro-naphthalene, methylenecylohexyl, indanyl, indenyl, and fluorenyl.
- “Cycloalkylcarbonyl” is the radical —C(O)R, wherein R is an optionally substituted cycloalkyl radical. Examples of cycloalkylcarbonyl radicals include, but are not limited to, cyclobutanoyl, cyclopentanoyl, cyclohexanoyl, and trifluorocyclopentanoyl.
- “Halogen” includes fluorine, chlorine, bromine, and iodine.
- “Heteroaryl” is a monovalent aromatic cyclic radical having one or more rings, preferably one to three rings, of four to eight atoms per ring, incorporating one or more heteroatoms selected independently from nitrogen, oxygen, silicon, and sulfur. Heteroaryls can be optionally substituted on one or more rings with one or more of halogen, hydroxyl, alkoxy, aryloxy, amino, N-alkylamino, N,N-dialkylamino, alkylcarbamoyl, arylcarbamoyl, aminocarbamoyl, N-alkylaminocarbamoyl, N,N-dialkylaminocarbamoyl, alkylsulfonylamino, arylsulfonylamino, carboxy, carboxyalkyl, N-alkylcarboxamido, N,N-dialkylcarboxamido, alkylthio, alkylsulfinyl, alkylsulfonyl, trifluoromethylsulfonylamino, arylthio, arylsulfinyl, arylsulfonyl, hydroxyalkyl, alkoxyalkyl, aryloxalkyl, aminoalkyl, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, alkylcarbamoylalkyl, arylcarbamoylalkyl, aminocarbamoylalkyl, N-alkylaminocarbamoylalkyl N,N-dialkylaminocarbamoylalkyl, alkylsulfonylaminoalkyl, arylsulfonylaminoalkyl, alkylcarboxy, alkylcarboxyalkyl, N-alkylcarboxamindoalkyl, N,N-dialkylcarboxamindoalkyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, trifluoromethylsulfonylaminoalkyl, arylthioalkyl, arylsulfinylalkyl, and arylsulfonylalkyl.
- Representative examples of monocyclic ring system heteroaryls include, but are not limited to, azetidinyl, azepinyl, aziridinyl, diazepinyl, 1,3-dioxolanyl, dioxanyl, dithianyl, furyl, imidazolyl, imidazolinyl, imidazolidinyl, isothiazolyl, isothiazolinyl, isothiazolidinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolyl, oxadiazolinyl, oxadiazolidinyl, oxazolyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, pyridazinyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, thiadiazolyl, thiadiazolinyl, thiadiazolidinyl, thiazolyl, thiazolinyl, thiazolidinyl, thiophenyl, thiomorpholinyl, 1,1-dioxidothiomorpholinyl, thiopyranyl, triazinyl, triazolyl, and trithianyl.
- Bicyclic ring systems include any of the above monocyclic ring systems fused to an aryl group, a cycloalkyl group, or another heteroaryl monocyclic ring system. Representative examples of bicyclic ring systems include but are not limited to, benzimidazolyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, benzofuranyl, benzopyranyl, benzothiopyranyl, benzodioxinyl, 1,3-benzodioxolyl, cinnolinyl, indazolyl, indolyl, indolinyl, indolizinyl, naphthyridinyl, isobenzofuranyl, isobenzothiophenyl, isoindolyl, isoindolinyl, isoquinolyl, phthalazinyl, pyranopyridyl, quinolyl, quinolizinyl, quinoxalinyl, quinazolinyl, tetrahydroisoquinolyl, tetrahydroquinolyl, and thiopyranopyridyl.
- Tricyclic rings systems include any of the above bicyclic ring systems fused to an aryl group, a cycloalkyl group, or a heteroaryl monocyclic ring system. Representative examples of tricyclic ring systems include, but are not limited to, acridinyl, carbazolyl, carbolinyl, dibenzofuranyl, dibenzothiophenyl, naphthofuranyl, naphthothiophenyl, oxanthrenyl, phenazinyl, phenoxathiinyl, phenoxazinyl, phenothiazinyl, thianthrenyl, thioxanthenyl, and xanthenyl.
- “Heteroarylaminocarbonyl” is the radical —C(O)NZZ′, wherein Z is an optionally substituted heteroaryl and Z′ is hydrogen or an optionally substituted heteroaryl. Examples of heteroarylaminocarbonyl include, but are not limited to, pyridinylaminocarbonyl, and thienylaminocarbonyl, furanylaminocarbonyl.
- “Heteroarylaminosulfonyl” is the radical —S(O)2NZZ′, wherein Z is an optionally substituted heteroaryl and Z′ is hydrogen or an optionally substituted heteroaryl. Examples of heteroarylaminosulfonyl include, but are not limited to, thienylaminosulfonyl, piperidinylamino sulfonyl, furanylaminosulfonyl, and imidazolylaminosulfonyl.
- “Heteroarylcarbonyl” is the radical —C(O)Z, wherein Z is an optionally substituted heteroaryl. Examples of heteroarylcarbonyl radicals include, but are not limited to, pyridinoyl, 3-methylisoxazoloyl, isoxazoloyl, thienyl, and furoyl.
- “Heteroarylsulfonyl” is the radical —S(O)2Z, wherein Z is an optionally substituted heteroaryl. Examples of heteroarylsulfonyl include, but are not limited to, thienylsulfonyl, furanylsulfonyl, imidazolylsulfonyl, and N-methylimidazolylsulfonyl.
- “Heteroarylsulfonyloxy” is the radical —OS(O)2Z, wherein Z is an optionally substituted heteroaryl. An examples of hetroarylsulfonyloxy is thienylsulfonyloxy.
- “Heterocycle” is a saturated or partially unsaturated carbocyclic radical having one, two, or three rings each containing one or more heteroatoms selected independently from nitrogen, oxygen, silicon, and sulfur. A heterocycle can be unsubstituted or substituted on any or all of the rings with one or more of halogen, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, amino, N-alkylamino, N,N-dialkylamino, alkylsulfonylamino, arylsulfonylamino, alkylcarbamoyl, arylcarbamoyl, aminocarbamoyl, N-alkylaminocarbamoyl, N,N-dialkylaminocarbamoyl, carboxy, alkylcarboxy, N-alkylcarboxamido, N,N-dialkylcarboxamido, alkylthio, alkylsulfinyl, alkylsulfonyl, trifluoromethylsulfonylamino, arylthio, arylsulfinyl, arylsulfonyl, carboxyalkyl, hydroxyalkyl, alkoxyalkyl, aryloxalkyl, aminoalkyl, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, alkylcarbamoylalkyl, arylcarbamoylalkyl, aminocarbamoylalkyl, N-alkylaminocarbamoylalkyl N,N-dialkylaminocarbamoylalkyl, alkylsulfonylaminoalkyl, arylsulfonylaminoalkyl, alkylcarboxyalkyl, N-alkylcarboxamindoalkyl, N,N-dialkylcarboxamindoalkyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, trihaloalkylsulfonylaminoalkyl, arylthioalkyl, arylsulfinylalkyl, and arylsulfonylalkyl. Examples of heterocycles include piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, thiamorpholinyl, pyrrolyl, phthalamide, succinamide, and maleimide.
- “Heterocyclylcarbonyl” (or “heterocyclocarbonyl”) is the radical —C(O)M′, wherein M′ is an optionally substituted heterocycle. Examples of heterocyclylcarbonyl include, but are not limited to, piperazinoyl, morpholinoyl, and pyrrolindinoyl.
- “Heterocyclylsulfonyl” is the radical —S(O)2Z′, wherein M′ is an optionally substituted heterocycle. Examples of heterocyclylsulfonyl include, but are not limited to, piperidinylsulfonyl and piperazinylsulfonyl.
- “Heterocyclylsulfonyloxy” is the radical —OS(O)2M′, wherein M′ is an optionally substituted heterocycle. Examples of heterocyclylsulfohyloxy include, but are not limited to, 3,5,dimethyl-isoxazolesulfonyloxy and pyrrolidinylsulfonyloxy.
- This invention provides compounds which inhibit tyrosine kinases, particularly Tec (e.g., ITK, BTK), Src (Src, Lck, etc.) and EGFR kinases (e.g., EGFR1, Her 2, Her 4), and Jak kinase (e.g., Jak3), having structures that exploit a discrete mechanistic rationale described herein. This mechanism provides for the utilization of the kinase catalytic machinery, described in the ITK crystallographic structures as the acid-base pair residues Lys391 and Asp500 (herein referred to as the “catalytic dyad”), to trigger a transformation that activates the proposed inhibitory compounds within the enzyme active site. This transformation involves the elimination of a leaving group, resulting in the in situ formation of an electrophilic intermediate capable of forming a covalent adduct with an active site cysteine residue thereby irreversibly inhibiting the function of the target enzyme. This cysteine residue is identifiable as Cys442 in the ITK crystallographic structure. The group of kinases with the above described triad, including ITK, BTK, BMX, Tec, TXK, BLK, EGFr, Her 2, Her 4 and JAK3, will be referred to as the DKC triad kinases. Various embodiments of the invention relate to this group, its possible sub-groupings, and to its individual members.
- It is known that several compounds, typically containing electrophilic Michael acceptors, form covalent adducts with enzymatic nucleophiles present in the active site to irreversibly inhibit the target enzyme (Slichenmeyer, W. J.; Elliott, W. C.; Fry, D. W. Semin. Oncol. 2001, 28, 80-85; Shimamura, T.; Ji, H.; Minami, Y.; Thomas, R. K.; Lowell, A. M.; Sha, K.; Greulich, H.; Glatt, K. A.; Meyerson, M.; Shapiro, I.; Wong, K.-K. Cancer Res. 2006, 66, 6487-6491). However, the compounds described in this invention are unique in that the transformation that forms the electrophilic intermediate takes place preferentially in situ, i.e. within the enzyme active site. Outside of an appropriate active site, these compounds are much less likely to undergo beta-elimination and form adducts with other proteins. The compounds described within must first bind in the active site of the target kinase and achieve a specific conformational geometry with respect to the relevant catalytic residues in order to effectively trigger elimination of the leaving group, thereby unmasking the adduct-forming intermediate. This intermediate forms a covalent, irreversible adduct with the proximal active site cysteine residue. In some embodiments the reaction proceeds stepwise; in other embodiments it is concerted. In preferred embodiments additional portions of the inhibitor molecule interact with other portions of the kinase, particularly in the active site, to promote favorable binding affinity and positioning. Such interactions contribute to the specificity of various inhibitors so that some inhibitors are inhibit a single kinase whereas others inhibit multiple kinases with similar or different IC50s. To our knowledge, this is the first example of an in situ formation of an active inhibitor in a kinase active site.
- Compound Interaction with the Kinase Domain
- Without specifying the kinetics of the reaction, the inhibition of the target kinase goes through the following sequence of steps to form the adduct with the inhibitory compounds:
-
- (1) The catalytic lysine N—H is positioned within hydrogen bonding distance (approximately 1.8-4.0 Angstroms) of a hydrogen bond acceptor Y in the compound that exists in the form of a C═Y (Y═O, S, NOR) functionality. Polarization of the C═Y bond results in increasing the acidity of the proton (HA) at a carbon atom alpha to the C═Y group.
- (2) Acting as a base, the aspartate of the catalytic dyad extracts the acidic proton HA, leaving behind a conjugated carbanion that forms for Y═O, an enol, H-bonded enolate through standard electronic rearrangement. For Y═S, it would form a thioenol or H-bonded thioenolate, and for Y═NOR, it would form an alkoxy (R=alkyl), aryloxy (R=aryl) or hydroxy (R═H) enamine.
- (3) The formation of the enol/thioenol/enamine facilitates the elimination of the leaving group attached at a carbon beta to C═Y, through a process known as “β-elimination.” The leaving group, attached to the compound through protonatable heteroatom Z, may optionally be additionally tethered to the rest of the compound.
- (4) Being a strong nucleophilic species, the sulfhydryl group of the neighboring cysteine residue reacts with the newly formed electrophilic elimination product. This addition reaction (thioalkylation) forms the covalent adduct to the kinase resulting in its irreversible inhibition and abrogation of activity.
- The inhibitory activity of this class of compounds toward select kinases is dependent on their ability to bind effectively in proximity to the appropriate calalytic environment, the existence of a polarizable C═Y group (C═O in formula (I), below) with appropriate reactivity and an adjacent alpha proton to allow elimination of the beta leaving group.
- In turn, the elimination process that generates a reactive electrophilic species requires removal of the abstractable alpha proton that is facilitated by adequate positioning of the C═Y group in the catalytic environment. The generated electrophilic Michael acceptor, in turn is required to be positioned within reactive distance of the key cysteine residue.
- The appropriate positioning of the abstractable proton in the kinase binding site is achieved through pharmacophoric elements that include:
-
- (i) a C═Y moiety that serves the dual purpose of polarizing the proximal C—H bond of the abstractable proton, and hydrogen bonding to the lysine residue of the catalytic pair;
- (ii) a hydrophobic aryl or heteroaryl group that interacts with specific hydrophobic residues in the binding site at an approximate distance of 3-5 Å from Y,
- (iii) several (one to 3) hydrophilic pharmacophores that interact with the backbone in the hinge region,
- (vi) a carbon atom in the beta position from the C═Y carbon atom, that is positioned within reactive distance of the sulfhydryl group of the relevant cysteine as explained below.
- The effective “reactive distance” to the cysteine sulfhydryl group as stated above is observed in the range of about 3-10 Å using computational design methods that test the binding of inhibitors to the ITK ATP binding site, wherein the enzyme is maintained in a fixed conformation. While a distance of 10 Å in a rigid system would be too far to effect a chemical reaction, the enzymatic nucleophilic moiety and the inhibitor's electrophilic moiety can readily be brought together through a series of low energy barrier rotations around the flexible inhibitor bonds as well as the cysteinyl side chain. Overall global conformational changes, common to kinase systems, cannot be ruled out either but are not readily measurable. Such conformational changes, which can be envisioned by computational predictions, are adequate in bringing the two reactive pieces in close enough proximity to effect covalent bond formation.
- Compounds according to the invention have the structural formula:
- wherein:
Ar is optionally substituted aryl or optionally substituted heteroaryl;
R3, R4, R5, and R6 are independently hydrogen or optionally substituted C1-C6 alkyl; and
R1 and R2 (a) are independently hydrogen, optionally substituted C1-C6 alkyl, piperidine, or furanyl; or (b) are taken together with the nitrogen atom to which they are attached to form (i) a 5- to 7-membered optionally substituted aryl, (ii) a 5- to 7-membered optionally substituted heteroaryl, or (iii) a 5- to 7-membered optionally substituted heterocycle which may be unfused or fused to an optionally substituted aryl. - In some embodiments Ar is selected from the group consisting of:
- wherein A, B, E, and Q are independently CH, O, or N; and D and D′ are independently CH2, NH, O, or S.
- In other embodiments Ar is selected from the group consisting of:
- Examples of 5- to 7-membered heterocycles include:
- wherein:
- n=0-2;
R1 and R2 are as defined above; and
R7 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl. - Preferred 5- to 7-membered heterocycles are piperazinyl, piperidinyl, pyrrolidinyl, and morpholinyl. Preferred substituents for piperazinyl are C1-C6 alkyl, dialkyl C1-C6 aminoalkyl, aryl, aralkyl, cycloalkyl, and cycloalkyl-alkyl. Preferred substituents for piperidinyl are C1-C6 alkyl and aralkyl. In some embodiments piperidinyl is benzofused to form isoquinolinyl. Preferred substituents for pyrrolidinyl are C1-C6 alkyl, aryl, and aralkyl. In some embodiments pyrrolidinyl is benzofused to form isoindolyl. Preferred substituents for morpholinyl are C1-C6 alkyl and arylalkyl.
- Some compounds have the structural formula:
- wherein:
-
- R3, R4, R5, and R6 are as defined above;
R9 is selected from,
- R3, R4, R5, and R6 are as defined above;
- and
-
- R10 is hydrogen, —OH, —COOH, —CONH2, or —NCO,
- wherein if R9 is naphthyl, then R5 and R6 are not both methyl.
- Examples of these compounds include:
- Other compounds have the structural formula:
- wherein:
-
- R3, R4, R5, and R6 are as defined above;
- R11 and R12 are independently selected from hydrogen, —OCH3, halogen, —NO2, —CN, —CF3, —NCOR′ (wherein R′ is hydrogen or C1-C4 alkyl), phenyloxy, —OCF3, —NR′R″ (wherein R′ and R″ are independently hydrogen or C1-C4 alkyl), C1-C4 alkyl, C1-C4 alkoxy, and —SO2R′ (wherein R′ is hydrogen or C1-C4 alkyl); and
- R13 is hydrogen, C1-C4 alkyl,
- with the proviso that formula (III) does not include the following compounds:
- One example of a compound of formula (III) is
- Some compounds of the invention have the structural formula:
- wherein R1 and R2 are as defined above, with the exception of
- Examples of such compounds include those of with the following structural formulae:
- in which:
-
- GG is hydrogen, dimethylaminoalkyl, aryl, C1-C6 alkyl, cyclohexylalkyl, pyridine, —COCF3; —CONR′R″, or
-
- J is hydrogen, aralkyl, C1-C6 alkyl, —CNHCOOR′, or NR′R″;
- K is hydrogen, pyridine, aryl, —COOH, —CONR′R″, —COH, or —CNR′R″;
- L is hydrogen or alkyloxy; and
- R2 is as defined above.
- Other compounds of formula (IV) include:
- Other compounds have the structural formula:
- wherein R3, R4, R5, R6, and R10 are as defined above.
- Other compounds have the structural formula:
- wherein:
-
- R1, R2, R3, R4, R5, and R6 are as defined above; and
- R14 is hydrogen or =0;
- and D is CH or NH,
with the exception of:
- Other compounds have the structural formula:
- wherein:
-
- R3, R4, R5, and R6 are as defined above; and
- R1 and R2 are independently hydrogen, C1-C4 alkyl,
- (wherein R15 is halogen or C1-C4 alkyl and R16 is C1-C4 alkyl), or R1 and R2 together with the nitrogen to which they are attached form an aryl group selected from
- (wherein R17 and R18 are independently hydrogen or —OCH3),
- (wherein R1 and R2 are independently hydrogen or C1-C4 alkyl),
- (n=1-4), phenyl-C1-C4 alkyl (optionally substituted with halogen), with the exception of
- Other compounds have the structural formula:
- wherein R3, R4, R5, and R6 are as defined above.
- Other compounds have the structural formula:
- wherein R3, R4, R5, and R6 are as defined above and wherein R1 is hydrogen and R2 is
- wherein R19 is selected from hydrogen and
- or R1 and R2 together with the nitrogen to which they are attached are
- R20 is phenyl-C1-C4 alkyl optionally substituted with one or more halogens, hydrogen, C1-C4 alkyl, amino-C1-C4 alkyl,
- R17 and R18 are independently hydrogen or —OCH3; R21 is —CONR′R″, —COR′,
- and
R′ and R″ are independently selected from hydrogen and C1-C4 alkyl. - In other embodiments compounds have the structural formula:
- wherein R3, R4, R5, and R6 are as defined above and wherein R22 is selected from hydrogen, C1-C4 alkyl, —NR′R″, —COH, —COOH, —CNR′R″, and —CONHR′,
wherein R′ and R″ are as defined above. - In other embodiments compounds have the structural formula:
- wherein R3, R4, R5, R6, G, and G′ are as defined above; and R23 is hydrogen, —NR′R″ C1-C4 linear alkyl, C1-C4 alkyl, phenyl-C1-C4 alkyl, —CONH2, and —COR′R″,
wherein R′ and R″ are as defined above. - In other embodiments compounds have the structural formula:
- R3, R4, R5, and R6 are as defined above and wherein R24 is
- In other embodiments compounds have the structural formula:
- wherein L is
- and wherein R3, R4, R5, and R6 are as defined above.
- Some compounds have the structural formula:
- wherein T, U, V, and W independently are selected from hydrogen; halogen; —O; C1-C3 alkyl; and C1-C3 alkyloxy; and wherein R25 is hydrogen or C1-C3 alkyl. Representative compounds include:
- Other compounds have the structural formula:
- wherein T, U, V, and W independently are selected from hydrogen; halogen; —O; C1-C3 alkyl; and C1-C3 alkyloxy; and wherein R8 is hydrogen or C1-C3 alkyl.
- Still other compounds have the structural formula:
- wherein T, U, V, and W independently are selected from hydrogen; halogen; —O; C1-C3 alkyl; and C1-C3 alkyloxy; and wherein R8 is hydrogen or C1-C3 alkyl.
- Other compounds have the structural formula:
- wherein D is S, O, or NH;
- Other compounds of the invention include those with the structural formula:
- wherein D is defined above;
- Other compounds of the invention include those with the structural formula:
- wherein G′ is NH or CH; i.e.,
- The invention also includes the compounds identified in Examples 15 and 16.
- The compounds of the present invention may have asymmetric centers and may occur as racemates, stereoisomers, and tautomers. The invention includes all possible racemates, tautomers, stereoisomers, and mixtures thereof
- Suitable methods of preparing compounds of the invention are illustrated by the representative examples provided below. Starting materials are known compounds and can be obtained by standard procedures of organic chemistry.
- Provisos for Compound Claims
- Compounds of the invention preferably do not have one or more of the following activities: vasodilator, hypotensive, bradycardiac, anti-depressant, anti-arrhythmic, anti-arteriosclerotic, serum cholesterol lowering, triglyceride level lowering, neuroleptic, anti-inflammatory, tranquilizing, anti-convulsant, anesthetic, muscle relaxing, anti-fungal, anti-bacterial, insecticidal, fumigant, anti-parasitic, central nervous system depressant, antagonization of sedation, antipollakiurea, antihistamine, anti-allergy, bronchodilating, analgesic, spasmolytic, muscarinic antagonist, preventing or decreasing production of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease, hypolipidemic, male anti-fertility, anti-sporicidal, inhibition of nitric oxide production, or central nervous system stimulant activities.
- To the extent any of the following compounds are not novel, Applicants reserve the right to present compound and/or composition claims which include a proviso excluding the compounds and/or their pharmaceutically acceptable salts from the scope of the claims:
-
- a. compounds having the structural formula:
-
-
- wherein n is 0, 1, or 3 and R1 and R2 together with the nitrogen atom to which they are attached are
-
- and Y is alkyl, halogen, halogenoalkyl, alkyoxy, alkylthio, halogenoalkyloxy, halogenoalkylthio, cycloalkyl, or a cyane radical;
-
- b. compounds of formula (I) in which Ar is phenyl, if R3, R4, R5, and R6 are each hydrogen, and R1 and R2 together form a ring with the nitrogen atom to which they are attached
-
- c. compounds having the structural formula:
-
-
- in which Ph is an optionally substituted monocyclic carbocyclic aryl radical, Alk is C1-C3 lower alkyl, and Am is a tertiary amino group, salts, N-oxides, or quaternary ammonium derivatives thereof;
- d. compounds having the structural formula:
-
-
-
- in which Ph1 and Ph2 are monocyclic carboxylic an radicals and the acid addition salts thereof;
- e. compounds having the structural formula:
-
-
-
- in which RR is selected from the group consisting of aliphatic, aromatic, and araliphatic radicals; RR1 is selected from the group consisting of hydrogen, aliphatic, aromatic, and araliphatic radicals; —N(XX) is the residue of a secondary amine selected from the group consisting of dialkylamine and dialkylamines;
- f. compounds having the structural formula:
-
-
-
- wherein R1 and R2 as defined in formula (I), including the compound
-
-
- g. compounds having the structural formula:
-
-
- wherein R30 is an ethyl-, propyl-, isopropyl-, butyl-, or isobutyl group or a cycloalkyl group having 5-7 carbon atoms;
- h. compounds having the structural formula:
-
-
-
- in which M2 is hydrogen, halogen, or C1-C12 alkoxy, M1 is hydrogen or halogen, and M3 and M4 are lower alkyl or, taken together with the nitrogen atom to which they are attached, (a) are a heterocyclic amino group or an N-lower alkyl quaternary heterocyclic ammonium group or (h) a tri-lower alkyl-ammonium;
- i. compounds having the structural formula:
-
-
-
- or a picrate salt thereof, wherein M5 is a simple or substituted aryl group and M6 is a simple or substituted amino group;
- j. compounds having the structural formula:
-
-
-
- in which M7 is thienyl, phenyl or substituted phenyl,
- k. compounds having the structural formula:
-
-
-
- in which each of X1, X2, and X3 are independently hydrogen or an alkyl group, and each of X5 and X4 are independently hydrogen or an alkyl group or, together with the nitrogen atom to which they are attached, form a heterocyclic group with 5, 6, or 7 ring atoms, optionally containing, in addition to N, a further heteroatom selected from N, S, and O;
- l. compounds of formula (II) in which R9 is phenyl and R3, R4, R5, and R6 are each hydrogen;
- m. compounds having the structural formula:
-
-
-
- in which X6 forms with the nitrogen atom pyrrolidine, piperidine, morpholine, hexamethyleneimine, 3-azabicyclo-3,2,2 nonane, including the compound
-
-
- n. compounds having the structural formula:
-
-
- in which X7 is hydrogen or fluorine; X8 is N(X9)phenyl (wherein the phenyl is optionally monosubstituted with C1-C8 alkoxy, C1-C8 alkyl, trifluoromethyl, or halogen), —C(OH)(X9) phenyl (wherein the phenyl is optionally monosubstituted with C1-C8 alkoxy, C1-C8 alkyl, trifluoromethyl, or halogen), or phenyl (Wherein the phenyl is optionally monosubstituted with C1-C8 alkoxy, C1-C8 alkyl, trifluoromethyl, or halogen); and X9 is hydrogen, C1-C8 alkyl, or lower alkanoyl;
- o. compounds having the structural formula:
-
-
-
- wherein X9 and X10 each designate a saturated or unsaturated aliphatic hydrocarbon having 1 to 4 carbon atoms or, together with the nitrogen to which they are attached, form a heterocyclic radical selected from pyrrolidino, piperidine, perhydroazepino, and morpholino;
- p. compounds having the structural formula:
-
-
-
- in which X11 is C2-C3 alkyl;
- q. compounds having the structural formula:
-
-
-
- in which X11 is hydrogen, halogen, C1-C4 alkoxy, nitro, or C1-C4 secondary amine; X12 is (CH2)nOX13; n is 2 or 3; and X13 is C1-C4 alkoxyphenyl, nitrophenyl, trifluoromethylphenyl, or phenyl disubstituted with two halogens, two C1-C4 alkyls, halogen and nitro, halogen and C1-C4 alkyl, halogen and C1-C4 alkoxy, or C1-C4 alkoxy and C1-C4 alkoyl;
- r. compounds having the structural formula:
-
-
-
- in which X14, X15, and X16 are independently hydrogen, halogen, C1-C4 alkyl, halogeno-C1-C4 alkyl, C1-C4 alkoxy, or a cycloalkyl group having 3-8 carbon atoms and two of X14, X15, and X16 may combine to form methylenedioxy or ethyleneoxy; X18 is hydrogen or C1-C4 alkyl, and X17 is pyrrolidinyl-, morpholinyl-, or azepinyl;
- s. compounds having the structural formula:
-
-
-
- Ar denotes an aryl radical; and X19 and X20 (a) are both C1-C6 alkyl or (b) together with the N atom form the remaining members of a saturated heterocyclic radical and X21 is —OH, C1-C6 alkyl, or aryl;
- t. compounds having the structural formula:
-
-
- wherein R1 and R2 independently represent an alkyl radical; or R1 and R2, together with the nitrogen atom to which they are bonded complete an optionally substituted heterocyclic radical of the formula
- R3 is hydrogen or C1-C4 alkyl; and X22, X23, and X24 are independently alkyl; halogen, or a halogeno-C1-C4 alkyl, C1-C4 alkoxy, alkylthio, halogeno-C1-C4 alkoxy, halogeno-C1-C4 alkylthio,
cycloalkyl 3 to 7 carbon atoms, or cyano; -
- u. compounds having the structural formula:
-
-
- wherein Ar is non-substituted an or an substituted with a hydroxyl group, lower alkoxy group or halogen, or non-substituted benzo[b]thienyl group or benzo[b]thienyl group substituted by hydroxyl group, lower alkyl group, lower alkoxy group, aryl group or halogen; R5 is hydrogen or C1-C4 alkyl; and X25 is a group other than piperidine;
- v. compounds having the structural formula:
-
-
-
- wherein L1 and L2 are independently halogen or alkyl; L6 and L7 are independently hydrogen or alkyl; and L3 and L4 are independently hydrogen or an aliphatic group or combine together with the nitrogen to which they are attached to form a ring;
- w. compounds of formula (I), (IV), (VI), (VII), (IX), and (XI) in which if R3 and R4 are hydrogen, then
-
- is not
- wherein L8 is a carbonyl, sulfonyl, methylene, or methylene substituted with optionally substituted phenyl; and Ar is an aryl group;
-
- x. compounds having the structural formula:
-
-
- in which T1 is O, S, or NT7; T7 is hydrogen, C1-C4 alkyl, and CH2CH2COAr1; T6 is hydrogen, C1-C6 alkyl, or T6 and a substituent on the an group together represent CH2, CH2CH2, CH2O, or CH2S to form a five or six membered ring where the ring is optionally substituted with C1-C6 alkyl or phenyl; T5 is hydrogen, C1-C6 alkyl, or optionally substituted phenyl; T2, T3, and T4 are independently hydrogen or C1-C6 alkyl; and Ar and Ar1 are aryl or optionally substituted phenyl; and
- y. the following compounds:
-
- Compounds of the invention can be formulated as pharmaceuticals using methods well known in the art. Pharmaceutical formulations of the invention typically comprise at least one compound of the invention mixed with a carrier, diluted with a diluent, and/or enclosed or encapsulated by an ingestible carrier in the form of a capsule, sachet, cachet, paper or other container or by a disposable container such as an ampoule.
- A carrier or diluent can be a solid, semi-solid or liquid material. Some examples of diluents or carriers which may be employed in the pharmaceutical compositions of the present invention are lactose, dextrose, sucrose, sorbitol, mannitol, propylene glycol, liquid paraffin, white soft paraffin, kaolin, microcrystalline cellulose, calcium silicate, silica polyvinylpyrrolidone, cetostearyl alcohol, starch, gum acacia, calcium phosphate, cocoa butter, oil of theobroma, arachis oil, alginates, tragacanth, gelatin, methyl cellulose, polyoxyethylene sorbitan monolaurate, ethyl lactate, propylhydroxybenzoate, sorbitan trioleate, sorbitan sesquioleate and oleyl alcohol.
- Pharmaceutical compositions of the invention can be manufactured by methods well known in the art, including conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.
- For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as acetate, Hanks's solution, Ringer's solution, or physiological saline buffer. Preferably the solutions are sterile and non-pyrogenic. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
- For oral administration, the active compound(s) can be combined with pharmaceutically acceptable carriers which enable the compound(s) to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like. Fillers can be used, such as gelatin, sugars (e.g., lactose, sucrose, mannitol, or sorbitol); cellulose preparations (e.g., maize starch, wheat starch, rice starch, potato starch, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose); and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compound(s) may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration preferably are in dosages suitable for such administration.
- For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.
- For administration by inhalation, pharmaceutical preparations of the invention can be delivered in the form of an aerosol sprays from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. If desired, a valve can be used to deliver a metered amount. Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator, may be formulated containing a powder mix of a compound and a suitable powder base such as lactose or starch.
- Compounds of the invention can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection can be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
- Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
- Compounds of the invention typically are soluble and stable in 50 mM acetate at a concentration of 10 mg/ml or above, and can be delivered intraperitoneally and orally in this buffer. Some compounds are soluble in hydroxypropyl-b-cyclodextrin (HBPCD, 3-5%), and can be delivered intraperitoneally and orally in this solvent. For intravenous delivery, compounds can be suspended or dissolved in 5% mannitol.
- In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
- In addition to the common dosage forms set out above, the compounds of the present invention may also be administered by controlled release means and/or delivery devices including ALZET® osmotic pumps which are available from Alza Corporation. Suitable delivery devices are described in U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 3,944,064 and 4,008,719.
- The identified compounds can be administered to a human patient, either alone or in pharmaceutical compositions where they are mixed with suitable carriers or excipient(s) at doses to treat or ameliorate blood-related cancers (e.g., lymphomas and leukemias) and autoimmune disorders. Reduction of intracellular kinase activity also is useful to suppress the immune system of transplant patients prior to, during, and/or after transplant.
- Lymphomas are malignant growths of B or T cells in the lymphatic system, including Hodgkin's lymphoma and non-Hodgkin's lymphoma. Non-Hodgkin's lymphomas include cutaneous T cell lymphomas (e.g., Sezary syndrome and Mycosis fungoides), diffuse large cell lymphoma, HTLV-1 associated T cell lymphoma, nodal peripheral T cell lymphoma, extranodal peripheral T cell lymphoma, central nervous system lymphoma, and AIDS-related lymphoma.
- Leukemias include acute and chronic types of both lymphocytic and myelogenous leukemia (e.g, acute lymphocytic or lymphoblastic leukemia, acute myelogenous leukemia, acute myeloid leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, T cell prolymphocytic leukemia, adult T cell leukemia, and hairy cell leukemia).
- Autoimmune disorders include systemic lupus erythematosus, anti-phospholipid antibody syndrome, multiple sclerosis, ulcerative colitis, Crohn's disease, rheumatoid arthritis, asthma, Hashimoto's thyroiditis, Reiter's syndrome, Sjögren's syndrome, Guillain-Barrésyndrome, myasthenia gravis, large vessel vasculitis, medium vessel vasculitis, polyarteritis nodosa, pemphigus vulgaris, scleroderma, Goodpasture's syndrome, glomerulonephritis, primary biliary cirrhosis, Grave's disease, membranous nephropathy, autoimmune hepatitis, celiac sprue, Addison's disease, polymyositis, dermatomyositis, monoclonal gammopathy, Factor VIII deficiency, cryoglobulinemia, peripheral neuropathy, IgM polyneuropathy, chronic neuropathy, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, pernicious anemia, ankylosing spondylitis, vasculitis, inflammatory bowel disease, and type I diabetes mellitus. The autoimmune disease may involve a secretory cell, such as a T lymphocyte, B lymphocyte, Mast cell, or dendritic cell. Compounds of the invention also can be used to treat patients who undergo protein replacement therapies and who develop antibodies to the replacement.
- Routes of Administration
- Pharmaceutical preparations of the invention can be administered locally or systemically. Suitable routes of administration include oral, pulmonary, rectal, transmucosal, intestinal, parenteral (including intramuscular, subcutaneous, intramedullary routes), intranodal, intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, intraocular, transdermal, topical, and vaginal routes. As described in more detail above, dosage forms include, but are not limited to, tablets, troches, dispersions, suspensions, suppositories, solutions, capsules, creams, patches, minipumps and the like. Targeted delivery systems also can be used (for example, a liposome coated with target-specific antibody).
- Dosage
- A pharmaceutical composition of the invention comprises at least one active ingredient in a therapeutically effective amount. A “therapeutically effective dose” is the amount of an active agent which, when administered to a patient, results in a measurable improvement in a characteristic of the disease being treated (e.g., improved laboratory values, retarded development of a symptom, reduced severity of a symptom, improved levels of a biological marker such as CD25a or IL2). The improvement can be evident after a single administration of the therapeutically effective dose. More usually multiple administrations are utilized in order to achieve or maintain optimal effect. In preferred embodiments frequency of administration can range from twice a month to once a week to several times a day, for example 1-4 times a day. In alternative embodiments administration can be by time-release formulations, or extended or continuous infusions. The frequency of administration can be selected to achieve a systemic or local concentration at or above some predetermined level for a period of time. The period of time can be all or a substantial portion of the interval between administrations or comprise the period of time-release or infusion. In some embodiments, the treatment schedule can require that a concentration of the compound be maintained for a period of time (e.g., several days or a week) and then allowed to decay by ceasing administration for a period of time (e.g., 1, 2, 3, or 4 weeks).
- Determination of therapeutically effective amounts is well within the capability of those skilled in the art. A therapeutically effective dose initially can be estimated from in vitro enzyme assays, cell culture assays and/or animal models. For example, a dose can be formulated in an animal model to achieve a circulating concentration range that includes the IC50 as determined in an in vitro enzyme assay or in a cell culture (i.e., the concentration of the test compound which achieves a half-maximal inhibition of ITK or BTK activity). Such information can be used to more accurately determine useful doses in humans.
- Appropriate animal models for the relevant diseases are known in the art. See, e.g., Exp Hematol. 34, 284-88, 2006 (aggressive systemic mastocytosis and mast cell leukemia); Leuk. Lymphoma. 47, 521-29, 2006 (acute myeloid leukemia); Leuk. Lymphoma. 7, 79-86, 1992 (disseminated human B-lineage acute lymphoblastic leukemia and non-Hodgkins lymphoma); J. Virol. 79, 9449-57, 2006 (adult T-cell leukemia); Neoplasia 7, 984-91, 2005 (lymphoma); Oligonucleotides 15, 85-93, 005 (lymphoma); Transfus. Apher. Sci. 32, 197-203, 2005 (cutaneous T cell lymphoma); Nature 17, 254-56, 1991 (follicular lymphoma and diffuse large cell lymphoma); Cell. Mol. Immunol. 2, 461-65, 2005 (myasthenia gravis); Proc. Natl. Acad. Sci. USA 102, 11823-28, 2005 (type I diabetes); Arthritis Rheum. 50, 3250-59, 2004 (lupus erythymatosus); Clin. Exp. Immunol. 99, 294-302, 1995 (Grave's disease); J. Clin. Invest. 116, 905-15, 2006 (multiple sclerosis); Pharmacol Res. e-published Feb. 1, 2006 (ulcerative colitis); J. Pathol. e-published Mar. 21, 2006 (Crohn's disease); J. Clin. Invest. 116, 961-973, 2006 (rheumatoid arthritis); Endocrinol. 147, 754-61, 2006 (asthma); Exp Mol Pathol. 77, 161-67, 2004 (Hashimoto's thyroiditis); J. Rheumatol. Suppl. 11, 114-17, 1983 (Reiter's syndrome); Rheumatol. 32, 1071-75, 2005 (Sjögren's syndrome); Brain Pathol. 12, 420-29, 2002 (Guillain-Barré syndrome); J. Clin. Invest. 110, 955-63, 2002 (vessel vasculitis); Vet. Pathol. 32, 337-45, 1995 (polyarteritis nodosa); Immunol. Invest. 3, 47-61, 2006 (pemphigus vulgaris); Arch. Dermatol. Res. 297, 333-44, 2006 (scleroderma); J. Exp. Med. 191, 899-906, 2000 (Goodpasture's syndrome); J. Vet. Med. Sci. 68, 65-68, 2006 (glomerulonephritis); Liver Int. 25, 595-603, 2005 (primary biliary cirrhosis); Clin. Exp. Immunol. 99, 294-302, 1995 (Grave's disease); J. Clin. Invest. 91, 1507-15, 1993 (membranous nephropathy); J. Immunol. 169, 4889-96, 2002 (autoimmune hepatitis); Isr. J. Med. Sci. 15, 348-55, 1979 (celiac sprue); Surgery 128, 999-1006, 2000 (Addison's disease); J. Neuroimmunol. 98, 130-35, 1999 (polymyositis); Am. J. Pathol. 120, 323-25, 1985 (dermatomyositis); Bone 20, 515-20, 1997 (monoclonal gammopathy); Haemophilia 11, 227-32, 2005 (Factor VIII deficiency); Proc. Natl. Acad. Sci. USA 94, 233-36, 1997 (cryoglobulinemia); Pain 110, 56-63, 2004 (peripheral neuropathy); Ann. Neurol. 49, 712-20, 2001 (IgM polyneuropathy); J. Neurosci. Res. 44, 58-65, 1996 (chronic neuropathy); Eur. J. Immunol. 32, 1147-56, 2002 (autoimmune hemolytic anemia); Haematologica 88, 679-87, 2003 (autoimmune thrombocytopenic purpura); Curr. Top. Microbiol. Immunol. 293, 153-77, 2005 (pernicious anemia); J. Immunol. 175, 2475-83, 2005 (ankylosing spondylitis); Inflamm. Res. 53, 72-77, 2004 (vasculitis); Vet. Pathol. 43, 2-14, 2006 (inflammatory bowel disease); and J. Biol. Chem. 276, -13821, 2001 (anti-phospholipid antibody syndrome).
- LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population) can be determined by standard pharmaceutical procedures in cell cultures and/or experimental animals. Data obtained from cell culture assays or animal studies can be used to determine initial human doses. As is known in the art, the dosage may vary depending upon the dosage form and route of administration used.
- As is well known, the FDA guidance document “Guidance for Industry and Reviewers Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers” (HFA-305) provides an equation for use in calculating a human equivalent dose (HED) based on in vivo animal studies. Based on the studies described in Example 16, below, the human equivalent dose ranges between 1.5 mg/kg and 8 mg/kg, with some compounds showing considerable efficacy at lower or higher doses than those estimated by the HED. Thus, human dosages for systemic administration can range from, e.g., 1.5 mg/kg to 3 mg/kg; 2 mg/kg to 4 mg/kg; 5 mg/kg to 7 mg/kg; and 4 mg/kg to 8 mg/kg. The amount of composition administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the disorder, the manner of administration and the judgment of the prescribing physician.
- All patents, patent applications, and references cited in this disclosure are expressly incorporated herein by reference. The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples, which are provided for purposes of illustration only and are not intended to limit the scope of the invention.
-
- Naphthaldehyde (5.0 g, 32.0 mmole) was dissolved in anhydrous tetrohydrofuran and stirred at −78° C. under N2 (g) atmosphere. To the mixture was added vinyl magnesium bromide (50 ml, 1 M solution in THF) and the reaction was warmed to room temperature and stirred overnight. The reaction was quenched with water and partitioned between EtOAc and water. The organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated under vacuum to give the desired product as yellow oil (5.0 g, 85%). ESI-MS m/z 185 (M+H)+.
-
- To a solution of 1-naphthalen-2-yl-prop-2-en-1-ol (1.3 g, 7.0 mmole) in 30 ml of dichloromethane was added pyridinium chlorochromate (1.5 g, 7.0 mmole). The mixture was stirred at room temperature until oxidation was complete. The solution was filtered through celite and the solvent was concentrated under vacuum. The residue was re-dissolved in EtOAc and washed with water and brine, dried over sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by HPLC using a 0-100% EtOAc-Hx gradient to give the desired product as yellow oil (280 mg, 22%). ESI-MS m/z 183 (M+H)+.
-
- 1-Naphthalen-2-yl-propenone (10 mg, 0.05 mmole) was dissolved in 100 μl of DMSO in one well of a 96 well polypropylene plate. To the mixture was added piperidine (12 μl, 0.10 mmole) and diisopropylethyl amine (17 μl, 0.1 mmole). After completion, the product was purified using HPLC to give the desired product (50 mm×10 mm Phenomenex GEMINI™ column using a 30-100% acetonitrile-water gradient). ESI-MS m/z 268 (M+H)+.
-
- 7-Azaindole (10 g, 84.7 mmol) was dissolved in ether (300 mL) at room temperature. M-CPBA (29.1 g, 1.5 eq.) was added in portions and stirred by manual agitation. After all oxidant was added, the mixture was stirred at room temperature for a further 3 hours. LC/MS showed complete conversion. The mixture was filtered, and the solid was washed with ether (40 mL×3) and air-dried. NMR analysis of this solid in d6-DMSO obtained showed the product as mostly the meta-Chloro benzoic acid salt of 1H-Pyrrolo[2,3-b]pyridine 7-oxide (off white, 17.9 g); MS: m/z 135.3 [MH+].
-
- The m-CBA salt of 1H-Pyrrolo[2,3-b]pyridine 7-oxide (9 g) was taken into POCl3 (46 mL, 7.5 eq.). The mixture was heated at 90° C. for 15 hours and to 106° C. for another 4 hours. The mixture was cooled to room temperature, and most of the POCl3 was distilled off under high vacuum. The residue was dissolved in CH3CN (10 mL). Water (20 mL) was added slowly to quench the reaction. The resulted mixture was adjusted to pH ˜9 using 10 N NaOH. The solid was filtered. The crude solid was redissolved in several ml of THF and combiflashed using 0-10% MeOH in DCM to give 4-Chloro-1H-pyrrolo[2,3-b]pyridine as a slightly yellowish solid. (4 g). MS: m/z 154.9 [MH+].
-
- 4-Chloro-1H-pyrrolo[2,3-b]pyridine (500 mg, 3.27 mmol) was dissolved in dioxane (11 mL). 4-Acetyl phenylboronic acid (802 mg, 4.9 mmol, 1.5 eq), dppfPdCl2 (41 mg, 0.03 mmol, 0.01 eq) and Na2CO3 (2 N aq., 8.6 mL) were charged. The mixture was vacuumed and flushed with N2 and microwaved at 160° C. for 15 minutes. Six batches of this same reaction were carried out. The crude mixture was pooled and partitioned between DCM (40 mL) and water (20 mL). Combi-flash of the residue using hexane/EtOAc (0% to 100%) gave the free base azaindole derivative as a slightly yellowish solid. The solid was redissolved in DCM (20 mL) and stirred in an ice bath. A 2M HCl solution in ether (10 mL) was added dropwise. The precipitate was filtered and dried to give 1-[4-(1H-Pyrrolo[2,3-b]pyridin-4-yl)-phenyl]-ethanone. (2.5 g, 48%). MS: m/z 237.3 [MH+].
-
- 2-Chloropyridine-4-boronic acid (11.0 g, 69.9 mmol), 3-Bromoacetophenone (11.2 mL, 83.9 mmol, 1.2 eq.), Na2CO3 (35 mL, 244.65 mmol, 3.5 eq.) and dppfPdCl2 (572 mg, 0.07 mmol, 0.01 eq.) were mixed in THF (200 mL). The mixture was heated to reflux and continued at this temperature for 6 hours. It was then cooled and concentrated in vacuo. The residue was partitioned between DCM and water (100 mL/40 mL). The layers were separated and the aqueous layer was washed further with DCM (2×40 mL). The combined organic layer was dried (Na2SO4) and filtered. The filtrate was concentrated, and the residue was chromatographed using 1/1 hexane/EtOAc to give 1-[3-(2-Chloro-pyridin-4-yl)-phenyl]-ethanone as a white solid (9.5 g, 58%). MS: m/z 232.1 [MH+].
-
- A degassed mixture of 1-[3-(2-Chloro-pyridin-4-yl)-phenyl]-ethanone (500 mg, 2.16 mmol), benzamide (523 mg, 4.32 mmol, 2 eq.), Xantphos (120 mg, 0.21 mmol, 0.1 eq.), Pd(OAc)2 (24 mg, 0.10 mmol, 0.05 eq.), K2CO3 (448 mg, 3.24 mmol, 1.5 eq.) in dioxane (12 mL) was irradiated with microwaves at 150° C. for 1 hour. LC/MS control. Conversion was mostly 100% based on disappearance of starting material. Dimer (M+: 392) being the major by-product. If any starting material is unreacted at this point, another portion of Xantphos and Pd(OAc)2 may be added and the mixture microwaved for another 30 minutes. The mixture was then partitioned between DCM and water (20 mL/10 mL). The layers were separated and the aqueous layer was washed further with DCM (2×20 mL). The combined organic layer was dried (Na2SO4) and filtered. The filtrate was concentrated and the residue was chromatographed using 1/1 Hexane/EtOAc to give N-[4-(3-Acetyl-phenyl)-pyridin-2-yl]-benzamide as a white solid (375 mg, 55%). MS: m/z 317.1 [MH+].
-
- N-[4-(3-Acetyl-phenyl)-pyridin-2-yl]-benzamide (200 mg, 0.632 mmol), morpholine HCl salt (78 mg, 0.632 mmol, 1 eq.) and paraformaldehyde (19 mg, 0.632 mmol, 1 eq.) were mixed with dioxane (2 mL) in a microwave tube. It was irradiated at 180° C. for 15 minutes. The mixture was partitioned between DCM/water (10 mL/5 mL). The aqueous layer was washed further with DCM (2×10 mL). The combined organic layer was dried (Na2SO4) and filtered. The filtrate was concentrated and the residue was chromatographed using 20/1 DCM/MeOH to give N-{4-[3-(3-Morpholin-4-yl-propionyl)-phenyl]-pyridin-2-yl}-benzamide as a slightly yellow solid (100 mg, 38%). MS: m/z 416.3 [MH+].
-
- N-{4-[3-(3-Morpholin-4-yl-propionyl)-phenyl]-pyridin-2-yl}-benzamide (100 mg, 0.32 mmol) was dissolved in HCl (2 mL, 6 N). The mixture was irradiated with microwaves at 140° C. for 30 minutes. The mixture was diluted with DCM (20 mL) and neutralized with NaOH to pH ˜9. The layers were separated and the aqueous layer was washed further with DCM (2×15 mL). The combined organic layer was dried (Na2SO4) and filtered. The filtrate was concentrated and the residue was purified to give 1-[3-(2-Amino-pyridin-4-yl)-phenyl]-3-morpholin-4-yl-propan-1-one (TFA salt) as a white solid (84 mg, 78%). MS: m/z 312.3 [MH+].
-
- According the same procedure for the preparation of N-[4-(3-Acetyl-phenyl)-pyridin-2-yl]-benzamide, N-[4-(3-Acetyl-phenyl)-pyridin-2-yl]-4-tert-butyl-benzamide (130 mg, 81%, slight impurity) was obtained from 1-[3-(2-Chloro-pyridin-4-yl)-phenyl]-ethanone (100 mg, 0.43 mmol) and 4-tert-butylbenzamide (153 mg, 0.86 mmol). MS: m/z 373.1 [MH+].
-
- According to the same procedure for the preparation of 1-[3-(2-Amino-pyridin-4-yl)-phenyl]-3-morpholin-4-yl-propan-1-one, 4-tert-Butyl-N-{4-3-(3-morpholin-4-yl-propionyl)-phenyl]-pyridin-2-yl}-benzamide (12 mg, 30%) was obtained from N-[4-(3-Acetyl-phenyl)-pyridin-2-yl]-4-tert-butyl-benzamide (36 mg, 0.1 mmol). MS: m/z 472.3 [MH+].
-
- According the same procedure for the preparation of N-[4-(3-Acetyl-phenyl)-pyridin-2-yl]-benzamide, N-[4-(3-Acetyl-phenyl)-pyridin-2-yl]-acetamide (50 mg, 50%, slight impurity) was obtained from 1-[3-(2-Chloro-pyridin-4-yl)-phenyl]-ethanone (100 mg, 0.43 mmol) and acetamide (26 mg, 0.86 mmol). MS: m/z 255.1 [MH+].
-
- According to the same procedure for the preparation of 1-[3-(2-Amino-pyridin-4-yl)-phenyl]-3-morpholin-4-yl-propan-1-one, N-{4-[3-(3-Morpholin-4-yl-propionyl)-phenyl]-pyridin-2-yl}-acetamide (10 mg, 20%) was obtained from N-[4-(3-Acetyl-phenyl)-pyridin-2-yl]-acetamide (50 mg, 0.2 mmol). MS: m/z 354.3 [MH+].
- Measurement of IL-2 Production
- Human T cell lines were plated in 96 well plates pre-coated with anti-CD3 monoclonal antibodies. Wells were either left untreated or treated with anti-CD28 for 2 days. The supernatant was collected and tested for IL-2 production in the presence or absence of a test compound using a human IL-2 ELISA assay.
- T Cell Proliferation Assay
- Human T cell lines were plated in 96 well plates pre-coated with anti-CD3 monoclonal antibodies. Wells were either left untreated or treated with anti-CD28 for 2 days. Cell proliferation was measured in the presence or absence of a test compound using a commercially available CELLTITER-GLO™ assay (Promega).
- In Vitro Kinase Assays
- Compounds were screened using the HITHUNTER™ enzyme fragment complementation method (Discoverx). Briefly, a recombinantly produced, N-terminally His-tagged ITK kinase domain (amino acids 352-617) was incubated with various concentrations of individual compounds. ATP and substrate were added, and the kinase reaction was allowed to proceed for 2-16 hours. Commercially available detection reagents were added and allowed to react for 2-4 hours. The reaction was evaluated by luminescence. Initial results were confirmed using full-length recombinant ITK protein.
- Similarly, commercially available reagents such as HITHUNTER™ were used to evaluate the effect of compounds on the activity of additional kinases. The kinase domains of BTK, LCK and ERK were expressed as recombinant purified proteins were used for these studies.
- The compounds in Table 1 were tested and shown to inhibit IL-2 production, to inhibit T cell proliferation, and to inhibit ITK with an IC50 of less than 1 μM.
- The compounds in Tables 2-5 were tested in in vitro kinase assays:
-
TABLE 2 IC50 ITK IC50 BTK IC50 LCK Compound (μM) (μM) (μM) 0.005 0.42482 12.55299 0.040 0.27584 2.89341 0.04022 0.0369 8.03843 0.013 1.41274 27.7419 0.013 0.10223 34.05941 0.014 1.83528 23.89837 0.020 0.025 0.36501 NO IC50 0.029 0.64341 413.06105 0.035 0.94241 16.4214 0.036 0.039 19.969 0.043 0.6561 27.11277 0.056 0.86517 NO IC50 0.065 1.24489 18.43928 0.067 0.12463 28.09552 0.072 0.7368 NO IC50 0.065 0.39763 23.16665 0.091 0.09415 18.46087 0.077 0.77538 47.61179 0.096 1.53948 20.8277 0.104 0.23242 NO IC50 0.148 0.77352 28.01341 0.180 1.52018 163.63704 0.186 3.67569 20.64831 0.199 0.4735 NO IC50 0.207 0.09415 18.46087 0.208 2.89272 33.1157 0.207 0.08071 NO IC50 0.219 1.30729 NO IC50 0.223 1.47599 21.15799 0.241 0.81405 NO IC50 0.290 0.68214 25.86619 0.305 0.74064 NO IC50 0.345 3.1355 21.10834 0.381 3.03351 32.57859 0.385 1.47531 25.34326 0.385 3.92321 23.25 0.385 0.75252 23.94596 0.468 1.21899 NO IC50 0.560 3.06627 24.36134 0.569 1.01979 NO IC50 0.611 2.31114 NO IC50 0.797 3.62429 NO IC50 0.935 0.99267 29.52378 0.874 2.57662 NO IC50 1.279 0.55617 704.77096 1.406 4.1378 27.08267 -
TABLE 5 IC50 ITK IC50 BTK Compound (μM) (μM) 0.0205 0.0395 0.1369 8.21849 0.0080 0.06706 0.0169 0.0602 0.12799 0.0148 0.5375 0.8516 0.0309 0.0212 0.1609 0.0242 0.0072 0.11532 0.3096 0.0069 0.0492 0.0187 0.0095 0.0162 0.0359 0.0147 0.0092 0.0062 0.16054 0.0163 0.117 0.410 0.023 0.153 0.056 0.452 0.060 0.242 0.066 0.089 0.064 0.360 0.054 0.018 0.087 0.051 0.031 0.071 0.066 0.117 0.049 0.123 0.086 0.084 0.284 0.486 0.217 0.266 0.163 0.100 0.036 0.004 0.737 0.373 - Several representative compounds were evaluated for efficacy in mouse in vivo tumor models. NOD/SCID mice were implanted intraperitoneally with T cell leukemia/lymphoma cells. One group was treated with vehicle alone (mock treatment) while the other groups were treated with several small molecule inhibitors via intraperitoneal route. Tumor growth was evaluated by peritoneal lavage and FACS analysis. Table 6 summarizes percent inhibition of tumor growth relative to a mock group treated with vehicle alone. Doses of compounds evaluated in this study were below the maximal tolerated dose, and showed minimal toxicity.
- The compounds in Table 6 were tested and inhibited tumor growth by at least 50% at the concentrations shown.
- The compound class interacts selectively with kinase domains of such kinase families as Tec and EGFR, as well as a few additional kinases. There is evidence indicating that this class of compounds reacts irreversibly at the ATP binding site of the kinase binding domain, through a mechanism that involves the exposure of a reactive aminoethyl C═Y warhead through the in situ elimination of a leaving group. The compounds contain an abstractable proton adjacent to the C═Y group, which upon exposure to an appropriate catalytic environment in the active site of a kinase of interest will promote elimination of the beta-amino functionality. This elimination thus generates a reactive electrophilic species (commonly termed a Michael acceptor moiety) which, due to the existence of a proximal cysteine residue in the kinase active site, rapidly forms a covalent adduct between this cysteine residue and the in situ generated electrophylic species. The combination of a kinase with the catalytic environment in close proximity to a nucleophilic cysteine, is a vital and unique requirement that describes this mechanism of action. The data below support that in situ elimination promotes the inhibitory activity of compounds in depicted in this invention. When a compound is modified in a manner that prevents elimination, the compound fails to exhibit inhibitory activity.
- As a result of elimination in proximity of a relevant cysteine, a covalent adduct is formed between the compound and the kinase domain. The irreversible binding that ensues can be demonstrated by several methods, including surface plasmon resonance (SPR) and co-precipitation of the compound with the kinase.
- BIACORE® is a SPR-based protein interaction approach, whereby the kinase is immobilized on the sensor chip, and a small molecule solution allowed to interact with the kinase. Detection of small molecule/kinase interaction occurs in real time, and is detected as a difference in SPR response.
FIG. 1 shows a BIACORE® experiment in which the ITK kinase domain was immobilized on a biosensor, and evaluated for its ability to bind and dissociate form a small molecule. The data indicates that compounds depicted in this application bind to the ITK kinase domain irreversibly. - In the co-precipitation assay, 1-10 mM labeled compound is incubated with cell lysates from either kinase expressing or kinase lacking cells. The label is then used to precipitate the compound and any bound proteins. The mixture is separated by SDS-PAGE and proteins are identified by western blotting and/or Mass spectrophotometry.
- In order to confirm the mechanism by which compounds depicted herein interact with the kinase domain of Tec and EGFR kinases, we created a point mutant of the ITK kinase domain, whereby the key amino acid, namely C442 was mutated to alanine The protein was expressed in a commercial baculovirus expression system using the manufacturer's general protocol (Invitrogen, pBlueBac). Protein was expressed and purified using standard techniques. Both wild type (WT) ITK kinase domain and C442A kinase domain exhibited kinase activity. While the activity of WT-ITK was inhibited by compounds depicted in this application, the same compounds had no activity towards the C442A mutant kinase domain.
Claims (13)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/177,657 US20110281850A1 (en) | 2006-05-18 | 2011-07-07 | Intracellular kinase inhibitors |
US14/696,348 US20150290200A1 (en) | 2006-05-18 | 2015-04-24 | Intracellular kinase inhibitors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80107406P | 2006-05-18 | 2006-05-18 | |
US86966406P | 2006-12-12 | 2006-12-12 | |
US11/750,866 US8604031B2 (en) | 2006-05-18 | 2007-05-18 | Intracellular kinase inhibitors |
US13/177,657 US20110281850A1 (en) | 2006-05-18 | 2011-07-07 | Intracellular kinase inhibitors |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/750,866 Continuation US8604031B2 (en) | 2006-05-18 | 2007-05-18 | Intracellular kinase inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/696,348 Continuation US20150290200A1 (en) | 2006-05-18 | 2015-04-24 | Intracellular kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110281850A1 true US20110281850A1 (en) | 2011-11-17 |
Family
ID=38723876
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/750,866 Expired - Fee Related US8604031B2 (en) | 2006-05-18 | 2007-05-18 | Intracellular kinase inhibitors |
US13/177,657 Abandoned US20110281850A1 (en) | 2006-05-18 | 2011-07-07 | Intracellular kinase inhibitors |
US14/076,457 Abandoned US20140080833A1 (en) | 2006-05-18 | 2013-11-11 | Intracellular kinase inhibitors |
US14/696,348 Abandoned US20150290200A1 (en) | 2006-05-18 | 2015-04-24 | Intracellular kinase inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/750,866 Expired - Fee Related US8604031B2 (en) | 2006-05-18 | 2007-05-18 | Intracellular kinase inhibitors |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/076,457 Abandoned US20140080833A1 (en) | 2006-05-18 | 2013-11-11 | Intracellular kinase inhibitors |
US14/696,348 Abandoned US20150290200A1 (en) | 2006-05-18 | 2015-04-24 | Intracellular kinase inhibitors |
Country Status (7)
Country | Link |
---|---|
US (4) | US8604031B2 (en) |
EP (2) | EP2865381A1 (en) |
JP (3) | JP5682051B2 (en) |
AU (1) | AU2007254179B2 (en) |
CA (2) | CA2858520A1 (en) |
MX (1) | MX2008014450A (en) |
WO (1) | WO2007136790A2 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100254905A1 (en) * | 2006-09-22 | 2010-10-07 | Lee Honigberg | Inhibitors of bruton's tyrosine kinase |
US8809273B2 (en) | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
US9145387B2 (en) | 2013-02-08 | 2015-09-29 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
US9212181B2 (en) | 2008-06-27 | 2015-12-15 | Celgene Avilomics Research, Inc. | Substituted 2,4-diaminopyrimidines as kinase inhibitors |
US9238629B2 (en) | 2010-11-01 | 2016-01-19 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US9273051B2 (en) | 2011-12-30 | 2016-03-01 | Pharmacyclics Llc | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US9364476B2 (en) | 2011-10-28 | 2016-06-14 | Celgene Avilomics Research, Inc. | Methods of treating a Bruton's Tyrosine Kinase disease or disorder |
US9375431B2 (en) | 2010-11-01 | 2016-06-28 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidine compounds useful as kinase inhibtors |
US9409921B2 (en) | 2008-06-27 | 2016-08-09 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines as kinase inhibitors |
US9409887B2 (en) | 2010-11-10 | 2016-08-09 | Celgene Avilomics Research, Inc. | Mutant-selective EGFR inhibitors and uses thereof |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
US9549927B2 (en) | 2012-12-21 | 2017-01-24 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
WO2017040617A1 (en) | 2015-08-31 | 2017-03-09 | Pharmacyclics Llc | Btk inhibitor combinations for treating multiple myeloma |
US9604936B2 (en) | 2010-08-10 | 2017-03-28 | Celgene Car Llc | Besylate salt of a BTK inhibitor |
US9624224B2 (en) | 2013-09-30 | 2017-04-18 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
US9814721B2 (en) | 2010-06-03 | 2017-11-14 | Pharmacyclics Llc | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
US9862722B2 (en) | 2011-07-13 | 2018-01-09 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
US9908884B2 (en) | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
WO2018085731A2 (en) | 2016-11-03 | 2018-05-11 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and a btk inhibitor |
US10005760B2 (en) | 2014-08-13 | 2018-06-26 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
WO2019213184A1 (en) | 2018-05-03 | 2019-11-07 | Juno Therapeutics, Inc. | Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor |
US10954567B2 (en) | 2012-07-24 | 2021-03-23 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK) |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1836169T3 (en) | 2004-12-28 | 2012-07-31 | Kinex Pharmaceuticals Llc | Compositions and methods of treating cell proliferation disorders |
US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
MX2008014450A (en) * | 2006-05-18 | 2009-03-09 | Mannkind Corp | Intracellular kinase inhibitors. |
AU2007265373B2 (en) | 2006-06-29 | 2013-02-21 | Atnx Spv, Llc | Biaryl compositions and methods for modulating a kinase cascade |
WO2008121742A2 (en) * | 2007-03-28 | 2008-10-09 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
US7935697B2 (en) | 2006-12-28 | 2011-05-03 | Kinex Pharmaceuticals, Llc | Compositions for modulating a kinase cascade and methods of use thereof |
US7939529B2 (en) | 2007-05-17 | 2011-05-10 | Kinex Pharmaceuticals, Llc | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof |
US8124605B2 (en) | 2007-07-06 | 2012-02-28 | Kinex Pharmaceuticals, Llc | Compositions and methods for modulating a kinase cascade |
US20100298329A1 (en) * | 2007-09-19 | 2010-11-25 | Massachusette Institute Of Technology | Tolperisone and tolperisone-like drugs for the treatment of k-ras associated cancers |
EP2217229B1 (en) * | 2007-10-20 | 2020-10-14 | Athenex, Inc. | Pharmaceutical compositions for modulating a kinase cascade and methods of use thereof |
CN102159214A (en) | 2008-07-16 | 2011-08-17 | 药品循环公司 | Inhibitors of bruton's tyrosine kinase for treatment of solid tumors |
WO2011034907A2 (en) * | 2009-09-16 | 2011-03-24 | Avila Therapeutics, Inc. | Protein kinase conjugates and inhibitors |
US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
MX2012007684A (en) | 2009-12-30 | 2012-10-05 | Avila Therapeutics Inc | Ligand-directed covalent modification of protein. |
CN102834380B (en) * | 2010-03-10 | 2015-04-01 | 阿斯利康公司 | Inhibitors of protein kinases |
US8748423B2 (en) | 2010-04-16 | 2014-06-10 | Kinex Pharmaceuticals, Llc | Compositions and methods for the prevention and treatment of cancer |
AU2013225592B2 (en) * | 2012-02-27 | 2017-11-09 | British Columbia Cancer Agency Branch | Reprogramming effector protein interactions to correct epigenetic defects in cancer |
WO2013153539A1 (en) | 2012-04-13 | 2013-10-17 | Glenmark Pharmaceuticals S.A. | Tricyclic compounds as tec kinase inhibitors |
CA3218491A1 (en) | 2012-06-04 | 2013-12-12 | Pharmacyclics Llc | Crystalline forms of a bruton's tyrosine kinase inhibitor |
SI2890680T1 (en) | 2012-08-30 | 2018-08-31 | Athenex, Inc. Conventus Building | N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl)pyridin-2-yl) acetamide as protein tyrosine kinase modulators |
JP2015532281A (en) | 2012-09-26 | 2015-11-09 | マンカインド コーポレイション | Multiple kinase pathway inhibitors |
BR112015011171A2 (en) | 2012-11-15 | 2017-07-11 | Pharmacyclics Inc | pyrrolopyrimidine compounds as kinase inhibitors |
PT2989106T (en) | 2013-04-25 | 2017-03-15 | Beigene Ltd | Fused heterocyclic compounds as protein kinase inhibitors |
WO2015017812A1 (en) | 2013-08-02 | 2015-02-05 | Pharmacyclics, Inc. | Methods for the treatment of solid tumors |
WO2015023703A1 (en) | 2013-08-12 | 2015-02-19 | Pharmacyclics, Inc. | Methods for the treatment of her2 amplified cancer |
PL3702373T3 (en) | 2013-09-13 | 2022-12-05 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
US9937171B2 (en) | 2014-04-11 | 2018-04-10 | Acerta Pharma B.V. | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
KR102003754B1 (en) | 2014-07-03 | 2019-07-25 | 베이진 엘티디 | Anti-PD-L1 Antibodies and Their Use as Therapeutics and Diagnostics |
EP3174539A4 (en) | 2014-08-01 | 2017-12-13 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase |
WO2016022942A1 (en) | 2014-08-07 | 2016-02-11 | Pharmacyclics Llc | Novel formulations of a bruton's tyrosine kinase inhibitor |
AU2016226279B2 (en) | 2015-03-03 | 2021-11-11 | Pharmacyclics Llc | Pharmaceutical formulations of Bruton's tyrosine kinase inhibtor |
WO2018007885A1 (en) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
KR20230162137A (en) | 2016-08-16 | 2023-11-28 | 베이진 스위찰랜드 게엠베하 | (S)-7-(1-Acryloylpiperidin-4-yl)-2-(4-Phenoxyphenyl)-4,5,6,7-tetra-Hydrazolo[1,5-a]Pyrimidine-3-Carboxamide, Preparation, and Uses Thereof |
TWI739887B (en) | 2016-08-19 | 2021-09-21 | 英屬開曼群島商百濟神州有限公司 | Treatment cancers using a combination comprising btk inhibitors |
CN109982687A (en) | 2016-09-19 | 2019-07-05 | 梅制药公司 | Conjoint therapy |
EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
CN110832070A (en) | 2017-05-10 | 2020-02-21 | 艾欧凡斯生物治疗公司 | Expansion of liquid tumor-derived tumor infiltrating lymphocytes and therapeutic uses thereof |
CA3066518A1 (en) | 2017-06-26 | 2019-01-03 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | Btk INHIBITORS WITH IMPROVED DUAL SELECTIVITY |
JP2021503885A (en) | 2017-11-22 | 2021-02-15 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Expanded culture of peripheral blood lymphocytes (PBL) from peripheral blood |
US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
WO2019217753A1 (en) | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
MX2021010288A (en) | 2019-03-01 | 2021-09-23 | Iovance Biotherapeutics Inc | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof. |
US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005037843A1 (en) * | 2003-10-14 | 2005-04-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
US7138420B2 (en) * | 2002-08-08 | 2006-11-21 | Boehringer Ingelheim Pharmaceuticals Inc. | Substituted benzimidazole compounds |
US20080261975A1 (en) * | 2005-11-12 | 2008-10-23 | Joerg Martin Bentzien | Tec Kinase Inhibitors |
US20120058996A1 (en) * | 2008-12-19 | 2012-03-08 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
Family Cites Families (215)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3314970A (en) | 1967-04-18 | Pykrolidino ketones | ||
US2282907A (en) | 1941-05-01 | 1942-05-12 | Us Rubber Co | Parasiticide |
US2649444A (en) | 1948-10-19 | 1953-08-18 | Burroughs Wellcome Co | Process for the preparation of amino ketones |
US2778853A (en) | 1952-09-10 | 1957-01-22 | Merck & Co Inc | Deamination process |
US2771391A (en) | 1953-08-20 | 1956-11-20 | Allied Lab Inc | Physiologically active p-alkoxy-beta-piperidinopropiophenones causing cns depressantand anesthetic effects in animals |
US2997479A (en) | 1955-07-01 | 1961-08-22 | Endo Lab | 1, 1-diphenyl-1-hydroxy-4-(pyrrolidyl)-butanone-2 |
BE561320A (en) | 1956-10-04 | 1960-05-20 | Lab Pharmaceutica Nv | PROCESS FOR THE PREPARATION OF NEW 4-CARBALKOXY-4-PHENYL PIPERIDINE DERIVATIVES. |
US3080372A (en) | 1960-03-25 | 1963-03-05 | Res Lab Dr C Janssen | 1-aroylalkyl-4-arylpiperidine derivatives |
CH402859A (en) | 1960-05-24 | 1965-11-30 | Wander Ag Dr A | Process for the preparation of α-pyrrolidino-valerophenones |
US3151124A (en) | 1961-11-20 | 1964-09-29 | Ciba Geigy Corp | Alpha oxy-beta alkyl-gamma tertiary amino-alpha phenyl propanes |
US3252996A (en) | 1962-10-02 | 1966-05-24 | Ciba Geigy Corp | Alpha-pyrrolidinomethyl valero and caprophenones |
NL125054C (en) | 1962-06-11 | |||
US3203962A (en) | 1962-10-11 | 1965-08-31 | Ciba Geigy Corp | Alpha-phenyl-beta pyrrolidino-propiophenones |
US3310566A (en) | 1963-11-18 | 1967-03-21 | American Home Prod | Substituted 4-piperidino-butyrophenone oximes |
US3284453A (en) | 1964-09-29 | 1966-11-08 | American Cyanamid Co | 4-(2-aroylethyl)-1-piperazinecarboxylic acid esters |
US3340300A (en) | 1964-10-05 | 1967-09-05 | American Cyanamid Co | Trimethoxy benzoylacetaldehyde oximes |
NL143925C (en) | 1965-03-09 | |||
US3816433A (en) | 1965-03-24 | 1974-06-11 | Ferrosan Ab | 4-fluoro-ypsilon-(4-methylpiperidino)-butyrophenone and its pharmaceutically acceptable salts |
GB1079520A (en) | 1965-07-19 | 1967-08-16 | Roche Products Ltd | Novel tetrahydro-isoquinoline derivatives and a process for the manufacture thereof |
US3317538A (en) | 1965-10-22 | 1967-05-02 | American Home Prod | 4, 4'-diamino-butyrophenones |
US3417087A (en) | 1965-12-27 | 1968-12-17 | Research Corp | 3(aminopropionyl)benzothiophenes |
US3364120A (en) * | 1966-01-24 | 1968-01-16 | Babcock & Wilcox Co | Nuclear control rod actuator |
US3637704A (en) | 1967-10-18 | 1972-01-25 | Dainippon Pharmaceutical Co | 1gamma-(p-fluorobenzoyl)propyl-4-phenylalkyl piperazine |
GB1186495A (en) | 1968-02-20 | 1970-04-02 | Delalande Sa | 0-[3-(4-Fluorobenzoyl) Proplyl]-4-Substituted Piperazines, their Acid Addition Salts and their method of preparation |
GB1196721A (en) | 1968-02-23 | 1970-07-01 | Ici Ltd | Piperazine Derivatives |
CH503726A (en) | 1968-04-29 | 1971-02-28 | Ciba Geigy Ag | Substd phenylacetic acid esters analgesic anti |
US3465080A (en) | 1968-10-07 | 1969-09-02 | American Cyanamid Co | Therapeutic compositions containing morpholinoalkylene - indoles and methods of administering such in the treatment of depression |
FR2035749A1 (en) | 1969-02-06 | 1970-12-24 | Bellon Labor Sa Roger | |
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
GB1262965A (en) | 1969-03-21 | 1972-02-09 | Ferrosan As | Butyrophenones |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3651085A (en) | 1969-04-14 | 1972-03-21 | Robins Co Inc A H | 1-(omega-benzoylalkyl)-3-substituted pyrrolidines |
US3703527A (en) | 1969-06-04 | 1972-11-21 | Hoffmann La Roche | Preparation of mannich-bases |
US3907812A (en) | 1969-07-16 | 1975-09-23 | Sumitomo Chemical Co | Butyrophenone derivatives |
US3936468A (en) | 1969-10-27 | 1976-02-03 | Sumitomo Chemical Company, Ltd. | Phenylbutanol derivatives |
US3799932A (en) | 1970-03-20 | 1974-03-26 | Sumitomo Chemical Co | Gamma-piperidinobutyrophenones |
US3651067A (en) | 1970-04-15 | 1972-03-21 | Usv Pharma Corp | Styrene ethers of amino alcohols |
DE2021470A1 (en) | 1970-05-02 | 1971-11-25 | Cassella Farbwerke Mainkur Ag | Piperazine derivatives |
FR2092133B1 (en) | 1970-05-06 | 1974-03-22 | Orsymonde | |
US4029801A (en) | 1970-09-03 | 1977-06-14 | John Wyeth & Brother Limited | Pharmaceutical compositions and methods of treating hypertension |
US4148796A (en) | 1971-03-15 | 1979-04-10 | Sumitomo Chemical Company, Limited | γ-Piperidinobutyrophenones |
US3794677A (en) | 1971-07-01 | 1974-02-26 | American Home Prod | Di(lower)alkylamino-and heteroamino-(lower)alkyl-alpha,alpha,alpha-trifluoro-m-toluic acid esters and derivatives |
US3969356A (en) | 1971-09-13 | 1976-07-13 | Kali-Chemie Aktiengesellschaft | N-[3-(p-f-benzoyl)-propyl]-N'-[2.(nitro,nitro-el, or methoxyphenyl)-ethyl]-p |
US3850935A (en) | 1971-10-16 | 1974-11-26 | Sumitomo Chemical Co | Process for producing piperidine derivatives by degrading quaternary piperidinium salts |
JPS4948957B2 (en) | 1971-10-26 | 1974-12-24 | ||
US3806526A (en) | 1972-01-28 | 1974-04-23 | Richardson Merrell Inc | 1-aroylalkyl-4-diphenylmethyl piperidines |
BE795671A (en) | 1972-02-21 | 1973-08-20 | Ugine Kuhlmann | NEW ANTIURIC DRUGS |
US3951978A (en) | 1972-04-22 | 1976-04-20 | Istituto Luso Farmaco D'italia S.R.L. | 1,3-Disubstituted 3-aroylpropanes and process for the preparation thereof |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3922266A (en) | 1972-06-28 | 1975-11-25 | Sumitomo Chemical Co | Aryl ketones and production thereof |
US3900478A (en) | 1973-01-29 | 1975-08-19 | Squibb & Sons Inc | 2-methyl-2-piperidino-3'-(trifluoromethyl) propiophenone |
CH602687A5 (en) | 1973-03-12 | 1978-07-31 | Kali Chemie Ag | |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US3873539A (en) | 1973-10-03 | 1975-03-25 | Sandoz Ag | Substituted-4-aminoacetyl alkanoylphenones |
US3992546A (en) | 1973-10-18 | 1976-11-16 | Ciba-Geigy Corporation | 4-Piperidinobutyrophenones as neuroleptics |
US4054570A (en) | 1973-10-18 | 1977-10-18 | Ciba-Geigy Corporation | 4-Piperidinobutyrophenones |
US3944064A (en) | 1973-10-26 | 1976-03-16 | Alza Corporation | Self-monitored device for releasing agent at functional rate |
US3995047A (en) | 1973-12-14 | 1976-11-30 | Eisai Co., Ltd. | Propiophenone derivatives in the treatment of pathological muscular conditions |
US4181803A (en) | 1973-12-14 | 1980-01-01 | Eisai Co., Ltd. | Propiophenone derivatives and preparation thereof |
US3912755A (en) | 1974-01-30 | 1975-10-14 | Lilly Co Eli | Preparation of pharmaceutical intermediates |
US3931197A (en) | 1974-02-08 | 1976-01-06 | Richardson-Merrell Inc. | Substituted piperidine derivatives |
US4069331A (en) | 1974-05-16 | 1978-01-17 | Boehringer Ingelheim Gmbh | N-(p-fluorobenzoyl-n-propyl)-4-piperidylamides and salts thereof |
IL48319A0 (en) | 1974-10-26 | 1975-12-31 | Merck Patent Gmbh | Araliphatic nitrogen compounds and a process for their preparation |
US4028366A (en) | 1975-01-20 | 1977-06-07 | Sterling Drug Inc. | 2-Naphthyl-lower-alkanoylamines |
US4169892A (en) * | 1975-04-03 | 1979-10-02 | Innothera | 1-(benzothien-2'-yl)-3-morpholino propanones and therapeutic compositions containing same |
GB1498884A (en) | 1975-04-15 | 1978-01-25 | Wyeth John & Brother Ltd | Aminoacetamide-pyridyl-tetrahydropyridyl and-piperidyl derivatives |
IL49971A0 (en) | 1975-07-08 | 1976-09-30 | Troponwerke Dinklage & Co | New 2-benzoypranone derivatives,their preparation and pharmaceutical compositions containing them |
FI60559C (en) | 1975-07-17 | 1982-02-10 | Sumitomo Chemical Co | FOERFARANDE FOER FRAMSTAELLNING AV NY- (TERTIAER AMINO) -ORTO-AMINOBUTYROFENONFOERENINGAR |
FR2325379A1 (en) | 1975-09-29 | 1977-04-22 | Cerm Cent Europ Rech Mauvernay | NEW DERIVATIVES OF 2- (2-HYDROXYETHYL) TETRAHYDRO-1,4 OXAZINES SUBSTITUTED AND THEIR APPLICATION AS ANTISPASMODIC MEDICINAL PRODUCTS |
DE2557341A1 (en) | 1975-12-19 | 1977-06-30 | Hoechst Ag | BASIC SUBSTITUTED INDOLDER DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION |
US4333941A (en) | 1975-12-22 | 1982-06-08 | The Dow Chemical Company | Inhibition of enveloped viruses with phenyl ketones |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
FR2361883A2 (en) | 1976-04-09 | 1978-03-17 | Fabre Sa Pierre | AMIDES OF PYRROLIDINO ETHYL AMINE USED IN PULMONARY THERAPEUTICS |
DE2718405A1 (en) | 1977-04-26 | 1978-11-02 | Boehringer Sohn Ingelheim | NEW N-NECK CLAMP ON 1- (3-BENZOYLPROPYL) -4-PIPERIDYL NECK CLAMP ON -SULPHONIC ACID AMIDES AND METHOD FOR THE PRODUCTION THEREOF |
JPS54125630A (en) | 1978-02-22 | 1979-09-29 | Nippon Zoki Pharmaceutical Co | Novel propanone derivative*its manufacture and medical composition containing it as active component |
DE2933636A1 (en) | 1978-08-30 | 1980-03-20 | Sandoz Ag | NEW N-PHENYLINDOL DERIVATIVES, THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS THAT CONTAIN THESE COMPOUNDS |
FR2443246A1 (en) | 1978-12-05 | 1980-07-04 | Pharmindustrie | NOVEL PHENYL-1 (PIPERIDYL-4) -3 PROPANONE-1 DERIVATIVES |
US4293561A (en) | 1979-03-09 | 1981-10-06 | Syntex (U.S.A.) Inc. | 1-(Naphthyl-n-propyl)imidazole derivatives |
US4283404A (en) | 1979-09-04 | 1981-08-11 | Richardson-Merrell Inc. | Aroylethenylpiperidinobutyrophenone antipsychotic agents |
DE2939292A1 (en) | 1979-09-28 | 1981-04-09 | Boehringer Mannheim Gmbh, 6800 Mannheim | N-PHENOXYALKYLPIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
DE3041199A1 (en) | 1979-11-14 | 1981-05-21 | Sandoz-Patent-GmbH, 7850 Lörrach | NEW STYLE CONNECTIONS, THEIR PRODUCTION AND USE |
FR2473518A1 (en) | 1980-01-16 | 1981-07-17 | Unicler | DERIVATIVES OF PHENYL-1 MORPHOLINO-4 BUTENE-1 OL-3, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
DE3019496A1 (en) | 1980-05-22 | 1981-11-26 | Bayer Ag, 5090 Leverkusen | AMINOPROPANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS FUNGICIDES |
DE3019497A1 (en) | 1980-05-22 | 1981-11-26 | Bayer Ag, 5090 Leverkusen | AMINOPROPIOPHENONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS FUNGICIDES |
US4400380A (en) | 1980-07-02 | 1983-08-23 | Merrell Dow Pharmaceuticals Inc. | Antiviral 1-aryl-5-amino-1-penten-3-ones |
US4397850A (en) | 1981-10-07 | 1983-08-09 | Sandoz, Inc. | Isoxazolyl indolamines |
JPS5944371A (en) | 1982-09-07 | 1984-03-12 | Dainippon Pharmaceut Co Ltd | 1-phenyl-2-methyl-3-(1-pyrrolidinyl)-1-propanone derivative and central muscle relaxant containing said derivative as active component |
FR2534912B1 (en) | 1982-10-26 | 1985-06-28 | Lafon Labor | NOVEL (2,4,6-TRIMETHOXYPHENYL) - (3-PIPERIDINOPROPYL) -CETONE DERIVATIVES, USE IN THERAPEUTICS AND METHOD OF PREPARATION |
EP0117233B1 (en) | 1983-02-18 | 1987-08-26 | Ciba-Geigy Ag | Coloured photo-curable mouldings |
US4515793A (en) * | 1983-07-27 | 1985-05-07 | Edna Mcconnell Clark Foundation | Phenylpiperazines which are useful in the treatment of schistosomiasis |
EP0138754B1 (en) | 1983-08-15 | 1988-05-25 | Ciba-Geigy Ag | Photocurable compositions |
HU33131A (en) | 1984-01-26 | 1984-10-29 | ||
FR2560873B1 (en) | 1984-03-09 | 1986-09-26 | Rhone Poulenc Sante | DRUGS BASED ON PIPERIDINE DERIVATIVES, NOVEL PIPERIDINE DERIVATIVES AND THEIR PREPARATION METHODS |
DE3413897A1 (en) | 1984-04-13 | 1985-10-17 | Bayer Ag, 5090 Leverkusen | (BETA) -NAPHTHYLALKYLAMINE |
US4544663A (en) | 1984-05-07 | 1985-10-01 | Sandoz, Inc. | Indolamine derivatives as anti-fertility agents |
DE3436450A1 (en) | 1984-10-05 | 1986-04-10 | Bayer Ag, 5090 Leverkusen | METHOD FOR PRODUCING P-AMINOETHYLKETONES |
US5057535A (en) | 1985-04-11 | 1991-10-15 | Nippon Kayaku Kabushiki Kaisha | Derivatives of an aminoketone |
FR2584715B1 (en) | 1985-07-10 | 1987-10-09 | Lafon Labor | PHENYL- (3-HEXAMETHYLENEIMINOPROPYL) -CETONE, PROCESS FOR PREPARATION AND THERAPEUTIC USE |
ES2061432T3 (en) | 1985-10-09 | 1994-12-16 | Shell Int Research | NEW ACRYLIC ACID AMIDES. |
DE3602016A1 (en) | 1985-12-05 | 1987-06-11 | Bayer Ag | PYRI (MI) DYL-OXY AND THIO-BENZOESIC ACID DERIVATIVES |
FR2597864B1 (en) | 1986-04-28 | 1990-11-16 | Lafon Labor | NOVEL N - ((TRIMETHOXY-2,4,6-BENZOYL) -3 PROPYL) PIPERIDINE DERIVATIVES, THEIR PREPARATION METHODS AND THEIR THERAPEUTIC APPLICATION |
KR910006138B1 (en) | 1986-09-30 | 1991-08-16 | 에자이 가부시끼가이샤 | Cyclic amine derivatives |
US4766118A (en) * | 1986-12-22 | 1988-08-23 | Ortho Pharmaceutical Corporation | 6-benzoxazinyl- and 6-benzothiazinyl-2,3,4,5-tetrahydropyridazin-3-ones and pharmaceutical use |
JPH0637389B2 (en) | 1986-12-26 | 1994-05-18 | 北陸製薬株式会社 | Treatment for frequent urination |
AU596499B2 (en) | 1987-01-20 | 1990-05-03 | Dainippon Pharmaceutical Co. Ltd. | Aromatic heterocyclic carboxylic acid amide derivatives, process for their preparation, and pharmaceutical composition containing same |
US4840950A (en) | 1987-02-11 | 1989-06-20 | Sterling Drug Inc. | 4-arylcarbonyl-1-[(4-morpholinyl)-lower-alkyl]-1H-indoles |
US4874761A (en) | 1987-02-11 | 1989-10-17 | Sterling Drug Inc. | 4-arylcarbonyl-1-[(4-morpholinyl)-lower-alkyl]-1H-indoles |
ES2054861T3 (en) | 1987-03-26 | 1994-08-16 | Ciba Geigy Ag | NEW ALPHA-AMINO ACETOPHENONES AS PHOTO INITIATORS. |
US4870083A (en) | 1987-11-24 | 1989-09-26 | Merrell Dow Pharmaceuticals Inc. | 1,4-Disubstituted-piperidinyl compounds useful as analgesics and muscle relaxants |
US5196439A (en) | 1987-11-27 | 1993-03-23 | Eisai Co., Ltd. | Piperidine compounds useful to treat cerebrovascular diseases |
US4791045A (en) | 1988-01-25 | 1988-12-13 | Minnesota Mining And Manufacturing Company | Photosensitizers and polymerizable compositions with mannich bases and iodonium salts |
IT1231260B (en) | 1988-11-16 | 1991-11-28 | Sergio Bertini Curri | DRUG AND METHOD TO INCREASE VOLUME AND SPEED OF CAPILLARY MICROCIRCULATOR FLOW AT SKIN LEVEL |
JPH0660141B2 (en) | 1989-09-12 | 1994-08-10 | 三井東圧化学株式会社 | Dihydrocaffeic acid derivative and therapeutic agent containing it as an active ingredient |
US5182284A (en) | 1990-01-26 | 1993-01-26 | Taiho Pharmaceutical Co., Ltd. | Piperazine compounds, processes for preparation thereof and medical uses thereof |
US5013837A (en) | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
US5276035A (en) | 1990-07-26 | 1994-01-04 | Novo Nordisk A/S | 1,4-disubstituted piperazines |
US5750542A (en) | 1993-09-28 | 1998-05-12 | Pfizer | Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors |
FR2680366B1 (en) | 1991-08-13 | 1995-01-20 | Adir | NOVEL ARYLETHYLAMINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
JP3157882B2 (en) | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | New benzothiophene derivatives |
US5674878A (en) | 1992-06-22 | 1997-10-07 | Boehringer Ingelheim Kg | Anellated dihydropyridines and the use thereof for the production of pharmaceutical preparations |
US5324483B1 (en) * | 1992-10-08 | 1996-09-24 | Warner Lambert Co | Apparatus for multiple simultaneous synthesis |
GB9301660D0 (en) | 1993-01-28 | 1993-03-17 | Smithkline Beecham Plc | Pharmaceuticals |
US6127379A (en) | 1993-02-01 | 2000-10-03 | Smithkline Beecham P.L.C. | Benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists |
ATE146775T1 (en) | 1993-02-23 | 1997-01-15 | Hoechst Ag | SUBSTITUTED BENZENESULFONYL UREAS AND THIOUREAS - METHOD FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS |
CA2136999C (en) | 1993-04-07 | 2004-05-11 | Takafumi Fujioka | Peripheral vasodilating agent containing piperidine derivative as active ingredient |
US5350748A (en) | 1993-08-18 | 1994-09-27 | Warner-Lambert Company | 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion |
GB9324018D0 (en) | 1993-11-23 | 1994-01-12 | Merck Sharp & Dohme | Therapeutic agents |
FR2713637B1 (en) | 1993-12-15 | 1996-01-05 | Cird Galderma | New bi-aromatic compounds derived from amide, pharmaceutical and cosmetic compositions containing them and uses. |
DK139593D0 (en) | 1993-12-16 | 1993-12-16 | Lundbeck & Co As H | COMPOUNDS |
EP0736012B1 (en) | 1993-12-21 | 2000-11-22 | Boehringer Ingelheim Pharma KG | Anellated dihydropyridines and their use in the production of pharmaceutical preparations |
GB9408185D0 (en) | 1994-04-25 | 1994-06-15 | Fujisawa Pharmaceutical Co | New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same |
US5552402A (en) | 1994-05-19 | 1996-09-03 | Merck, Sharp & Dohme Ltd. | Five-membered heteroaromatic compounds as 5-HT receptor agonists |
US5618819A (en) | 1994-07-07 | 1997-04-08 | Adir Et Compagnie | 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-(3H)-one compounds |
US6214994B1 (en) | 1997-04-21 | 2001-04-10 | Molecular Geriatrics Corporation | Certain substituted 1-aryl-3-piperazin-1′-yl propanones |
US5705501A (en) | 1994-11-17 | 1998-01-06 | Molecular Geriatrics Corporation | Certain substituted 1-aryl-3-morpholinopropanones to treat Alzheimer's Disease |
GB9423460D0 (en) | 1994-11-21 | 1995-01-11 | Merck Sharp & Dohme | Therapeutic agents |
PT869945E (en) | 1995-06-07 | 2003-09-30 | Pfizer | DERIVATIVES OF CATECH UETH DIETERS AS PHARMACEUTICAL AGENTS |
GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
WO1997036871A1 (en) | 1996-03-29 | 1997-10-09 | Pfizer Inc. | 6-phenylpyridyl-2-amine derivatives |
CN1098256C (en) | 1996-04-12 | 2003-01-08 | G·D·瑟尔公司 | Substd. benzenesulfonamide derivs as prodrugs of COX-2 inhibitors |
CZ371998A3 (en) | 1996-05-20 | 1999-03-17 | Darwin Discovery Limited | Benzofuran carboxamides and their therapeutic application |
US6555690B2 (en) | 1996-06-21 | 2003-04-29 | Allergan, Inc. | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
EP0927167A1 (en) | 1996-08-14 | 1999-07-07 | Warner-Lambert Company | 2-phenyl benzimidazole derivatives as mcp-1 antagonists |
TW452575B (en) | 1996-12-06 | 2001-09-01 | Ciba Sc Holding Ag | New Α-aminoacetophenone photoinitiators and photopolymerizable compositions comprising these photoinitiators |
US5994398A (en) | 1996-12-11 | 1999-11-30 | Elan Pharmaceuticals, Inc. | Arylsulfonamides as phospholipase A2 inhibitors |
US6281227B1 (en) | 1996-12-13 | 2001-08-28 | Aventis Pharma Deutschland Gmbh | Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds |
FR2761358B1 (en) | 1997-03-27 | 1999-05-07 | Adir | NOVEL N-ARYL PIPERIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US6207665B1 (en) | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
US20010049379A1 (en) | 1997-08-27 | 2001-12-06 | Lowe John Adams | 2-aminopyridines containing fused ring substituents |
HN1998000125A (en) | 1997-08-28 | 1999-02-09 | Pfizer Prod Inc | 2-AMINOPYRIDIDS WITH BRANCHED ALCOXY SUBSTITUTES |
US5972986A (en) | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
US6140349A (en) | 1998-02-02 | 2000-10-31 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
US6462036B1 (en) * | 1998-11-06 | 2002-10-08 | Basf Aktiengesellschaft | Tricyclic pyrazole derivatives |
AR022338A1 (en) | 1999-02-04 | 2002-09-04 | Hokuriku Pharmaceutical | A BENZAMIDE COMPOUND, A MEDICINAL PRODUCT CONTAINING IT, AND USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF A DIGESTIVE DISEASE OR TO IMPROVE THE MOBILITY OF THE GASTROINTESTINAL TRACT. |
AUPP873799A0 (en) | 1999-02-17 | 1999-03-11 | Fujisawa Pharmaceutical Co., Ltd. | Pyridine compounds |
EP1163910B1 (en) | 1999-03-25 | 2007-09-26 | Mitsubishi Pharma Corporation | Rho kinase inhibitors for the prevention or treatment of interstitial pneumonia and pulmonary fibrosis |
US7361666B2 (en) | 1999-05-25 | 2008-04-22 | Sepracor, Inc. | Heterocyclic analgesic compounds and methods of use thereof |
US6677332B1 (en) | 1999-05-25 | 2004-01-13 | Sepracor, Inc. | Heterocyclic analgesic compounds and methods of use thereof |
ES2253233T3 (en) | 1999-07-09 | 2006-06-01 | Boehringer Ingelheim Pharmaceuticals Inc. | PROCEDURE FOR SYNTHESIS OF UREA HETEROARIL SUBSTITUTED COMPOUNDS. |
US7253165B2 (en) | 1999-09-14 | 2007-08-07 | Aventis Pharmaceuticals Inc. | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists |
CO5271715A1 (en) | 1999-12-21 | 2003-04-30 | Sugen Inc | 7-AZA-INDOLIN-2-WAVES SUBSTITUTED IN 4 AND ITS USE AS PROTEIUNA QUINASA INHIBITORS |
MXPA02006338A (en) | 1999-12-24 | 2002-12-13 | Aventis Pharma Ltd | Azaindoles. |
GB0004149D0 (en) | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel compounds |
US7001905B2 (en) | 2000-03-15 | 2006-02-21 | Warner-Lambert Company | Substituted diarylamines as MEK inhibitors |
CA2402516A1 (en) | 2000-03-20 | 2001-09-27 | Roopa Rai | Non-amidine containing protease inhibitors |
EE200200567A (en) | 2000-03-31 | 2004-06-15 | Pfizer Products Inc. | New piperazine derivatives |
IL152702A0 (en) | 2000-06-05 | 2003-06-24 | Fmc Corp | Process to prepare sulfonamides |
US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
TWI262920B (en) | 2000-10-27 | 2006-10-01 | Elbion Ag | New 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them |
DE60108420T2 (en) | 2000-11-28 | 2005-12-22 | Smithkline Beecham P.L.C., Brentford | MORPHOLIN DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS |
PT1347971E (en) | 2000-12-21 | 2006-06-30 | Bristol Myers Squibb Co | TIAHOLYLIC INHIBITORS OF TYROSINE-CINASES OF THE TEC FAMILY |
US20030105144A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
US6673818B2 (en) | 2001-04-20 | 2004-01-06 | Pharmacia Corporation | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation |
DE10123129A1 (en) | 2001-05-02 | 2002-11-14 | Berolina Drug Dev Ab Svedala | Deuterated 3-piperidinopropiophenones and medicinal products containing these compounds |
JP2004536057A (en) | 2001-05-11 | 2004-12-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | Derivatives of 2,5-disubstituted pyridines, pyrimidines, pyridazines and 1,2,4-triazines used as p38 inhibitors |
GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
SE0102809D0 (en) | 2001-08-22 | 2001-08-22 | Astrazeneca Ab | Novel compounds |
US20030236293A1 (en) | 2001-09-18 | 2003-12-25 | Pharmacia Corporation | Compositions of tricyclic cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain |
CA2469730A1 (en) | 2001-12-10 | 2003-06-19 | Aryx Therapeutics | Novel methods for treatment of cardiac arrhythmia, synthesis, and methods of use |
DE10161644A1 (en) | 2001-12-14 | 2003-06-26 | Gruenenthal Gmbh | New N,N'-disubstituted piperazine derivatives are noradrenaline reuptake inhibitors, useful e.g. for the treatment of arrhythmia, emesis, diarrhea, inflammation or especially depression or pain |
US7161008B2 (en) | 2002-05-03 | 2007-01-09 | Sanofi - Aventis Deutschland GmbH | Optically active β-aminoketones, optically active 1,3-amino alcohols and processes for preparing them |
CN1150176C (en) | 2002-05-22 | 2004-05-19 | 上海医药工业研究院 | Aralkylone pipeazine derivative and its application |
AU2003229370B2 (en) | 2002-05-23 | 2009-02-26 | Ym Biosciences Australia Pty Ltd | Kinase inhibitors |
WO2003104216A1 (en) * | 2002-06-10 | 2003-12-18 | Acadia Pharmaceuticals Inc. | Urotensin ii receptor modulators |
US20040072839A1 (en) | 2002-06-14 | 2004-04-15 | Amedeo Leonardi | 1-Phenylalkylpiperazines |
SE0202463D0 (en) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
KR20110050745A (en) | 2002-10-03 | 2011-05-16 | 탈자진 인코포레이티드 | Vasculostatic agents and methods of use thereof |
AU2003276458A1 (en) | 2002-11-07 | 2004-06-07 | Astrazeneca Ab | 2-oxo-ethanesulfonamide derivates |
GB0227240D0 (en) * | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
BRPI0409221A (en) | 2003-04-08 | 2006-03-28 | Basf Aktiengeeellschaft | compound, process for the preparation of benzenesulfonamide derivatives, agent, processes for the preparation of agents, for combating unwanted vegetation, and for desiccation and / or defoliation of plants, and use of the benzenesulfonamide derivatives |
US7514438B2 (en) | 2003-08-13 | 2009-04-07 | Amgen, Inc. | Melanin concentrating hormone receptor antagonist |
US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
DE602004019698D1 (en) | 2003-12-23 | 2009-04-09 | Lilly Co Eli | MORPHOLINE DERIVATIVES AS INHIBITORS OF THE RECOVERY OF NOREPINEPHRIN |
JP2007519742A (en) * | 2004-01-26 | 2007-07-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Compositions useful as inhibitors of protein kinases |
MXPA06011327A (en) | 2004-03-30 | 2006-12-15 | Vertex Pharma | Azaindoles useful as inhibitors of jak and other protein kinases. |
US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
MX2007001127A (en) | 2004-07-27 | 2007-07-11 | Sgx Pharmaceuticals Inc | Pyrrolo-pyridine kinase modulators. |
US7361764B2 (en) | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
AR050365A1 (en) | 2004-08-02 | 2006-10-18 | Osi Pharm Inc | INHIBITING COMPOUNDS OF ARIL-AMINO PIRROLOPIRIMIDINE PULROLOPIRIMIDINE REPLACED |
AU2005286592A1 (en) * | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Novel pyrimidine compounds, process for their preparation and compositions containing them |
CA2590841A1 (en) | 2004-12-14 | 2006-06-22 | Wyeth | Use of a 5-ht6 agonist for the treatment and prevention of neurodegenerative disorders |
DE102004060659A1 (en) | 2004-12-15 | 2006-07-06 | Lanxess Deutschland Gmbh | Novel substituted 1H-pyrrolo [2,3-b] pyridines and their preparation |
AU2006204724A1 (en) | 2005-01-14 | 2006-07-20 | Millennium Pharmaceuticals, Inc. | Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity |
US20060246099A1 (en) | 2005-04-21 | 2006-11-02 | L'oreal | Compositions containing piperazine compounds |
NZ563444A (en) | 2005-05-17 | 2011-04-29 | Plexxikon Inc | Pyrrolo(2,3-b)pyridine derivatives as protein kinase inhibitors |
RU2435769C2 (en) * | 2005-05-20 | 2011-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Pyrrolopyridines effective as proteinkinase inhibitors |
CA2528849C (en) * | 2005-06-08 | 2014-01-14 | Janssen Pharmaceutica N.V. | Quinoline derivatives as antibacterial agents |
GB0516156D0 (en) | 2005-08-05 | 2005-09-14 | Eisai London Res Lab Ltd | JNK inhibitors |
AR056544A1 (en) | 2005-09-29 | 2007-10-10 | Wyeth Corp | PHENYLAMINOPROPANOL DERIVATIVES AND METHODS OF USE OF THE SAME |
US20080293714A1 (en) * | 2005-12-20 | 2008-11-27 | Joerg Martin Bentzien | Tec Kinase Inhibitors |
CA2635899A1 (en) * | 2006-01-19 | 2007-07-26 | Osi Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
UY30121A1 (en) * | 2006-02-03 | 2007-08-31 | Glaxo Group Ltd | NEW COMPOUNDS |
MX2008014450A (en) * | 2006-05-18 | 2009-03-09 | Mannkind Corp | Intracellular kinase inhibitors. |
ES2585902T3 (en) | 2006-09-22 | 2016-10-10 | Pharmacyclics Llc | Bruton tyrosine kinase inhibitors |
-
2007
- 2007-05-18 MX MX2008014450A patent/MX2008014450A/en active IP Right Grant
- 2007-05-18 EP EP20140183381 patent/EP2865381A1/en not_active Withdrawn
- 2007-05-18 AU AU2007254179A patent/AU2007254179B2/en active Active
- 2007-05-18 CA CA2858520A patent/CA2858520A1/en not_active Abandoned
- 2007-05-18 WO PCT/US2007/011974 patent/WO2007136790A2/en active Application Filing
- 2007-05-18 US US11/750,866 patent/US8604031B2/en not_active Expired - Fee Related
- 2007-05-18 CA CA2651732A patent/CA2651732C/en active Active
- 2007-05-18 JP JP2009511099A patent/JP5682051B2/en not_active Expired - Fee Related
- 2007-05-18 EP EP20070795056 patent/EP2027087A2/en not_active Withdrawn
-
2011
- 2011-07-07 US US13/177,657 patent/US20110281850A1/en not_active Abandoned
-
2013
- 2013-11-11 US US14/076,457 patent/US20140080833A1/en not_active Abandoned
-
2014
- 2014-01-24 JP JP2014010925A patent/JP2014098004A/en active Pending
-
2015
- 2015-04-24 US US14/696,348 patent/US20150290200A1/en not_active Abandoned
- 2015-08-21 JP JP2015164169A patent/JP2016040248A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7138420B2 (en) * | 2002-08-08 | 2006-11-21 | Boehringer Ingelheim Pharmaceuticals Inc. | Substituted benzimidazole compounds |
WO2005037843A1 (en) * | 2003-10-14 | 2005-04-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
US20080261975A1 (en) * | 2005-11-12 | 2008-10-23 | Joerg Martin Bentzien | Tec Kinase Inhibitors |
US20120058996A1 (en) * | 2008-12-19 | 2012-03-08 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
Non-Patent Citations (1)
Title |
---|
Lin T. et al. Selective Itk Inhibitors Block T-Cell Activation and Murine Lung Inflammation. Biochemistry 43:11056-11062, 2004. * |
Cited By (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100254905A1 (en) * | 2006-09-22 | 2010-10-07 | Lee Honigberg | Inhibitors of bruton's tyrosine kinase |
US8883435B2 (en) | 2006-09-22 | 2014-11-11 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
US8809273B2 (en) | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
US8940750B2 (en) | 2007-03-28 | 2015-01-27 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
US9079908B2 (en) | 2007-03-28 | 2015-07-14 | Pharmacyclics, Inc. | Inhibitors of Bruton'S tyrosine kinase |
US9139591B2 (en) | 2007-03-28 | 2015-09-22 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
US9556182B2 (en) | 2007-03-28 | 2017-01-31 | Pharmacylics LLC | Inhibitors of Bruton's tyrosine kinase |
US9181263B2 (en) | 2007-03-28 | 2015-11-10 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
US9212181B2 (en) | 2008-06-27 | 2015-12-15 | Celgene Avilomics Research, Inc. | Substituted 2,4-diaminopyrimidines as kinase inhibitors |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US10828300B2 (en) | 2008-06-27 | 2020-11-10 | Celgene Car Llc | Substituted 2,4-diaminopyrimidines as kinase inhibitors |
US9296737B2 (en) | 2008-06-27 | 2016-03-29 | Celgene Avilomics Research, Inc. | Substituted 2,4-diaminopyrimidines as kinase inhibitors |
US9987276B2 (en) | 2008-06-27 | 2018-06-05 | Celgene Car Llc | Substituted 2,4-diaminopyrimidines as kinase inhibitors |
US10010548B2 (en) | 2008-06-27 | 2018-07-03 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US9409921B2 (en) | 2008-06-27 | 2016-08-09 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines as kinase inhibitors |
US10596172B2 (en) | 2008-06-27 | 2020-03-24 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US9908884B2 (en) | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
US10751342B2 (en) | 2010-06-03 | 2020-08-25 | Pharmacyclics Llc | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
US10016435B2 (en) | 2010-06-03 | 2018-07-10 | Pharmacyclics Llc | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
US10478439B2 (en) | 2010-06-03 | 2019-11-19 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (Btk) |
US10653696B2 (en) | 2010-06-03 | 2020-05-19 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (BTK) |
US10004745B2 (en) | 2010-06-03 | 2018-06-26 | Pharmacyclics Llc | Use of inhibitors of Bruton'S tyrosine kinase (Btk) |
US10004746B2 (en) | 2010-06-03 | 2018-06-26 | Pharmacyclics Llc | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
US9814721B2 (en) | 2010-06-03 | 2017-11-14 | Pharmacyclics Llc | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
US11672803B2 (en) | 2010-06-03 | 2023-06-13 | Pharmacyclics Llc | Use of inhibitors of Brutons tyrosine kinase (Btk) |
US9604936B2 (en) | 2010-08-10 | 2017-03-28 | Celgene Car Llc | Besylate salt of a BTK inhibitor |
US9375431B2 (en) | 2010-11-01 | 2016-06-28 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidine compounds useful as kinase inhibtors |
US10081606B2 (en) | 2010-11-01 | 2018-09-25 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
US9867824B2 (en) | 2010-11-01 | 2018-01-16 | Celgene Car Llc | Heterocyclic compounds and uses thereof |
US9238629B2 (en) | 2010-11-01 | 2016-01-19 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US9765038B2 (en) | 2010-11-01 | 2017-09-19 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
US11096942B2 (en) | 2010-11-01 | 2021-08-24 | Celgene Car Llc | Heterocyclic compounds and uses thereof |
US10434101B2 (en) | 2010-11-01 | 2019-10-08 | Celgene Car Llc | Heterocyclic compounds and uses thereof |
US9868723B2 (en) | 2010-11-10 | 2018-01-16 | Celgene Car Llc | Mutant-selective EGFR inhibitors and uses thereof |
US9409887B2 (en) | 2010-11-10 | 2016-08-09 | Celgene Avilomics Research, Inc. | Mutant-selective EGFR inhibitors and uses thereof |
US9862722B2 (en) | 2011-07-13 | 2018-01-09 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
US9364476B2 (en) | 2011-10-28 | 2016-06-14 | Celgene Avilomics Research, Inc. | Methods of treating a Bruton's Tyrosine Kinase disease or disorder |
US9273051B2 (en) | 2011-12-30 | 2016-03-01 | Pharmacyclics Llc | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US9546172B2 (en) | 2011-12-30 | 2017-01-17 | Pharmacyclics Llc | Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US10954567B2 (en) | 2012-07-24 | 2021-03-23 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK) |
US9549927B2 (en) | 2012-12-21 | 2017-01-24 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US9504686B2 (en) | 2013-02-08 | 2016-11-29 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
US9796700B2 (en) | 2013-02-08 | 2017-10-24 | Celgene Car Llc | ERK inhibitors and uses thereof |
US9145387B2 (en) | 2013-02-08 | 2015-09-29 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
US9980964B2 (en) | 2013-02-08 | 2018-05-29 | Celgene Car Llc | ERK inhibitors and uses thereof |
US9561228B2 (en) | 2013-02-08 | 2017-02-07 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
US9624224B2 (en) | 2013-09-30 | 2017-04-18 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
US10202364B2 (en) | 2014-08-13 | 2019-02-12 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
US10005760B2 (en) | 2014-08-13 | 2018-06-26 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
WO2017040617A1 (en) | 2015-08-31 | 2017-03-09 | Pharmacyclics Llc | Btk inhibitor combinations for treating multiple myeloma |
WO2018085731A2 (en) | 2016-11-03 | 2018-05-11 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and a btk inhibitor |
WO2019213184A1 (en) | 2018-05-03 | 2019-11-07 | Juno Therapeutics, Inc. | Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
Also Published As
Publication number | Publication date |
---|---|
JP5682051B2 (en) | 2015-03-11 |
MX2008014450A (en) | 2009-03-09 |
CA2858520A1 (en) | 2007-11-29 |
EP2865381A1 (en) | 2015-04-29 |
AU2007254179A1 (en) | 2007-11-29 |
CA2651732A1 (en) | 2007-11-29 |
WO2007136790A2 (en) | 2007-11-29 |
US20140080833A1 (en) | 2014-03-20 |
WO2007136790A3 (en) | 2008-11-27 |
AU2007254179B2 (en) | 2013-03-21 |
CA2651732C (en) | 2014-10-14 |
JP2009537552A (en) | 2009-10-29 |
JP2016040248A (en) | 2016-03-24 |
US20070293499A1 (en) | 2007-12-20 |
EP2027087A2 (en) | 2009-02-25 |
JP2014098004A (en) | 2014-05-29 |
US8604031B2 (en) | 2013-12-10 |
US20150290200A1 (en) | 2015-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8604031B2 (en) | Intracellular kinase inhibitors | |
US11337956B2 (en) | IRE-1α inhibitors | |
US20200140425A1 (en) | Compounds for the treatment of tuberculosis | |
US20100324017A1 (en) | Acylguanidine derivative | |
US9856266B2 (en) | IRE-1alpha inhibitors | |
US20160297835A1 (en) | Use of small molecule inhibitors targeting the interaction between rac gtpase and p67(phox) | |
US8822688B2 (en) | Imidazo[1,2-a]pyridine derivative | |
US20090131412A1 (en) | Novel 2-quinolone derivative | |
US11905244B2 (en) | Chemical modulators of store-operated calcium channels and their therapeutic applications | |
AU2013200229B2 (en) | Intracellular kinase inhibitors | |
CN112209917B (en) | Application of heterocyclic substituted phenylpiperazine or phenylpiperidine derivatives in antidepressant drugs | |
AU2014250696A1 (en) | Intracellular kinase inhibitors | |
US20230052740A1 (en) | Modulators of circadian rhythms and uses thereof | |
US20240034727A1 (en) | Imidazole compounds as inhibitors of enpp1 | |
WO2024044553A1 (en) | Use of (isoindolin-2-yl)(4-hydroxy-3-(isoindoline-2-carbonyl)phenyl)methanones in the treatment of tumor necrosis factor receptor-associated protein 1 dysfunction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MANNKIND CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FLYNN, GARY A.;LEE, SANDRA AEYOUNG;FARIS, MARY;AND OTHERS;SIGNING DATES FROM 20070615 TO 20070622;REEL/FRAME:026575/0598 |
|
AS | Assignment |
Owner name: PHARMACYCLICS INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MANNKIND CORPORATION;REEL/FRAME:033454/0968 Effective date: 20140508 |
|
AS | Assignment |
Owner name: PHARMACYCLICS LLC, CALIFORNIA Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:PHARMACYCLICS, INC.;OXFORD AMHERST LLC;REEL/FRAME:036126/0368 Effective date: 20150526 Owner name: PHARMACYCLICS, INC., CALIFORNIA Free format text: MERGER;ASSIGNOR:OXFORD AMHERST CORPORATION;REEL/FRAME:036126/0359 Effective date: 20150526 |
|
AS | Assignment |
Owner name: PHARMACYCLICS, INC., CALIFORNIA Free format text: MERGER;ASSIGNOR:OXFORD AMHERST CORPORATION;REEL/FRAME:036130/0098 Effective date: 20150526 Owner name: PHARMACYCLICS LLC, CALIFORNIA Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:PHARMACYCLICS, INC.;OXFORD AMHERST LLC;REEL/FRAME:036130/0104 Effective date: 20150526 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: PHARMACYCLICS, INC., CALIFORNIA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036130 FRAME 0098. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER;ASSIGNORS:OXFORD AMHERST CORPORATION;PHARMACYCLICS, INC.;REEL/FRAME:038701/0102 Effective date: 20150526 |
|
AS | Assignment |
Owner name: PHARMACYCLICS, INC., CALIFORNIA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036126 FRAME 0359. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER;ASSIGNORS:OXFORD AMHERST CORPORATION;PHARMACYCLICS, INC.;REEL/FRAME:038742/0064 Effective date: 20150526 |
|
AS | Assignment |
Owner name: PHARMACYCLICS LLC, CALIFORNIA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036126 FRAME 0368. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER AND CHANGE OF NAME;ASSIGNORS:PHARMACYCLICS, INC.;OXFORD AMHERST LLC;REEL/FRAME:038742/0371 Effective date: 20150526 |
|
AS | Assignment |
Owner name: PHARMACYCLICS LLC, CALIFORNIA Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:PHARMACYCLICS, INC.;OXFORD AMHERST LLC;OXFORD AMHERST LLC;REEL/FRAME:038799/0697 Effective date: 20150526 |